Patent Application
20230242586
The Sequence Listing written in file 048536-684N01US_Sequence_Listing_ST25, created Oct. 10, 2022, 23,084 bytes, machine format IBM-PC, MS Windows operating system, is hereby incorporated by reference.
Missense mutations of the RAS genes (KRAS, HRAS, and NRAS) occur frequently in human cancer and drive oncogenic transformation. Among these, KRAS G12D is the most prevalent point mutation associated with poor clinical outcome. The G12D mutation impairs both intrinsic and GTPase-accelerating protein (GAP)-mediated GTP hydrolysis and liberates K-Ras protein from functional control by GTPase activity. As a result, K-Ras(G12D) is enriched in its GTP-bound, signaling-competent state, given the near 10-fold higher concentration of GTP than GDP inside the cell. Disclosed herein, inter alia, are solutions to these and other problems in the art.
In an aspect is provided a compound having the formula:
L1A, L2A, L3A, L4A, L5A, L6A, L7A, L8A, L9A, L10A, L10A, and L12A are independently a bond, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.
R1A, R5A, and R11A are independently substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
R2A and R8A are independently hydrogen, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
R3A is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted aryl.
R4A is hydrogen, —NH2, —COOH, —CONH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted aryl.
R6A and R9A are independently hydrogen, —CN, —NH2, —CONH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHOH, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.
R7A is hydrogen, —NH2, —COOH, —CONH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.
R3A and R9A may optionally be joined to form a covalent linker.
R10A is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —C(O)OH, —C(O)NH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, -L10DL10E-E, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
L10D is a bond, —S(O)2—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
L10E is a bond, —S(O)2—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted heteroalkylene, substituted or unsubstituted heterocycloalkylene, or substituted or unsubstituted heteroarylene.
R12A is hydrogen, —CN, —NH2, —CONH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted aryl.
E is an electrophilic moiety.
R1D, R2D, R3D, R4D, R5D, R6D, R7D, R8D, R9D, R10D, R11D, and R12D are independently hydrogen, unsubstituted C1-C8 alkyl.
L16 is a covalent linker.
In an aspect is provided a compound having the formula:
R1D, L2D, R3D, R4D, R5D, R6D, R7D, R8D, R7R9D, R10D, R11D, R12D, and L16 are as described herein, including in embodiments.
L1B, L2B, L3B, L4B, L5B, L6B, L7B, L8B, L9B, L10B, L11B, L12B, and L13B are independently a bond, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.
R1B, R8B, and R10B are independently substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
R2B, R3B, R4B, R9B, and R11B are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted aryl.
R5B is independently hydrogen, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.
R6B is independently hydrogen, —OH, —COOH, —NO2, —SO3H, —OSO3H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.
R7B, R12B, and R13B independently hydrogen, —NH2, —CONH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted heteroaryl.
Two substituents selected from R1B, R2B, R3B, R4B, R5B, R6B, L7B, R8B, R9B, R10B, R11B, R12B, and R13B may optionally be joined to form a covalent linker.
R13D is independently hydrogen or unsubstituted C1-C4 alkyl.
In an aspect is provided a compound having the formula:
R1D, R2D, R3D, R4D, R5D, R6D, R7D, R8D, R9D, R10D, R11D, R12D, R13D, and L16 are as described herein, including in embodiments.
L1C, L2C, L3C, L4C, L5C, L6C, L7C, L8C, L9C, L10C, L11C, L12C, L13C, L14C, and L15C are independently a bond, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene.
R1C is independently substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
R2C is independently hydrogen, —OH, —NO2, —CN, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.
L3 is independently a bond or
R3C is independently hydrogen, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
L4 is independently a bond or
R4C is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted aryl.
L5 is independently a bond or
R5C is independently substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
L6 is independently a bond,
R6C is independently hydrogen, —CN, —NH2, —C(O)NH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHOH, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.
R7C and R8C are independently hydrogen, —CN, —NH2, —C(O)NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
L9 is independently a bond,
R9C is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted aryl.
L10 is independently a bond,
R10C is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
L11 is independently a bond or
R11C is independently hydrogen, —CN, —OH, —C(O)OH, —NO2, —SO3H, —OSO3H, —NH2, —C(O)NH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.
R12C is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
L13 is independently
R13C is independently hydrogen, —OH, —NH2, —C(O)OH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl.
L14 is independently a bond or
R14C is independently hydrogen, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
L15 is independently a bond or
R15C is independently hydrogen, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
Two substituents selected from R1C, R2C, R3C, R4C, R5C, R6C, R7C, R8C, R9C, R10C, R11C, R12C, R13C, R14C, and R15C may optionally be joined to form a covalent linker.
R14D and R15D are independently hydrogen or unsubstituted C1-C4 alkyl.
In an aspect is provided a pharmaceutical composition including a compound described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
In an aspect is provided a method of treating a cancer in a patient in need of such treatment, the method including administering a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, to the patient.
In an aspect is provided a method of modulating the activity of a human Ras protein, the method including contacting the human Ras protein with an effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof.
The abbreviations used herein have their conventional meaning within the chemical and biological arts. The chemical structures and formulae set forth herein are constructed according to the standard rules of chemical valency known in the chemical arts.
Where substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents that would result from writing the structure from right to left, e.g., —CH2O— is equivalent to —OCH2—.
The term “alkyl,” by itself or as part of another substituent, means, unless otherwise stated, a straight (i.e., unbranched) or branched carbon chain (or carbon), or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include mono-, di-, and multivalent radicals. The alkyl may include a designated number of carbons (e.g., C1-C10 means one to ten carbons). Alkyl is an uncyclized chain. Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, methyl, homologs and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. An unsaturated alkyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homologs and isomers. An alkoxy is an alkyl attached to the remainder of the molecule via an oxygen linker (—O—). An alkyl moiety may be an alkenyl moiety. An alkyl moiety may be an alkynyl moiety. An alkyl moiety may be fully saturated. An alkenyl may include more than one double bond and/or one or more triple bonds in addition to the one or more double bonds. An alkynyl may include more than one triple bond and/or one or more double bonds in addition to the one or more triple bonds. In embodiments, the alkyl is fully saturated. In embodiments, the alkyl is monounsaturated. In embodiments, the alkyl is polyunsaturated.
The term “alkylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyl, as exemplified, but not limited by, —CH2CH2CH2CH2—. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred herein. A “lower alkyl” or “lower alkylene” is a shorter chain alkyl or alkylene group, generally having eight or fewer carbon atoms. The term “alkenylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkene. The term “alkynylene” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from an alkyne. In embodiments, the alkylene is fully saturated. In embodiments, the alkylene is monounsaturated. In embodiments, the alkylene is polyunsaturated. In embodiments, an alkenylene includes one or more double bonds. In embodiments, an alkynylene includes one or more triple bonds.
The term “heteroalkyl,” by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or combinations thereof, including at least one carbon atom and at least one heteroatom (e.g., O, N, P, Si, and S), and wherein the nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) (e.g., N, S, Si, or P) may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Heteroalkyl is an uncyclized chain. Examples include, but are not limited to: —CH2—CH2—O—CH3, —CH2—CH2—NH—CH3, —CH2—CH2—N(CH3)—CH3, —CH2—S—CH2—CH3, —S—CH2—CH2, —S(O)—CH3, —CH2—CH2—S(O)2—CH3, —CH═CH—O—CH3, —Si(CH3)3, —CH2—CH═N—OCH3, —CH═CH—N(CH3)—CH3, —O—CH3, —O—CH2—CH3, and —CN. Up to two or three heteroatoms may be consecutive, such as, for example, —CH2—NH—OCH3 and —CH2—O—Si(CH3)3. A heteroalkyl moiety may include one heteroatom (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include two optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include three optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include four optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include five optionally different heteroatoms (e.g., O, N, S, Si, or P). A heteroalkyl moiety may include up to 8 optionally different heteroatoms (e.g., O, N, S, Si, or P). The term “heteroalkenyl,” by itself or in combination with another term, means, unless otherwise stated, a heteroalkyl including at least one double bond. A heteroalkenyl may optionally include more than one double bond and/or one or more triple bonds in additional to the one or more double bonds. The term “heteroalkynyl,” by itself or in combination with another term, means, unless otherwise stated, a heteroalkyl including at least one triple bond. A heteroalkynyl may optionally include more than one triple bond and/or one or more double bonds in additional to the one or more triple bonds. In embodiments, the heteroalkyl is fully saturated. In embodiments, the heteroalkyl is monounsaturated. In embodiments, the heteroalkyl is polyunsaturated.
Similarly, the term “heteroalkylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from heteroalkyl, as exemplified, but not limited by, —CH2—CH2—S—CH2—CH2— and —CH2—S—CH2—CH2—NH—CH2—. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula —C(O)2R′— represents both —C(O)2R′- and —R′C(O)2—. As described above, heteroalkyl groups, as used herein, include those groups that are attached to the remainder of the molecule through a heteroatom, such as —C(O)R′, —C(O)NR′, —NR′R″, —OR′, —SR′, and/or —SO2R′. Where “heteroalkyl” is recited, followed by recitations of specific heteroalkyl groups, such as —NR′R″ or the like, it will be understood that the terms heteroalkyl and —NR′R″ are not redundant or mutually exclusive. Rather, the specific heteroalkyl groups are recited to add clarity. Thus, the term “heteroalkyl” should not be interpreted herein as excluding specific heteroalkyl groups, such as —NR′R″ or the like. The term “heteroalkenylene,” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from a heteroalkene. The term “heteroalkynylene” by itself or as part of another substituent, means, unless otherwise stated, a divalent radical derived from a heteroalkyne. In embodiments, the heteroalkylene is fully saturated. In embodiments, the heteroalkylene is monounsaturated. In embodiments, the heteroalkylene is polyunsaturated. In embodiments, a heteroalkenylene includes one or more double bonds. In embodiments, a heteroalkynylene includes one or more triple bonds.
The terms “cycloalkyl” and “heterocycloalkyl,” by themselves or in combination with other terms, mean, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl,” respectively. Cycloalkyl and heterocycloalkyl are not aromatic. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1-piperazinyl, 2-piperazinyl, and the like. A “cycloalkylene” and a “heterocycloalkylene,” alone or as part of another substituent, means a divalent radical derived from a cycloalkyl and heterocycloalkyl, respectively. In embodiments, the cycloalkyl is fully saturated. In embodiments, the cycloalkyl is monounsaturated. In embodiments, the cycloalkyl is polyunsaturated. In embodiments, the heterocycloalkyl is fully saturated. In embodiments, the heterocycloalkyl is monounsaturated. In embodiments, the heterocycloalkyl is polyunsaturated.
In embodiments, the term “cycloalkyl” means a monocyclic, bicyclic, or a multicyclic cycloalkyl ring system. In embodiments, monocyclic ring systems are cyclic hydrocarbon groups containing from 3 to 8 carbon atoms, where such groups can be saturated or unsaturated, but not aromatic. In embodiments, cycloalkyl groups are fully saturated. A bicyclic or multicyclic cycloalkyl ring system refers to multiple rings fused together wherein at least one of the fused rings is a cycloalkyl ring and wherein the multiple rings are attached to the parent molecular moiety through any carbon atom contained within a cycloalkyl ring of the multiple rings.
In embodiments, the term “heterocycloalkyl” means a monocyclic, bicyclic, or a multicyclic heterocycloalkyl ring system. In embodiments, heterocycloalkyl groups are fully saturated. A bicyclic or multicyclic heterocycloalkyl ring system refers to multiple rings fused together wherein at least one of the fused rings is a heterocycloalkyl ring and wherein the multiple rings are attached to the parent molecular moiety through any atom contained within a heterocycloalkyl ring of the multiple rings.
The terms “halo” or “halogen,” by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as “haloalkyl” are meant to include monohaloalkyl and polyhaloalkyl. For example, the term “halo(C1-C4)alkyl” includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
The term “acyl” means, unless otherwise stated, —C(O)R where R is a substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
The term “aryl” means, unless otherwise stated, a polyunsaturated, aromatic, hydrocarbon substituent, which can be a single ring or multiple rings (preferably from 1 to 3 rings) that are fused together (i.e., a fused ring aryl) or linked covalently. A fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring. In embodiments, a fused ring aryl refers to multiple rings fused together wherein at least one of the fused rings is an aryl ring and wherein the multiple rings are attached to the parent molecular moiety through any carbon atom contained within an aryl ring of the multiple rings. The term “heteroaryl” refers to aryl groups (or rings) that contain at least one heteroatom such as N, O, or S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. Thus, the term “heteroaryl” includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one of the fused rings is a heteroaromatic ring). In embodiments, the term “heteroaryl” includes fused ring heteroaryl groups (i.e., multiple rings fused together wherein at least one of the fused rings is a heteroaromatic ring and wherein the multiple rings are attached to the parent molecular moiety through any atom contained within a heteroaromatic ring of the multiple rings). A 5,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. Likewise, a 6,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. And a 6,5-fused ring heteroarylene refers to two rings fused together, wherein one ring has 6 members and the other ring has 5 members, and wherein at least one ring is a heteroaryl ring. A heteroaryl group can be attached to the remainder of the molecule through a carbon or heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, naphthyl, pyrrolyl, pyrazolyl, pyridazinyl, triazinyl, pyrimidinyl, imidazolyl, pyrazinyl, purinyl, oxazolyl, isoxazolyl, thiazolyl, furyl, thienyl, pyridyl, pyrimidyl, benzothiazolyl, benzooxazoyl benzimidazolyl, benzofuran, isobenzofuranyl, indolyl, isoindolyl, benzothiophenyl, isoquinolyl, quinoxalinyl, quinolyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl, pyrazinyl, 2-oxazolyl, 4-oxazolyl, 2-phenyl-4-oxazolyl, 5-oxazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-indolyl, 1-isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below. An “arylene” and a “heteroarylene,” alone or as part of another substituent, mean a divalent radical derived from an aryl and heteroaryl, respectively. A heteroaryl group substituent may be —O— bonded to a ring heteroatom nitrogen.
Spirocyclic rings are two or more rings wherein adjacent rings are attached through a single atom. The individual rings within spirocyclic rings may be identical or different. Individual rings in spirocyclic rings may be substituted or unsubstituted and may have different substituents from other individual rings within a set of spirocyclic rings. Possible substituents for individual rings within spirocyclic rings are the possible substituents for the same ring when not part of spirocyclic rings (e.g., substituents for cycloalkyl or heterocycloalkyl rings). Spirocyclic rings may be substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heterocycloalkylene and individual rings within a spirocyclic ring group may be any of the immediately previous list, including having all rings of one type (e.g., all rings being substituted heterocycloalkylene wherein each ring may be the same or different substituted heterocycloalkylene). When referring to a spirocyclic ring system, heterocyclic spirocyclic rings means a spirocyclic rings wherein at least one ring is a heterocyclic ring and wherein each ring may be a different ring. When referring to a spirocyclic ring system, substituted spirocyclic rings means that at least one ring is substituted and each substituent may optionally be different.
The symbol “” denotes the point of attachment of a chemical moiety to the remainder of a molecule or chemical formula.
The term “oxo,” as used herein, means an oxygen that is double bonded to a carbon atom.
The term “alkylarylene” as an arylene moiety covalently bonded to an alkylene moiety (also referred to herein as an alkylene linker). In embodiments, the alkylarylene group has the formula:
An alkylarylene moiety may be substituted (e.g., with a substituent group) on the alkylene moiety or the arylene linker (e.g., at carbons 2, 3, 4, or 6) with halogen, oxo, —N3, —CF3, —CCl3, —CBr3, —CI3, —CN, —CHO, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO2CH3, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, substituted or unsubstituted C1-C8 alkyl or substituted or unsubstituted 2 to 5 membered heteroalkyl). In embodiments, the alkylarylene is unsubstituted.
Each of the above terms (e.g., “alkyl,” “heteroalkyl,” “cycloalkyl,” “heterocycloalkyl,” “aryl,” and “heteroaryl”) includes both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.
Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or more of a variety of groups selected from, but not limited to, —OR′, ═O, ═NR′, ═N—OR′, —NR′R″, —SR′, halogen, —SiR′R″R′″, —OC(O)R′, —C(O)R′, —CO2R′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′, —NR′C(O)NR″R′″, —NR″C(O)2R′, —NRC(NR′R″R′″)═NR″″, —NRC(NR′R″)═NR′″, —S(O)R′, —S(O)2R′, —S(O)2NR′R″, —NRSO2R′, —NR′NR″R′″, —ONR′R″, —NR′C(O)NR″NR′″R″″, —CN, —NO2, —NR′SO2R″, —NR′C(O)R″, —NR′C(O)OR″, —NR′OR″, in a number ranging from zero to (2m′+1), where m′ is the total number of carbon atoms in such radical. R, R′, R″, R′″, and R″″ each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, alkoxy, or thioalkoxy groups, or arylalkyl groups. When a compound described herein includes more than one R group, for example, each of the R groups is independently selected as are each R′, R″, R′″, and R″″ group when more than one of these groups is present. When R′ and R″ are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example, —NR′R″ includes, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term “alkyl” is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl (e.g., —CF3 and —CH2CF3) and acyl (e.g., —C(O)CH3, —C(O)CF3, —C(O)CH2OCH3, and the like).
Similar to the substituents described for the alkyl radical, substituents for the aryl and heteroaryl groups are varied and are selected from, for example: —OR′, —NR′R″, —SR′, halogen, —SiR′R″R′″, —OC(O)R′, —C(O)R′, —CO2R′, —CONR′R″, —OC(O)NR′R″, —NR″C(O)R′, —NR′C(O)NR″R′″, —NR″C(O)2R′, —NR—C(NR′R″R′″)═NR″″, —NR—C(NR′R″)═NR′″, —S(O)R′, —S(O)2R′, —S(O)2NR′R″, —NRSO2R′, —NR′NR″R′″, —ONR′R″, —NR′C(O)NR″NR′″R″″, —CN, —NO2, —R′, —N3, —CH(Ph)2, fluoro(C1-C4)alkoxy, and fluoro(C1-C4)alkyl, —NR′SO2R″, —NR′C(O)R″, —NR′C(O)OR″, —NR′OR″, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R′, R″, R′″, and R″″ are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. When a compound described herein includes more than one R group, for example, each of the R groups is independently selected as are each R′, R″, R′″, and R″″ groups when more than one of these groups is present.
Substituents for rings (e.g., cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylene, heterocycloalkylene, arylene, or heteroarylene) may be depicted as substituents on the ring rather than on a specific atom of a ring (commonly referred to as a floating substituent). In such a case, the substituent may be attached to any of the ring atoms (obeying the rules of chemical valency) and in the case of fused rings or spirocyclic rings, a substituent depicted as associated with one member of the fused rings or spirocyclic rings (a floating substituent on a single ring), may be a substituent on any of the fused rings or spirocyclic rings (a floating substituent on multiple rings). When a substituent is attached to a ring, but not a specific atom (a floating substituent), and a subscript for the substituent is an integer greater than one, the multiple substituents may be on the same atom, same ring, different atoms, different fused rings, different spirocyclic rings, and each substituent may optionally be different. Where a point of attachment of a ring to the remainder of a molecule is not limited to a single atom (a floating substituent), the attachment point may be any atom of the ring and in the case of a fused ring or spirocyclic ring, any atom of any of the fused rings or spirocyclic rings while obeying the rules of chemical valency. Where a ring, fused rings, or spirocyclic rings contain one or more ring heteroatoms and the ring, fused rings, or spirocyclic rings are shown with one more floating substituents (including, but not limited to, points of attachment to the remainder of the molecule), the floating substituents may be bonded to the heteroatoms. Where the ring heteroatoms are shown bound to one or more hydrogens (e.g., a ring nitrogen with two bonds to ring atoms and a third bond to a hydrogen) in the structure or formula with the floating substituent, when the heteroatom is bonded to the floating substituent, the substituent will be understood to replace the hydrogen, while obeying the rules of chemical valency.
Two or more substituents may optionally be joined to form aryl, heteroaryl, cycloalkyl, or heterocycloalkyl groups. Such so-called ring-forming substituents are typically, though not necessarily, found attached to a cyclic base structure. In one embodiment, the ring-forming substituents are attached to adjacent members of the base structure. For example, two ring-forming substituents attached to adjacent members of a cyclic base structure create a fused ring structure. In another embodiment, the ring-forming substituents are attached to a single member of the base structure. For example, two ring-forming substituents attached to a single member of a cyclic base structure create a spirocyclic structure. In yet another embodiment, the ring-forming substituents are attached to non-adjacent members of the base structure.
Two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally form a ring of the formula -T-C(O)—(CRR′)q—U—, wherein T and U are independently —NR—, —O—, —CRR′—, or a single bond, and q is an integer of from 0 to 3. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH2)r—B—, wherein A and B are independently —CRR′—, —O—, —NR—, —S—, —S(O)—, —S(O)2—, —S(O)2NR′—, or a single bond, and r is an integer of from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula —(CRR′)s—X′—(C″R″R′″)d—, where s and d are independently integers of from 0 to 3, and X′ is —O—, —NR′—, —S—, —S(O)—, —S(O)2—, or —S(O)2NR′—. The substituents R, R′, R″, and R′″ are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
As used herein, the terms “heteroatom” or “ring heteroatom” are meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), selenium (Se), and silicon (Si). In embodiments, the terms “heteroatom” or “ring heteroatom” are meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).
A “substituent group,” as used herein, means a group selected from the following moieties:
A “size-limited substituent” or “size-limited substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C20 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C10 aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl.
A “lower substituent” or “lower substituent group,” as used herein, means a group selected from all of the substituents described above for a “substituent group,” wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C10 aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl.
In some embodiments, each substituted group described in the compounds herein is substituted with at least one substituent group. More specifically, in some embodiments, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene described in the compounds herein are substituted with at least one substituent group. In other embodiments, at least one or all of these groups are substituted with at least one size-limited substituent group. In other embodiments, at least one or all of these groups are substituted with at least one lower substituent group.
In other embodiments of the compounds herein, each substituted or unsubstituted alkyl may be a substituted or unsubstituted C1-C20 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C10 aryl, and/or each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 10 membered heteroaryl. In some embodiments of the compounds herein, each substituted or unsubstituted alkylene is a substituted or unsubstituted C1-C20 alkylene, each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 20 membered heteroalkylene, each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C8 cycloalkylene, each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 8 membered heterocycloalkylene, each substituted or unsubstituted arylene is a substituted or unsubstituted C6-C10 arylene, and/or each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 10 membered heteroarylene.
In some embodiments, each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2 to 8 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3 to 7 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C10 aryl, and/or each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5 to 9 membered heteroaryl. In some embodiments, each substituted or unsubstituted alkylene is a substituted or unsubstituted C1-C8 alkylene, each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2 to 8 membered heteroalkylene, each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C7 cycloalkylene, each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3 to 7 membered heterocycloalkylene, each substituted or unsubstituted arylene is a substituted or unsubstituted C6-C10 arylene, and/or each substituted or unsubstituted heteroarylene is a substituted or unsubstituted 5 to 9 membered heteroarylene. In some embodiments, the compound is a chemical species set forth in the Examples section, figures, or tables below.
In embodiments, a substituted or unsubstituted moiety (e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and/or substituted or unsubstituted heteroarylene) is unsubstituted (e.g., is an unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, unsubstituted alkylene, unsubstituted heteroalkylene, unsubstituted cycloalkylene, unsubstituted heterocycloalkylene, unsubstituted arylene, and/or unsubstituted heteroarylene, respectively). In embodiments, a substituted or unsubstituted moiety (e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and/or substituted or unsubstituted heteroarylene) is substituted (e.g., is a substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene, respectively).
In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, wherein if the substituted moiety is substituted with a plurality of substituent groups, each substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of substituent groups, each substituent group is different.
In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one size-limited substituent group, wherein if the substituted moiety is substituted with a plurality of size-limited substituent groups, each size-limited substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of size-limited substituent groups, each size-limited substituent group is different.
In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one lower substituent group, wherein if the substituted moiety is substituted with a plurality of lower substituent groups, each lower substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of lower substituent groups, each lower substituent group is different.
In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted moiety is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, if the substituted moiety is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group is different.
In a recited claim or chemical formula description herein, each R substituent or L linker that is described as being “substituted” without reference as to the identity of any chemical moiety that composes the “substituted” group (also referred to herein as an “open substitution” on an R substituent or L linker or an “openly substituted” R substituent or L linker), the recited R substituent or L linker may, in embodiments, be substituted with one or more first substituent groups as defined below.
The first substituent group is denoted with a corresponding first decimal point numbering system such that, for example, R1 may be substituted with one or more first substituent groups denoted by R1.1, R2 may be substituted with one or more first substituent groups denoted by R2.1, R3 may be substituted with one or more first substituent groups denoted by R3.1, R4 may be substituted with one or more first substituent groups denoted by R4.1, R5 may be substituted with one or more first substituent groups denoted by R5.1, and the like up to or exceeding an R100 that may be substituted with one or more first substituent groups denoted by R100.1. As a further example, R1A may be substituted with one or more first substituent groups denoted by R1A.1, R2A may be substituted with one or more first substituent groups denoted by R2A.1, R3A may be substituted with one or more first substituent groups denoted by RA.1, R4A may be substituted with one or more first substituent groups denoted by R4A.1, R5A may be substituted with one or more first substituent groups denoted by R5A.1 and the like up to or exceeding an R100A may be substituted with one or more first substituent groups denoted by R100A.1. As a further example, L1 may be substituted with one or more first substituent groups denoted by RL1.1, L2 may be substituted with one or more first substituent groups denoted by RL2.1, L3 may be substituted with one or more first substituent groups denoted by RL3.1, L4 may be substituted with one or more first substituent groups denoted by RL4.1, L5 may be substituted with one or more first substituent groups denoted by RL5.1 and the like up to or exceeding an L100 which may be substituted with one or more first substituent groups denoted by RL100.1. Thus, each numbered R group or L group (alternatively referred to herein as RWW or LWW wherein “WW” represents the stated superscript number of the subject R group or L group) described herein may be substituted with one or more first substituent groups referred to herein generally as RWW.1 or RLWW.1, respectively. In turn, each first substituent group (e.g., R1.1, R2.1, R3.1, R4.1, R5.1 . . . R100.1; R1A.1, R2A.1, R3A.1, R4A.1, R5A.1 . . . R100A.1; RL1.1, RL2.1, RL3.1, RL4.1, RL5.1 . . . RL100.1) may be further substituted with one or more second substituent groups (e.g., R1.2, R2.2, R3.2, R4.2, R5.2 . . . R100.2; R1A.2, R2A.2, R3A.2, R4A.2, R5A.2 . . . R100A.2; RL1.2, RL2.2, RL3.2, RL4.2, RL5.2 . . . RL100.2, respectively). Thus, each first substituent group, which may alternatively be represented herein as RWW.1 as described above, may be further substituted with one or more second substituent groups, which may alternatively be represented herein as RWW.2.
Finally, each second substituent group (e.g., R1.2, R2.2, R3.2, R4.2, R5.2 . . . R100.2; R1A.2, R2A.2, R3A.2, R4A.2, R5A.2 . . . R100A.2; RL1.2, RL2.2, RL3.2, RL4.2, RL5.2 . . . RL100.2) may be further substituted with one or more third substituent groups (e.g., R1.3, R2.3, R3.3, R4.3, R5.3 . . . R100.3; R1A.3, R2A.3, R3A.3, R4A.3, R5A.3 . . . R100A.3; RL1.3, RL2.3, RL3.3, RL4.3, RL5.3, RL100.3; respectively). Thus, each second substituent group, which may alternatively be represented herein as RWW.2 as described above, may be further substituted with one or more third substituent groups, which may alternatively be represented herein as RWW.3. Each of the first substituent groups may be optionally different. Each of the second substituent groups may be optionally different. Each of the third substituent groups may be optionally different.
Thus, as used herein, RWW represents a substituent recited in a claim or chemical formula description herein which is openly substituted. “WW” represents the stated superscript number of the subject R group (1, 2, 3, 1A, 2A, 3A, 1B, 2B, 3B, etc.). Likewise, LWW is a linker recited in a claim or chemical formula description herein which is openly substituted. Again, “WW” represents the stated superscript number of the subject L group (1, 2, 3, 1A, 2A, 3A, 1B, 2B, 3B, etc.). As stated above, in embodiments, each RWW may be unsubstituted or independently substituted with one or more first substituent groups, referred to herein as RWW.1; each first substituent group, RWW.1, may be unsubstituted or independently substituted with one or more second substituent groups, referred to herein as RWW.2; and each second substituent group may be unsubstituted or independently substituted with one or more third substituent groups, referred to herein as RWW.3. Similarly, each LWW linker may be unsubstituted or independently substituted with one or more first substituent groups, referred to herein as RLWW.1; each first substituent group, RLWW.1, may be unsubstituted or independently substituted with one or more second substituent groups, referred to herein as RLWW.2; and each second substituent group may be unsubstituted or independently substituted with one or more third substituent groups, referred to herein as RLWW.3. Each first substituent group is optionally different. Each second substituent group is optionally different. Each third substituent group is optionally different. For example, if RWW is phenyl, the said phenyl group is optionally substituted by one or more RWW.1 groups as defined herein below, e.g., when RWW.1 is RWW.2-substituted or unsubstituted alkyl, examples of groups so formed include but are not limited to itself optionally substituted by 1 or more RWW.2, which RWW.2 is optionally substituted by one or more RWW.3. By way of example when the RWW group is phenyl substituted by RWW.1, which is methyl, the methyl group may be further substituted to form groups including but not limited to:
RWW.1 is independently oxo, halogen, —CXWW.13, —CHXWW.12, —CH2XWW.1, —OCXWW.13, —OCH2XWW.1, —OCHXWW.12, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —N3, RWW.2-substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), RWW.2-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), RWW.2-substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), RWW.2-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), RWW.2-substituted or unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or RWW.2-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, RWW.1 is independently oxo, halogen, —CXWW.13, —CHXWW.12, —CH2XWW.1, —OCXWW.13, —OCH2XWW.1, —OCHXWW.12, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NH4NH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —N3, unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). XWW.1 is independently —F, —Cl, —Br, or —I.
RWW.2 is independently oxo, halogen, —CXWW.23, —CHXWW.22, —CH2XWW.2, —OCXWW.23, —OCH2XWW.2, —OCHXWW.22, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —N3, RWW.3-substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), RWW.3-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), RWW.3-substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), RWW.3-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), RWW.3-substituted or unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or RWW.3-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, RWW.2 is independently oxo, halogen, —CXWW.23, —CHXWW.22, —CH2XWW.2, —OCXWW.23, —OCH2XWW.2, —OCHXWW.22, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NH4NH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —N3, unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). XWW.2 is independently —F, —Cl, —Br, or —I.
RWW.3 is independently oxo, halogen, —CXWW.33, —CHXWW.32, —CH2XWW.3, —OCXWW.33, —OCH2XWW.3, —OCHXWW.32, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —N3, unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). XWW.3 is independently —F, —Cl, —Br, or —I.
Where two different RWW substituents are joined together to form an openly substituted ring (e.g., substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl or substituted heteroaryl), in embodiments the openly substituted ring may be independently substituted with one or more first substituent groups, referred to herein as RWW.1; each first substituent group, RWW.1, may be unsubstituted or independently substituted with one or more second substituent groups, referred to herein as RWW.2; and each second substituent group, RWW.2, may be unsubstituted or independently substituted with one or more third substituent groups, referred to herein as RWW.3; and each third substituent group, RWW.3, is unsubstituted. Each first substituent group is optionally different. Each second substituent group is optionally different. Each third substituent group is optionally different. In the context of two different RWW substituents joined together to form an openly substituted ring, the “WW” symbol in the RWW.1, RWW.2 and RWW.3 refers to the designated number of one of the two different RWW substituents. For example, in embodiments where R100A and R100B are optionally joined together to form an openly substituted ring, RWW.1 is R100A.1, RWW.2 is R100A.2, and RWW.3 is R100A.3. Alternatively, in embodiments where R100A and R100B are optionally joined together to form an openly substituted ring, RWW.1 is R100B.1, RWW.2 is R100B.2, and RWW.3 is R100B.3. RWW.1, RWW.2 and RWW.3 in this paragraph are as defined in the preceding paragraphs.
RLWW.1 is independently oxo, halogen, —CXLWW.13, —CHXLWW.12, —CH2XLWW.1, —OCXLWW.13, —OCH2XLWW.1, —OCHXLWW.12, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —N3, RLWW.2-substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), RLWW.2-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), RLWW.2-substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), RLWW.2-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), RLWW.2-substituted or unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or RLWW.2-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, RLWW.1 is independently oxo, halogen, —CXLWW.13, —CHXLWW.12, —CH2XLWW.1, —OCXLWW.13, —OCH2XLWW.1, —OCHXLWW.12, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —N3, unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). XLWW.1 is independently —F, —Cl, —Br, or —I.
RLWW.2 is independently oxo, halogen, —CXLWW.23, —CHXLWW.22, —CH2XLWW.2—OCXLWW.23, —OCH2XLWW.2, —OCHXLWW.22, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —N3, RLWW.3-substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), RLWW.3-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), RWW.3-substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), RLWW.3-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), RLWW.3-substituted or unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or RLWW.3-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). In embodiments, RLWW.2 is independently oxo, halogen, —CXLWW.23, —CHXLWW.22, —CH2XLWW.2, —OCXLWW.23, —OCH2XLWW.2, —OCHXLWW.22, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —N3, unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). XLWW.2 is independently —F, —Cl, —Br, or —I.
RLWW.3 is independently oxo, halogen, —CXLWW.33, —CHXLWW.32, —CH2XLWW.3, —OCXLWW.33, —OCH2XLWW.3, —OCHXLWW.32, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —N3, unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). XLWW.3 is independently —F, —Cl, —Br, or —I.
In the event that any R group recited in a claim or chemical formula description set forth herein (RWW substituent) is not specifically defined in this disclosure, then that R group (RWW group) is hereby defined as independently oxo, halogen, —CXWW3, —CHXWW2, —CH2XWW, —OCXWW3, —OCH2XWW, —OCHXWW2, —CN, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —N3, RWW.1-substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), RWW.1-substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), RWW.1-substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), RWW.1-substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), RWW.1-substituted or unsubstituted aryl (e.g., C6-C12, C6-C10, or phenyl), or RWW.1-substituted or unsubstituted heteroaryl (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). XWW is independently —F, —Cl, —Br, or —I. Again, “WW” represents the stated superscript number of the subject R group (e.g., 1, 2, 3, 1A, 2A, 3A, 1B, 2B, 3B, etc.). RWW.1, RWW.2, and RWW.3 are as defined above.
In the event that any L linker group recited in a claim or chemical formula description set forth herein (i.e., an LWW substituent) is not explicitly defined, then that L group (LWW group) is herein defined as independently a bond, —O—, —NH—, —C(O)—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, —S—, —SO2—, —SO2NH—, RLWW.1-substituted or unsubstituted alkylene (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), RLWW.1-substituted or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), RLWW.1-substituted or unsubstituted cycloalkylene (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), RLWW.1-substituted or unsubstituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), RLWW.1-substituted or unsubstituted arylene (e.g., C6-C12, C6-C10, or phenyl), or RLWW.1-substituted or unsubstituted heteroarylene (e.g., 5 to 12 membered, 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered). Again, “WW” represents the stated superscript number of the subject L group (1, 2, 3, 1A, 2A, 3A, 1B, 2B, 3B, etc.). RLWW.1, as well as RLWW.2 and RLWW.3 are as defined above.
Certain compounds of the present disclosure possess asymmetric carbon atoms (optical or chiral centers) or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids, and individual isomers are encompassed within the scope of the present disclosure. The compounds of the present disclosure do not include those that are known in art to be too unstable to synthesize and/or isolate. The present disclosure is meant to include compounds in racemic and optically pure forms. Optically active (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.
As used herein, the term “isomers” refers to compounds having the same number and kind of atoms, and hence the same molecular weight, but differing in respect to the structural arrangement or configuration of the atoms.
The term “tautomer,” as used herein, refers to one of two or more structural isomers which exist in equilibrium and which are readily converted from one isomeric form to another.
It will be apparent to one skilled in the art that certain compounds of this disclosure may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the disclosure.
Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the disclosure.
Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13C- or 14C-enriched carbon are within the scope of this disclosure.
The compounds of the present disclosure may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (3H), iodine-125 (125I), or carbon-14 (14C). All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are encompassed within the scope of the present disclosure.
It should be noted that throughout the application that alternatives are written in Markush groups, for example, each amino acid position that contains more than one possible amino acid. It is specifically contemplated that each member of the Markush group should be considered separately, thereby comprising another embodiment, and the Markush group is not to be read as a single unit.
As used herein, the terms “bioconjugate” and “bioconjugate linker” refer to the resulting association between atoms or molecules of bioconjugate reactive groups or bioconjugate reactive moieties. The association can be direct or indirect. For example, a conjugate between a first bioconjugate reactive group (e.g., —NH2, —COOH, —N-hydroxysuccinimide, or -maleimide) and a second bioconjugate reactive group (e.g., sulfhydryl, sulfur-containing amino acid, amine, amine sidechain containing amino acid, or carboxylate) provided herein can be direct, e.g., by covalent bond or linker (e.g., a first linker of second linker), or indirect, e.g., by non-covalent bond (e.g., electrostatic interactions (e.g., ionic bond, hydrogen bond, halogen bond), van der Waals interactions (e.g., dipole-dipole, dipole-induced dipole, London dispersion), ring stacking (pi effects), hydrophobic interactions and the like). In embodiments, bioconjugates or bioconjugate linkers are formed using bioconjugate chemistry (i.e., the association of two bioconjugate reactive groups) including, but are not limited to nucleophilic substitutions (e.g., reactions of amines and alcohols with acyl halides, active esters), electrophilic substitutions (e.g., enamine reactions) and additions to carbon-carbon and carbon-heteroatom multiple bonds (e.g., Michael reaction, Diels-Alder addition). These and other useful reactions are discussed in, for example, March, ADVANCED ORGANIC CHEMISTRY, 3rd Ed., John Wiley & Sons, New York, 1985; Hermanson, BIOCONJUGATE TECHNIQUES, Academic Press, San Diego, 1996; and Feeney et al., MODIFICATION OF PROTEINS; Advances in Chemistry Series, Vol. 198, American Chemical Society, Washington, D.C., 1982. In embodiments, the first bioconjugate reactive group (e.g., maleimide moiety) is covalently attached to the second bioconjugate reactive group (e.g., a sulfhydryl). In embodiments, the first bioconjugate reactive group (e.g., haloacetyl moiety) is covalently attached to the second bioconjugate reactive group (e.g., a sulfhydryl). In embodiments, the first bioconjugate reactive group (e.g., pyridyl moiety) is covalently attached to the second bioconjugate reactive group (e.g., a sulfhydryl). In embodiments, the first bioconjugate reactive group (e.g., —N-hydroxysuccinimide moiety) is covalently attached to the second bioconjugate reactive group (e.g., an amine). In embodiments, the first bioconjugate reactive group (e.g., maleimide moiety) is covalently attached to the second bioconjugate reactive group (e.g., a sulfhydryl). In embodiments, the first bioconjugate reactive group (e.g., -sulfo-N-hydroxysuccinimide moiety) is covalently attached to the second bioconjugate reactive group (e.g., an amine).
Useful bioconjugate reactive moieties used for bioconjugate chemistries herein include, for example: (a) carboxyl groups and various derivatives thereof including, but not limited to, N-hydroxysuccinimide esters, N-hydroxybenzotriazole esters, acid halides, acyl imidazoles, thioesters, p-nitrophenyl esters, alkyl, alkenyl, alkynyl and aromatic esters; (b) hydroxyl groups which can be converted to esters, ethers, aldehydes, etc.; (c) haloalkyl groups wherein the halide can be later displaced with a nucleophilic group such as, for example, an amine, a carboxylate anion, thiol anion, carbanion, or an alkoxide ion, thereby resulting in the covalent attachment of a new group at the site of the halogen atom; (d) dienophile groups which are capable of participating in Diels-Alder reactions such as, for example, maleimido or maleimide groups; (e) aldehyde or ketone groups such that subsequent derivatization is possible via formation of carbonyl derivatives such as, for example, imines, hydrazones, semicarbazones or oximes, or via such mechanisms as Grignard addition or alkyllithium addition; (f) sulfonyl halide groups for subsequent reaction with amines, for example, to form sulfonamides; (g) thiol groups, which can be converted to disulfides, reacted with acyl halides, or bonded to metals such as gold, or react with maleimides; (h) amine or sulfhydryl groups (e.g., present in cysteine), which can be, for example, acylated, alkylated or oxidized; (i) alkenes, which can undergo, for example, cycloadditions, acylation, Michael addition, etc.; (j) epoxides, which can react with, for example, amines and hydroxyl compounds; (k) phosphoramidites and other standard functional groups useful in nucleic acid synthesis; (l) metal silicon oxide bonding; (m) metal bonding to reactive phosphorus groups (e.g., phosphines) to form, for example, phosphate diester bonds; (n) azides coupled to alkynes using copper catalyzed cycloaddition click chemistry; and (o) biotin conjugate can react with avidin or streptavidin to form a avidin-biotin complex or streptavidin-biotin complex.
The bioconjugate reactive groups can be chosen such that they do not participate in, or interfere with, the chemical stability of the conjugate described herein. Alternatively, a reactive functional group can be protected from participating in the crosslinking reaction by the presence of a protecting group. In embodiments, the bioconjugate comprises a molecular entity derived from the reaction of an unsaturated bond, such as a maleimide, and a sulfhydryl group.
“Analog,” “analogue,” or “derivative” is used in accordance with its plain ordinary meaning within Chemistry and Biology and refers to a chemical compound that is structurally similar to another compound (i.e., a so-called “reference” compound) but differs in composition, e.g., in the replacement of one atom by an atom of a different element, or in the presence of a particular functional group, or the replacement of one functional group by another functional group, or the absolute stereochemistry of one or more chiral centers of the reference compound. Accordingly, an analog is a compound that is similar or comparable in function and appearance but not in structure or origin to a reference compound.
The terms “a” or “an”, as used in herein means one or more. In addition, the phrase “substituted with a[n]”, as used herein, means the specified group may be substituted with one or more of any or all of the named substituents. For example, where a group, such as an alkyl or heteroaryl group, is “substituted with an unsubstituted C1-C20 alkyl, or unsubstituted 2 to 20 membered heteroalkyl”, the group may contain one or more unsubstituted C1-C20 alkyls, and/or one or more unsubstituted 2 to 20 membered heteroalkyls.
Moreover, where a moiety is substituted with an R substituent, the group may be referred to as “R-substituted.” Where a moiety is R-substituted, the moiety is substituted with at least one R substituent and each R substituent is optionally different. Where a particular R group is present in the description of a chemical genus (such as Formula (I)), a Roman alphabetic symbol may be used to distinguish each appearance of that particular R group. For example, where multiple R13 substituents are present, each R13 substituent may be distinguished as R13A, R13B, R13C, R13D, etc., wherein each of R13A, R13B, R13C, R13D, etc. is defined within the scope of the definition of R13 and optionally differently.
Descriptions of compounds of the present disclosure are limited by principles of chemical bonding known to those skilled in the art. Accordingly, where a group may be substituted by one or more of a number of substituents, such substitutions are selected so as to comply with principles of chemical bonding and to give compounds which are not inherently unstable and/or would be known to one of ordinary skill in the art as likely to be unstable under ambient conditions, such as aqueous, neutral, and several known physiological conditions. For example, a heterocycloalkyl or heteroaryl is attached to the remainder of the molecule via a ring heteroatom in compliance with principles of chemical bonding known to those skilled in the art thereby avoiding inherently unstable compounds.
The term “pharmaceutically acceptable salts” is meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present disclosure contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present disclosure contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, oxalic, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present disclosure contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
Thus, the compounds of the present disclosure may exist as salts, such as with pharmaceutically acceptable acids. The present disclosure includes such salts. Non-limiting examples of such salts include hydrochlorides, hydrobromides, phosphates, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, propionates, tartrates (e.g., (+)-tartrates, (−)-tartrates, or mixtures thereof including racemic mixtures), succinates, benzoates, and salts with amino acids such as glutamic acid, and quaternary ammonium salts (e.g., methyl iodide, ethyl iodide, and the like). These salts may be prepared by methods known to those skilled in the art.
The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound may differ from the various salt forms in certain physical properties, such as solubility in polar solvents.
In addition to salt forms, the present disclosure provides compounds, which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present disclosure. Prodrugs of the compounds described herein may be converted in vivo after administration. Additionally, prodrugs can be converted to the compounds of the present disclosure by chemical or biochemical methods in an ex vivo environment, such as, for example, when contacted with a suitable enzyme or chemical reagent.
Certain compounds of the present disclosure can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present disclosure. Certain compounds of the present disclosure may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present disclosure and are intended to be within the scope of the present disclosure.
A polypeptide, or a cell is “recombinant” when it is artificial or engineered, or derived from or contains an artificial or engineered protein or nucleic acid (e.g., non-natural or not wild type). For example, a polynucleotide that is inserted into a vector or any other heterologous location, e.g., in a genome of a recombinant organism, such that it is not associated with nucleotide sequences that normally flank the polynucleotide as it is found in nature is a recombinant polynucleotide. A protein expressed in vitro or in vivo from a recombinant polynucleotide is an example of a recombinant polypeptide. Likewise, a polynucleotide sequence that does not appear in nature, for example a variant of a naturally occurring gene, is recombinant.
“Co-administer” is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies. The compounds of the invention can be administered alone or can be co-administered to the patient. Co-administration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound). Thus, the preparations can also be combined, when desired, with other active substances (e.g., to reduce metabolic degradation).
A “cell” as used herein, refers to a cell carrying out metabolic or other function sufficient to preserve or replicate its genomic DNA. A cell can be identified by well-known methods in the art including, for example, presence of an intact membrane, staining by a particular dye, ability to produce progeny or, in the case of a gamete, ability to combine with a second gamete to produce a viable offspring. Cells may include prokaryotic and eukaryotic cells. Prokaryotic cells include but are not limited to bacteria. Eukaryotic cells include but are not limited to yeast cells and cells derived from plants and animals, for example mammalian, insect (e.g., Spodoptera) and human cells. Cells may be useful when they are naturally nonadherent or have been treated not to adhere to surfaces, for example by trypsinization.
The terms “treating” or “treatment” refers to any indicia of success in the treatment or amelioration of an injury, disease, pathology or condition, including any objective or subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient's physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters; including the results of a physical examination, neuropsychiatric exams, and/or a psychiatric evaluation. For example, the certain methods presented herein successfully treat cancer by decreasing the incidence of cancer and or causing remission of cancer. In some embodiments of the compositions or methods described herein, treating cancer includes slowing the rate of growth or spread of cancer cells, reducing metastasis, or reducing the growth of metastatic tumors. The term “treating” and conjugations thereof, include prevention of an injury, pathology, condition, or disease. In embodiments, treating is preventing. In embodiments, treating does not include preventing. In embodiments, the treating or treatment is no prophylactic treatment.
An “effective amount” is an amount sufficient for a compound to accomplish a stated purpose relative to the absence of the compound (e.g., achieve the effect for which it is administered, treat a disease, reduce enzyme activity, increase enzyme activity, reduce signaling pathway, reduce one or more symptoms of a disease or condition. An example of an “effective amount” is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a “therapeutically effective amount” when referred to in this context. A “reduction” of a symptom or symptoms (and grammatical equivalents of this phrase) means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s). A “prophylactically effective amount” of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or condition, or their symptoms. The full prophylactic effect does not necessarily occur by administration of one dose, and may occur only after administration of a series of doses. Thus, a prophylactically effective amount may be administered in one or more administrations. An “activity decreasing amount,” as used herein, refers to an amount of antagonist required to decrease the activity of an enzyme relative to the absence of the antagonist. A “function disrupting amount,” as used herein, refers to the amount of antagonist required to disrupt the function of an enzyme or protein relative to the absence of the antagonist. An “activity increasing amount,” as used herein, refers to an amount of agonist required to increase the activity of an enzyme relative to the absence of the agonist. A “function increasing amount,” as used herein, refers to the amount of agonist required to increase the function of an enzyme or protein relative to the absence of the agonist. The exact amounts will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).
“Control” or “control experiment” is used in accordance with its plain ordinary meaning and refers to an experiment in which the subjects or reagents of the experiment are treated as in a parallel experiment except for omission of a procedure, reagent, or variable of the experiment. In some instances, the control is used as a standard of comparison in evaluating experimental effects. In some embodiments, a control is the measurement of the activity (e.g., signaling pathway) of a protein in the absence of a compound as described herein (including embodiments, examples, figures, or Tables).
“Contacting” is used in accordance with its plain ordinary meaning and refers to the process of allowing at least two distinct species (e.g., chemical compounds including biomolecules, or cells) to become sufficiently proximal to react, interact or physically touch. It should be appreciated; however, the resulting reaction product can be produced directly from a reaction between the added reagents or from an intermediate from one or more of the added reagents which can be produced in the reaction mixture.
The term “contacting” may include allowing two species to react, interact, or physically touch, wherein the two species may be a compound as described herein and a cellular component (e.g., protein, ion, lipid, nucleic acid, nucleotide, amino acid, protein, particle, organelle, cellular compartment, microorganism, virus, lipid droplet, vesicle, small molecule, protein complex, protein aggregate, or macromolecule). In some embodiments contacting includes allowing a compound described herein to interact with a cellular component (e.g., protein, ion, lipid, nucleic acid, nucleotide, amino acid, protein, particle, virus, lipid droplet, organelle, cellular compartment, microorganism, vesicle, small molecule, protein complex, protein aggregate, or macromolecule) that is involved in a signaling pathway.
As defined herein, the term “activation,” “activate,” “activating” and the like in reference to a protein refers to conversion of a protein into a biologically active derivative from an initial inactive or deactivated state. The terms reference activation, or activating, sensitizing, or up-regulating signal transduction or enzymatic activity or the amount of a protein decreased in a disease.
The terms “agonist,” “activator,” “upregulator,” etc. refer to a substance capable of detectably increasing the expression or activity of a given gene or protein. The agonist can increase expression or activity by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% in comparison to a control in the absence of the agonist. In certain instances, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or higher than the expression or activity in the absence of the agonist.
As defined herein, the term “inhibition,” “inhibit,” “inhibiting” and the like in reference to a cellular component-inhibitor interaction means negatively affecting (e.g., decreasing) the activity or function of the cellular component (e.g., decreasing the signaling pathway stimulated by a cellular component (e.g., protein, ion, lipid, virus, lipid droplet, nucleic acid, nucleotide, amino acid, protein, particle, organelle, cellular compartment, microorganism, vesicle, small molecule, protein complex, protein aggregate, or macromolecule)), relative to the activity or function of the cellular component in the absence of the inhibitor. In embodiments inhibition means negatively affecting (e.g., decreasing) the concentration or levels of the cellular component relative to the concentration or level of the cellular component in the absence of the inhibitor. In some embodiments, inhibition refers to reduction of a disease or symptoms of disease. In some embodiments, inhibition refers to a reduction in the activity of a signal transduction pathway or signaling pathway (e.g., reduction of a pathway involving the cellular component). Thus, inhibition includes, at least in part, partially or totally blocking stimulation, decreasing, preventing, or delaying activation, or inactivating, desensitizing, or down-regulating the signaling pathway or enzymatic activity or the amount of a cellular component.
The terms “inhibitor,” “repressor,” “antagonist,” or “downregulator” interchangeably refer to a substance capable of detectably decreasing the expression or activity of a given gene or protein. The antagonist can decrease expression or activity by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% in comparison to a control in the absence of the antagonist. In certain instances, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or lower than the expression or activity in the absence of the antagonist.
The term “modulator” refers to a composition that increases or decreases the level of a target molecule or the function of a target molecule or the physical state of the target of the molecule (e.g., a target may be a cellular component (e.g., protein, ion, lipid, virus, lipid droplet, nucleic acid, nucleotide, amino acid, protein, particle, organelle, cellular compartment, microorganism, vesicle, small molecule, protein complex, protein aggregate, or macromolecule)) relative to the absence of the composition.
The term “expression” includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion. Expression can be detected using conventional techniques for detecting protein (e.g., ELISA, Western blotting, flow cytometry, immunofluorescence, immunohistochemistry, etc.).
The term “modulate” is used in accordance with its plain ordinary meaning and refers to the act of changing or varying one or more properties. “Modulation” refers to the process of changing or varying one or more properties. For example, as applied to the effects of a modulator on a target protein, to modulate means to change by increasing or decreasing a property or function of the target molecule or the amount of the target molecule.
“Patient” or “subject in need thereof” refers to a living organism suffering from or prone to a disease or condition that can be treated by administration of a pharmaceutical composition as provided herein. Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals. In some embodiments, a patient is human.
“Disease” or “condition” refer to a state of being or health status of a patient or subject capable of being treated with the compounds or methods provided herein. In some embodiments, the disease is a disease related to (e.g., caused by) a cellular component (e.g., protein, ion, lipid, nucleic acid, nucleotide, amino acid, protein, particle, organelle, cellular compartment, microorganism, vesicle, small molecule, protein complex, protein aggregate, or macromolecule). In embodiments, the disease is a cancer.
As used herein, the term “cancer” refers to all types of cancer, neoplasm or malignant tumors found in mammals (e.g., humans), including leukemia, lymphoma, carcinomas and sarcomas. Exemplary cancers that may be treated with a compound or method provided herein include cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head and neck, liver, kidney, lung, non-small cell lung, melanoma, mesothelioma, ovary, sarcoma, stomach, uterus, medulloblastoma, colorectal cancer, or pancreatic cancer. Additional examples include, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumors, cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, premalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, neoplasms of the endocrine or exocrine pancreas, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, or prostate cancer.
The term “leukemia” refers broadly to progressive, malignant diseases of the blood-forming organs and is generally characterized by a distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemia is generally clinically classified on the basis of (1) the duration and character of the disease-acute or chronic; (2) the type of cell involved; myeloid (myelogenous), lymphoid (lymphogenous), or monocytic; and (3) the increase or non-increase in the number abnormal cells in the blood-leukemic or aleukemic (subleukemic). Exemplary leukemias that may be treated with a compound or method provided herein include, for example, acute nonlymphocytic leukemia, chronic lymphocytic leukemia, acute granulocytic leukemia, chronic granulocytic leukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemic leukemia, a leukocythemic leukemia, basophilic leukemia, blast cell leukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis, embryonal leukemia, eosinophilic leukemia, Gross' leukemia, hairy-cell leukemia, hemoblastic leukemia, hemocytoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphogenous leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblastic leukemia, myelocytic leukemia, myeloid granulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasmacytic leukemia, promyelocytic leukemia, Rieder cell leukemia, Schilling's leukemia, stem cell leukemia, subleukemic leukemia, or undifferentiated cell leukemia.
As used herein, the term “lymphoma” refers to a group of cancers affecting hematopoietic and lymphoid tissues. It begins in lymphocytes, the blood cells that are found primarily in lymph nodes, spleen, thymus, and bone marrow. Two main types of lymphoma are non-Hodgkin lymphoma and Hodgkin's disease. Hodgkin's disease represents approximately 15% of all diagnosed lymphomas. This is a cancer associated with Reed-Sternberg malignant B lymphocytes. Non-Hodgkin's lymphomas (NHL) can be classified based on the rate at which cancer grows and the type of cells involved. There are aggressive (high grade) and indolent (low grade) types of NHL. Based on the type of cells involved, there are B-cell and T-cell NHLs. Exemplary B-cell lymphomas that may be treated with a compound or method provided herein include, but are not limited to, small lymphocytic lymphoma, Mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, extranodal (MALT) lymphoma, nodal (monocytoid B-cell) lymphoma, splenic lymphoma, diffuse large cell B-lymphoma, Burkitt's lymphoma, lymphoblastic lymphoma, immunoblastic large cell lymphoma, or precursor B-lymphoblastic lymphoma. Exemplary T-cell lymphomas that may be treated with a compound or method provided herein include, but are not limited to, cutaneous T-cell lymphoma, peripheral T-cell lymphoma, anaplastic large cell lymphoma, mycosis fungoides, and precursor T-lymphoblastic lymphoma.
The term “sarcoma” generally refers to a tumor which is made up of a substance like the embryonic connective tissue and is generally composed of closely packed cells embedded in a fibrillar or homogeneous substance. Sarcomas that may be treated with a compound or method provided herein include a chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, chorio carcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple pigmented hemorrhagic sarcoma, immunoblastic sarcoma of B cells, lymphoma, immunoblastic sarcoma of T-cells, Jensen's sarcoma, Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, leukosarcoma, malignant mesenchymoma sarcoma, parosteal sarcoma, reticulocytic sarcoma, Rous sarcoma, serocystic sarcoma, synovial sarcoma, or telangiectaltic sarcoma.
The term “melanoma” is taken to mean a tumor arising from the melanocytic system of the skin and other organs. Melanomas that may be treated with a compound or method provided herein include, for example, acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungual melanoma, or superficial spreading melanoma.
The term “carcinoma” refers to a malignant new growth made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. Exemplary carcinomas that may be treated with a compound or method provided herein include, for example, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cystic carcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinoma basocellulare, basaloid carcinoma, basosquamous cell carcinoma, bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogenic carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorionic carcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma, cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum, cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma, carcinoma durum, embryonal carcinoma, encephaloid carcinoma, epidermoid carcinoma, carcinoma epitheliale adenoides, exophytic carcinoma, carcinoma ex ulcere, carcinoma fibrosum, gelatinifori carcinoma, gelatinous carcinoma, giant cell carcinoma, carcinoma gigantocellulare, glandular carcinoma, granulosa cell carcinoma, hair-matrix carcinoma, hematoid carcinoma, hepatocellular carcinoma, Hurthle cell carcinoma, hyaline carcinoma, hypernephroid carcinoma, infantile embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Krompecher's carcinoma, Kulchitzky-cell carcinoma, large-cell carcinoma, lenticular carcinoma, carcinoma lenticulare, lipomatous carcinoma, lymphoepithelial carcinoma, carcinoma medullare, medullary carcinoma, melanotic carcinoma, carcinoma molle, mucinous carcinoma, carcinoma muciparum, carcinoma mucocellulare, mucoepidermoid carcinoma, carcinoma mucosum, mucous carcinoma, carcinoma myxomatodes, nasopharyngeal carcinoma, oat cell carcinoma, carcinoma ossificans, osteoid carcinoma, papillary carcinoma, periportal carcinoma, preinvasive carcinoma, prickle cell carcinoma, pultaceous carcinoma, renal cell carcinoma of kidney, reserve cell carcinoma, carcinoma sarcomatodes, schneiderian carcinoma, scirrhous carcinoma, carcinoma scroti, signet-ring cell carcinoma, carcinoma simplex, small-cell carcinoma, solanoid carcinoma, spheroidal cell carcinoma, spindle cell carcinoma, carcinoma spongiosum, squamous carcinoma, squamous cell carcinoma, string carcinoma, carcinoma telangiectaticum, carcinoma telangiectodes, transitional cell carcinoma, carcinoma tuberosum, tuberous carcinoma, verrucous carcinoma, or carcinoma villosum.
The term “drug” is used in accordance with its common meaning and refers to a substance which has a physiological effect (e.g., beneficial effect, is useful for treating a subject) when introduced into or to a subject (e.g., in or on the body of a subject or patient). A drug moiety is a radical of a drug.
A “detectable agent,” “detectable compound,” “detectable label,” or “detectable moiety” is a substance (e.g., element), molecule, or composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, magnetic resonance imaging, or other physical means. For example, detectable agents include 18F, 32P, 33P, 45Ti, 47Sc, 52Fe, 59Fe, 62Cu, 64Cu, 67Cu, 67Ga, 68Ga, 77As, 86Y, 90Y, 89Sr, 89Zr, 94Tc, 94Tc, 99mTc, 99Mo, 105Pd, 105Rh, 111Ag, 111In, 123I, 124I 125I 131I, 142Pr, 143Pr, 149Pm, 153Sm, 154-1581Gd, 161Tb, 166Dy, 166Ho, 169Er, 175Lu, 177Lu, 186Re, 188Re, 189Re, 194Ir, 198Au, 199Au, 211At, 211Pb, 212Bi, 212Pb, 213Bi, 223Ra, 225Ac, Cr, V, Mn, Fe, Co, Ni, Cu, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, 32P, fluorophore (e.g., fluorescent dyes), modified oligonucleotides (e.g., moieties described in PCT/US2015/022063, which is incorporated herein by reference), electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, paramagnetic molecules, paramagnetic nanoparticles, ultrasmall superparamagnetic iron oxide (“USPIO”) nanoparticles, USPIO nanoparticle aggregates, superparamagnetic iron oxide (“SPIO”) nanoparticles, SPIO nanoparticle aggregates, monocrystalline iron oxide nanoparticles, monocrystalline iron oxide, nanoparticle contrast agents, liposomes or other delivery vehicles containing Gadolinium chelate (“Gd-chelate”) molecules, Gadolinium, radioisotopes, radionuclides (e.g., carbon-11, nitrogen-13, oxygen-15, fluorine-18, rubidium-82), fluorodeoxyglucose (e.g., fluorine-18 labeled), any gamma ray emitting radionuclides, positron-emitting radionuclide, radiolabeled glucose, radiolabeled water, radiolabeled ammonia, biocolloids, microbubbles (e.g., including microbubble shells including albumin, galactose, lipid, and/or polymers; microbubble gas core including air, heavy gas(es), perfluorocarbon, nitrogen, octafluoropropane, perflexane lipid microsphere, perflutren, etc.), iodinated contrast agents (e.g., iohexol, iodixanol, ioversol, iopamidol, ioxilan, iopromide, diatrizoate, metrizoate, ioxaglate), barium sulfate, thorium dioxide, gold, gold nanoparticles, gold nanoparticle aggregates, fluorophores, two-photon fluorophores, or haptens and proteins or other entities which can be made detectable, e.g., by incorporating a radiolabel into a peptide or antibody specifically reactive with a target peptide.
Radioactive substances (e.g., radioisotopes) that may be used as imaging and/or labeling agents in accordance with the embodiments of the disclosure include, but are not limited to, 18F, 32P, 33P, 45Ti, 47Sc, 52Fe, 59Fe, 62Cu, 64Cu, 67Cu, 67Ga, 68Ga, 77As, 86Y, 90Y. 89Sr, 89Zr, 94Tc, 94Tc, 99mTc, 99Mo, 105Pd, 105Rh, 111Ag, 111In, 123I, 124I 125I, 131I, 142Pr, 143Pr, 149Pm, 153Sm, 154-1581Gd, 161Tb, 166Dy, 166Ho, 169Er, 175Lu, 177Lu, 186Re, 188Re, 189Re, 194Ir, 198Au, 199Au, 211At, 211Pb, 212Bi, 212Pb, 213Bi, 223Ra and 225Ac. Paramagnetic ions that may be used as additional imaging agents in accordance with the embodiments of the disclosure include, but are not limited to, ions of transition and lanthanide metals (e.g., metals having atomic numbers of 21-29, 42, 43, 44, or 57-71). These metals include ions of Cr, V, Mn, Fe, Co, Ni, Cu, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, and Lu.
“Pharmaceutically acceptable excipient” and “pharmaceutically acceptable carrier” refer to a substance that aids the administration of an active agent to and absorption by a subject and can be included in the compositions of the present invention without causing a significant adverse toxicological effect on the patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer's, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors, salt solutions (such as Ringer's solution), alcohols, oils, gelatins, carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, polyvinyl pyrrolidine, and colors, and the like. Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like that do not deleteriously react with the compounds of the invention. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present invention.
The term “preparation” is intended to include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
As used herein, the term “about” means a range of values including the specified value, which a person of ordinary skill in the art would consider reasonably similar to the specified value. In embodiments, about means within a standard deviation using measurements generally acceptable in the art. In embodiments, about means a range extending to +/−10% of the specified value. In embodiments, about includes the specified value.
As used herein, the term “administering” means oral administration, administration as a suppository, topical contact, intravenous, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject. Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other modes of delivery include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, etc. By “co-administer” it is meant that a composition described herein is administered at the same time, just prior to, or just after the administration of one or more additional therapies, for example cancer therapies such as chemotherapy, hormonal therapy, radiotherapy, or immunotherapy. The compounds of the invention can be administered alone or can be co-administered to the patient. Co-administration is meant to include simultaneous or sequential administration of the compounds individually or in combination (more than one compound). Thus, the preparations can also be combined, when desired, with other active substances (e.g., to reduce metabolic degradation). The compositions of the present invention can be delivered by transdermally, by a topical route, formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
The compounds described herein can be used in combination with one another, with other active agents known to be useful in treating a disease associated with cells expressing a disease associated cellular component, or with adjunctive agents that may not be effective alone, but may contribute to the efficacy of the active agent.
In some embodiments, co-administration includes administering one active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, or 24 hours of a second active agent. Co-administration includes administering two active agents simultaneously, approximately simultaneously (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order. In some embodiments, co-administration can be accomplished by co-formulation, i.e., preparing a single pharmaceutical composition including both active agents. In other embodiments, the active agents can be formulated separately. In another embodiment, the active and/or adjunctive agents may be linked or conjugated to one another.
The compounds described herein can be co-administered with conventional neurodegenerative disease treatments including, but not limited to, Parkinson's disease treatments such as levodopa, carbidopa, selegiline, amantadine, donepezil, galanthamine, rivastigmine, tacrine, dopamine agonists (e.g., bromocriptine, pergolide, pramipexole, ropinirole), anticholinergic drugs (e.g., trihexyphenidyl, benztropine, biperiden, procyclidine), and catechol-O-methyl-transferase inhibitors (e.g., tolcapone, entacapone).
The compounds described herein can also be co-administered with conventional anti-inflammatory disease treatments including, but not limited to, analgesics (e.g., acetaminophen, duloxetine), nonsteroidal anti-inflammatory drugs (e.g., aspirin, ibuprofen, naproxen, diclofenac), corticosteroids (e.g., prednisone, betamethasone, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone), and opioids (e.g., codeine, fentanyl, hydrocodone, hydromorphone, morphine, meperidine, oxycodone).
“Anti-cancer agent” is used in accordance with its plain ordinary meaning and refers to a composition (e.g., compound, drug, antagonist, inhibitor, modulator) having antineoplastic properties or the ability to inhibit the growth or proliferation of cells. In some embodiments, an anti-cancer agent is a chemotherapeutic. In some embodiments, an anti-cancer agent is an agent identified herein having utility in methods of treating cancer. In some embodiments, an anti-cancer agent is an agent approved by the FDA or similar regulatory agency of a country other than the USA, for treating cancer. In embodiments, an anti-cancer agent is an agent with antineoplastic properties that has not (e.g., yet) been approved by the FDA or similar regulatory agency of a country other than the USA, for treating cancer. Examples of anti-cancer agents include, but are not limited to, MEK (e.g., MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g., XL518, CI-1040, PD035901, selumetinib/AZD6244, GSK1120212/trametinib, GDC-0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS703026, BAY 869766), alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uramustine, thiotepa, nitrosoureas, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, meiphalan), ethylenimine and methylmelamines (e.g., hexamethylmelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomustine, semustine, streptozocin), triazenes (decarbazine)), anti-metabolites (e.g., 5-azathioprine, leucovorin, capecitabine, fludarabine, gemcitabine, pemetrexed, raltitrexed, folic acid analog (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxuridine, Cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin), etc.), plant alkaloids (e.g., vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel, docetaxel, etc.), topoisomerase inhibitors (e.g., irinotecan, topotecan, amsacrine, etoposide (VP16), etoposide phosphate, teniposide, etc.), antitumor antibiotics (e.g., doxorubicin, adriamycin, daunorubicin, epirubicin, actinomycin, bleomycin, mitomycin, mitoxantrone, plicamycin, etc.), platinum-based compounds (e.g., cisplatin, oxaliplatin, carboplatin), anthracenedione (e.g., mitoxantrone), substituted urea (e.g., hydroxyurea), methyl hydrazine derivative (e.g., procarbazine), adrenocortical suppressant (e.g., mitotane, aminoglutethimide), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), inhibitors of mitogen-activated protein kinase signaling (e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002, Syk inhibitors, mTOR inhibitors, antibodies (e.g., rituxan), gossyphol, genasense, polyphenol E, Chlorofusin, all trans-retinoic acid (ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2′-deoxycytidine, all trans retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec®), geldanamycin, 17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 11-7082, PKC412, PD184352, 20-epi-1, 25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; 9-dioxamycin; diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; elfomithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarine-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cell wall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylerie conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen-binding protein; sizofuran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; zinostatin stimalamer, Adriamycin, Dactinomycin, Bleomycin, Vinblastine, Cisplatin, acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; elfomithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; ilmofosine; interleukin I1 (including recombinant interleukin II, or rlL.sub.2), interferon alfa-2a; interferon alfa-2b; interferon alfa-n1; interferon alfa-n3; interferon beta-1a; interferon gamma-1b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazoie; nogalamycin; ormaplatin; oxisuran; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride, agents that arrest cells in the G2-M phases and/or modulate the formation or stability of microtubules, (e.g., Taxol™ (i.e., paclitaxel), Taxotere™, compounds comprising the taxane skeleton, Erbulozole (i.e., R-55104), Dolastatin 10 (i.e., DLS-10 and NSC-376128), Mivobulin isethionate (i.e., as CI-980), Vincristine, NSC-639829, Discodermolide (i.e., as NVP-XX-A-296), ABT-751 (Abbott, i.e., E-7010), Altorhyrtins (e.g., Altorhyrtin A and Altorhyrtin C), Spongistatins (e.g., Spongistatin 1, Spongistatin 2, Spongistatin 3, Spongistatin 4, Spongistatin 5, Spongistatin 6, Spongistatin 7, Spongistatin 8, and Spongistatin 9), Cemadotin hydrochloride (i.e., LU-103793 and NSC-D-669356), Epothilones (e.g., Epothilone A, Epothilone B, Epothilone C (i.e., desoxyepothilone A or dEpoA), Epothilone D (i.e., KOS-862, dEpoB, and desoxyepothilone B), Epothilone E, Epothilone F, Epothilone B N-oxide, Epothilone A N-oxide, 16-aza-epothilone B, 21-aminoepothilone B (i.e., BMS-310705), 21-hydroxyepothilone D (i.e., Desoxyepothilone F and dEpoF), 26-fluoroepothilone, Auristatin PE (i.e., NSC-654663), Soblidotin (i.e., TZT-1027), LS-4559-P (Pharmacia, i.e., LS-4577), LS-4578 (Pharmacia, i.e., LS-477-P), LS-4477 (Pharmacia), LS-4559 (Pharmacia), RPR-112378 (Aventis), Vincristine sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, i.e., WS-9885B), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences), BSF-223651 (BASF, i.e., ILX-651 and LU-223651), SAH-49960 (Lilly/Novartis), SDZ-268970 (Lilly/Novartis), AM-97 (Armad/Kyowa Hakko), AM-132 (Armad), AM-138 (Armad/Kyowa Hakko), IDN-5005 (Indena), Cryptophycin 52 (i.e., LY-355703), AC-7739 (Ajinomoto, i.e., AVE-8063A and CS-39.HCl), AC-7700 (Ajinomoto, i.e., AVE-8062, AVE-8062A, CS-39-L-Ser.HCl, and RPR-258062A), Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (i.e., NSC-106969), T-138067 (Tularik, i.e., T-67, TL-138067 and TI-138067), COBRA-1 (Parker Hughes Institute, i.e., DDE-261 and WHI-261), H10 (Kansas State University), H16 (Kansas State University), Oncocidin A1 (i.e., BTO-956 and DIME), DDE-313 (Parker Hughes Institute), Fijianolide B, Laulimalide, SPA-2 (Parker Hughes Institute), SPA-1 (Parker Hughes Institute, i.e., SPIKET-P), 3-IAABU (Cytoskeleton/Mt. Sinai School of Medicine, i.e., MF-569), Narcosine (also known as NSC-5366), Nascapine, D-24851 (Asta Medica), A-105972 (Abbott), Hemiasterlin, 3-BAABU (Cytoskeleton/Mt. Sinai School of Medicine, i.e., MF-191), TMPN (Arizona State University), Vanadocene acetylacetonate, T-138026 (Tularik), Monsatrol, lnanocine (i.e., NSC-698666), 3-IAABE (Cytoskeleton/Mt. Sinai School of Medicine), A-204197 (Abbott), T-607 (Tuiarik, i.e., T-900607), RPR-115781 (Aventis), Eleutherobins (such as Desmethyleleutherobin, Desaetyleleutherobin, lsoeleutherobin A, and Z-Eleutherobin), Caribaeoside, Caribaeolin, Halichondrin B, D-64131 (Asta Medica), D-68144 (Asta Medica), Diazonamide A, A-293620 (Abbott), NPI-2350 (Nereus), Taccalonolide A, TUB-245 (Aventis), A-259754 (Abbott), Diozostatin, (−)-Phenylahistin (i.e., NSCL-96F037), D-68838 (Asta Medica), D-68836 (Asta Medica), Myoseverin B, D-43411 (Zentaris, i.e., D-81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286 (i.e., SPA-110, trifluoroacetate salt) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC-12983 (NCI), Resverastatin phosphate sodium, BPR-OY-007 (National Health Research Institutes), and SSR-250411 (Sanofi)), steroids (e.g., dexamethasone), finasteride, aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRH) such as goserelin or leuprolide, adrenocorticosteroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethylstilbestrol, ethinyl estradiol), antiestrogen (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogen (e.g., flutamide), immunostimulants (e.g., Bacillus Calmette-Guerin (BCG), levamisole, interleukin-2, alpha-interferon, etc.), monoclonal antibodies (e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR, and anti-VEGF monoclonal antibodies), immunotoxins (e.g., anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody-pseudomonas exotoxin conjugate, etc.), radioimmunotherapy (e.g., anti-CD20 monoclonal antibody conjugated to 111In, 90Y, or 131I, etc.), triptolide, homoharringtonine, dactinomycin, doxorubicin, epirubicin, topotecan, itraconazole, vindesine, cerivastatin, vincristine, deoxyadenosine, sertraline, pitavastatin, irinotecan, clofazimine, 5-nonyloxytryptamine, vemurafenib, dabrafenib, erlotinib, gefitinib, EGFR inhibitors, epidermal growth factor receptor (EGFR)-targeted therapy or therapeutic (e.g., gefitinib (Iressa™), erlotinib (Tarceva™), cetuximab (Erbitux™), lapatinib (Tykerb™) panitumumab (Vectibix™), vandetanib (Caprelsa™), afatinib/BIBW2992, CI-1033/canertinib, neratinib/HKI-272, CP-724714, TAK-285, AST-1306, ARRY334543, ARRY-380, AG-1478, dacomitinib/PF299804, OSI-420/desmethyl erlotinib, AZD8931, AEE788, pelitinib/EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), sorafenib, imatinib, sunitinib, dasatinib, or the like. A moiety of an anti-cancer agent is a monovalent anti-cancer agent (e.g., a monovalent form of an agent listed above).
In therapeutic use for the treatment of a disease, compound utilized in the pharmaceutical compositions of the present invention may be administered at the initial dosage of about 0.001 mg/kg to about 1000 mg/kg daily. A daily dose range of about 0.01 mg/kg to about 500 mg/kg, or about 0.1 mg/kg to about 200 mg/kg, or about 1 mg/kg to about 100 mg/kg, or about 10 mg/kg to about 50 mg/kg, can be used. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound or drug being employed. For example, dosages can be empirically determined considering the type and stage of cancer diagnosed in a particular patient. The dose administered to a patient, in the context of the present invention, should be sufficient to affect a beneficial therapeutic response in the patient over time. The size of the dose will also be determined by the existence, nature, and extent of any adverse side effects that accompany the administration of a compound in a particular patient. Determination of the proper dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day, if desired.
The compounds described herein can be used in combination with one another, with other active agents known to be useful in treating cancer or with adjunctive agents that may not be effective alone, but may contribute to the efficacy of the active agent.
The term “associated” or “associated with” in the context of a substance or substance activity or function associated with a disease (e.g., a protein associated disease, disease associated with a cellular component) means that the disease (e.g., cancer) is caused by (in whole or in part), or a symptom of the disease is caused by (in whole or in part) the substance or substance activity or function or the disease or a symptom of the disease may be treated by modulating (e.g., inhibiting or activating) the substance (e.g., cellular component). As used herein, what is described as being associated with a disease, if a causative agent, could be a target for treatment of the disease.
The term “aberrant” as used herein refers to different from normal. When used to describe enzymatic activity, aberrant refers to activity that is greater or less than a normal control or the average of normal non-diseased control samples. Aberrant activity may refer to an amount of activity that results in a disease, wherein returning the aberrant activity to a normal or non-disease-associated amount (e.g., by administering a compound or using a method as described herein), results in reduction of the disease or one or more disease symptoms.
The term “electrophilic” as used herein refers to a chemical group that is capable of accepting electron density. An “electrophilic substituent,” “electrophilic chemical moiety,” or “electrophilic moiety” refers to an electron-poor chemical group, substituent, or moiety (monovalent chemical group), which may react with an electron-donating group, such as a nucleophile, by accepting an electron pair or electron density to form a bond. In some embodiments, the electrophilic substituent of the compound is capable of reacting with a cysteine residue. In some embodiments, the electrophilic substituent is capable of forming a covalent bond with a cysteine residue and may be referred to as a “covalent cysteine modifier moiety” or “covalent cysteine modifier substituent.” The covalent bond formed between the electrophilic substituent and the sulfhydryl group of the cysteine may be a reversible or irreversible bond. In some embodiments, the electrophilic substituent of the compound is capable of reacting with a lysine residue. In some embodiments, the electrophilic substituent of the compound is capable of reacting with a serine residue. In some embodiments, the electrophilic substituent of the compound is capable of reacting with a methionine residue.
“Nucleophilic” as used herein refers to a chemical group that is capable of donating electron density.
The term “isolated,” when applied to a nucleic acid or protein, denotes that the nucleic acid or protein is essentially free of other cellular components with which it is associated in the natural state. It can be, for example, in a homogeneous state and may be in either a dry or aqueous solution. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein that is the predominant species present in a preparation is substantially purified.
The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, i.e., an α carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions in a manner similar to a naturally occurring amino acid. The terms “non-naturally occurring amino acid” and “unnatural amino acid” refer to amino acid analogs, synthetic amino acids, and amino acid mimetics which are not found in nature.
Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues, wherein the polymer may in embodiments be conjugated to a moiety that does not consist of amino acids. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers.
An amino acid or nucleotide base “position” is denoted by a number that sequentially identifies each amino acid (or nucleotide base) in the reference sequence based on its position relative to the N-terminus (or 5′-end). Due to deletions, insertions, truncations, fusions, and the like that must be taken into account when determining an optimal alignment, in general the amino acid residue number in a test sequence determined by simply counting from the N-terminus will not necessarily be the same as the number of its corresponding position in the reference sequence. For example, in a case where a variant has a deletion relative to an aligned reference sequence, there will be no amino acid in the variant that corresponds to a position in the reference sequence at the site of deletion. Where there is an insertion in an aligned reference sequence, that insertion will not correspond to a numbered amino acid position in the reference sequence. In the case of truncations or fusions there can be stretches of amino acids in either the reference or aligned sequence that do not correspond to any amino acid in the corresponding sequence.
The terms “numbered with reference to” or “corresponding to,” when used in the context of the numbering of a given amino acid or polynucleotide sequence, refers to the numbering of the residues of a specified reference sequence when the given amino acid or polynucleotide sequence is compared to the reference sequence.
The term “protein complex” is used in accordance with its plain ordinary meaning and refers to a protein which is associated with an additional substance (e.g., another protein, protein subunit, or a compound). Protein complexes typically have defined quaternary structure. The association between the protein and the additional substance may be a covalent bond. In embodiments, the association between the protein and the additional substance (e.g., compound) is via non-covalent interactions. In embodiments, a protein complex refers to a group of two or more polypeptide chains. Proteins in a protein complex are linked by non-covalent protein-protein interactions. A non-limiting example of a protein complex is the proteasome.
The term “protein aggregate” is used in accordance with its plain ordinary meaning and refers to an aberrant collection or accumulation of proteins (e.g., misfolded proteins). Protein aggregates are often associated with diseases (e.g., amyloidosis). Typically, when a protein misfolds as a result of a change in the amino acid sequence or a change in the native environment which disrupts normal non-covalent interactions, and the misfolded protein is not corrected or degraded, the unfolded/misfolded protein may aggregate. There are three main types of protein aggregates that may form: amorphous aggregates, oligomers, and amyloid fibrils. In embodiments, protein aggregates are termed aggresomes.
The term “K-Ras” refers to the protein that in humans is encoded by the KRAS gene. The K-Ras protein is a GTPase, which converts guanosine triphosphate to guanosine diphosphate. A mutation in the K-Ras protein (e.g., an amino acid substitution) can result in various malignancies (e.g., lung adenocarcinoma, pancreatic cancer, or colorectal cancer). The term “K-Ras” may refer to the nucleotide sequence or protein sequence of human KRAS (e.g., Entrez 3845, UniProt P01116, RefSeq NM_004985.4, RefSeq NM_033360.3, RefSeq NP_004976.2, or RefSeq NP_203524.1). In embodiments, K-Ras has the following amino acid sequence:
The term “H-Ras” refers to the enzyme that in humans is encoded by the HRAS gene. The H-Ras protein is a GTPase, which converts guanosine triphosphate to guanosine diphosphate. Mutations in the H-Ras protein (e.g., an amino acid substitution) can result in various malignancies (e.g., bladder cancer, thyroid cancer, salivary duct carcinoma, epithelial carcinoma, or kidney cancer). The term “H-Ras” may refer to the nucleotide sequence or protein sequence of human HRAS (e.g., Entrez 3265, UniProt P01112, RefSeq NM_001130442.2, RefSeq NM_001318054.1, RefSeq NM_005343.3, RefSeq NM_00176795.4, RefSeq NP_001123914.1, RefSeq NP_001304983.1, RefSeq NP_005334.1, or RefSeq NP_789765.1). In embodiments, H-Ras has the following amino acid sequence:
The term “N-Ras” refers to the enzyme that in humans is encoded by the NRAS gene. The N-Ras protein is a GTPase, which converts guanosine triphosphate to guanosine diphosphate. The term “N-Ras” may refer to the nucleotide sequence or protein sequence of human NRAS (e.g., Entrez 4893, UniProt P01111, RefSeq NM_002524.4, or RefSeq NP_002515.1). In embodiments, N-Ras has the following amino acid sequence:
The term “Raf” refers to a serine/threonine-specific protein kinase. The Raf kinases participate in the RAS-RAF-MEK-ERK signal transduction cascade. In embodiments, activation of Raf kinases requires interaction with Ras GTPases. In embodiments, Raf is A-Raf (e.g., Entrez 369), B-Raf (e.g., Entrez 673), or c-Raf (e.g., Entrez 5894).
In an aspect is provided a compound having the formula:
L1A, L2A, L3A, L4A, L5A, L6A, L7A, L8A, L9A, L10A, L11A, and L12A are independently a bond, substituted or unsubstituted alkylene (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), or substituted or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
R1A, R5A, and R11A are independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
R2A and R8A are independently hydrogen, substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
R3A is hydrogen, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), or substituted or unsubstituted aryl (e.g., C6-C10 or phenyl).
R4A is hydrogen, —NH2, —COOH, —CONH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), or substituted or unsubstituted aryl (e.g., C6-C10 or phenyl).
R6A and R9A are independently hydrogen, —CN, —NH2, —CONH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), or substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
R7A is hydrogen, —NH2, —COOH, —CONH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), or substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
R3A and R9A may optionally be joined to form a covalent linker.
R10A is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —C(O)OH, —C(O)NH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, -L10D-L10E-E, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
L10D is a bond, —S(O)2—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkylene (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted arylene (e.g., C6-C10 or phenylene), or substituted or unsubstituted heteroarylene (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
L10E is a bond, —S(O)2—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), or substituted or unsubstituted heteroarylene (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
R12A is hydrogen, —CN, —NH2, —CONH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), or substituted or unsubstituted aryl (e.g., C6-C10 or phenyl).
E is an electrophilic moiety.
R1D, R2D, R3D, R4D, R5D, R6D, R7D, R8D, R9D, R10D, R11D, and R12D are independently hydrogen, unsubstituted C1-C8 alkyl.
L16 is a covalent linker.
In embodiments, the compound has the formula:
L1A, L2A, L3A, L4A, L5A, L6A, L7A, L8A, L9A, L10A, L11A, and L12A are independently a bond, substituted or unsubstituted alkylene (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), or substituted or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered); R1A, R2A, R5A, R8A, and R11A are independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered); R3A is independently hydrogen, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), or substituted or unsubstituted aryl (e.g., C6-C10 or phenyl). R4A and R7A are independently hydrogen, —NH2, —COOH, —CONH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), or substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered); R6A, R9A, and R12A are independently hydrogen, —CN, —NH2, —CONH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), or substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered); R3A and R9A may optionally be joined to form a covalent linker; R10A is independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —C(O)OH, —C(O)NH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, -L10D-L10E-E, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered); L10D is independently a bond, —S(O)2—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkylene (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted arylene (e.g., C6-C10 or phenylene), or substituted or unsubstituted heteroarylene (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered); L10E is independently a bond, —S(O)2—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), or substituted or unsubstituted heteroarylene (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered); E is an electrophilic moiety; R1D, R2D, R3D, R4D, R5D, R6D, R7D, R8D, R9D, R10D, R11D, and R12D are independently hydrogen or unsubstituted C1-C4 alkyl; and L16 is a covalent linker.
In embodiments, the compound has the formula:
L1A, L2A, L3A, L4A, L5A, L6A, L7A, L8A, L9A, L10A, L11A, L12A, L16, R1A, R2A, R3A, R4A, R5A, R6A, R7A, R8A, R9A, R10A, R11A, and R12A are as described herein, including in embodiments.
In embodiments, the compound has the formula:
L2A, L3A, L4A, L5A, L6A, L7A, L8A, L9A, L10A, L11A, L12A, L16, R1A, R2A, R3A, R4A, R5A, R6A, R7A, R8A, R9A, R10A, R11A, and R12A are as described herein, including in embodiments.
In embodiments, a substituted L1A (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L1A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L1A is substituted, it is substituted with at least one substituent group. In embodiments, when L1A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L1A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L2A (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L2A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L2A is substituted, it is substituted with at least one substituent group. In embodiments, when L2A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L2A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L3A (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L3A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L3A is substituted, it is substituted with at least one substituent group. In embodiments, when L3A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L3A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L4A (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L4A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L4A is substituted, it is substituted with at least one substituent group. In embodiments, when L4A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L4A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L5A (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L5A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L5A is substituted, it is substituted with at least one substituent group. In embodiments, when L5A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L5A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L6A (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L6A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L6A is substituted, it is substituted with at least one substituent group. In embodiments, when L6A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L6A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L7A (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L7A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L7A is substituted, it is substituted with at least one substituent group. In embodiments, when L7A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L7A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L8A (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L8A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L8A is substituted, it is substituted with at least one substituent group. In embodiments, when L8A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L8A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L9A (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L9A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L9A is substituted, it is substituted with at least one substituent group. In embodiments, when L9A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L9A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L10A (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L10A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L10A is substituted, it is substituted with at least one substituent group. In embodiments, when L10A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L10A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L11A (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L11A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L11A is substituted, it is substituted with at least one substituent group. In embodiments, when L11A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L11A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L12A (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L12A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L12A is substituted, it is substituted with at least one substituent group. In embodiments, when L12A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L12A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R1A (e.g., substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R1A is substituted, it is substituted with at least one substituent group. In embodiments, when R1A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R2A (e.g., substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R2A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R2A is substituted, it is substituted with at least one substituent group. In embodiments, when R2A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R2A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R3A (e.g., substituted alkyl, substituted cycloalkyl, and/or substituted aryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R3A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R3A is substituted, it is substituted with at least one substituent group. In embodiments, when R3A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R3A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R4A (e.g., substituted alkyl, substituted heteroalkyl, and/or substituted aryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R4A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R4A is substituted, it is substituted with at least one substituent group. In embodiments, when R4A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R4A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R5A (e.g., substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R5A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R5A is substituted, it is substituted with at least one substituent group. In embodiments, when R5A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R5A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R6A (e.g., substituted alkyl and/or substituted heteroalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R6A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R6A is substituted, it is substituted with at least one substituent group. In embodiments, when R6A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R6A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R7A (e.g., substituted alkyl and/or substituted heteroalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R7A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R7A is substituted, it is substituted with at least one substituent group. In embodiments, when R7A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R7A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R8A (e.g., substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R8A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R8A is substituted, it is substituted with at least one substituent group. In embodiments, when R8A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R8A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R9A (e.g., substituted alkyl and/or substituted heteroalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R9A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R9A is substituted, it is substituted with at least one substituent group. In embodiments, when R9A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R9A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R10A (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R10A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R10A is substituted, it is substituted with at least one substituent group. In embodiments, when R10A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R10A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L10D (e.g., substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L10D is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L10D is substituted, it is substituted with at least one substituent group. In embodiments, when L10D is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L10D is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L10E (e.g., substituted heteroalkylene, substituted heterocycloalkylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L10E is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L10E is substituted, it is substituted with at least one substituent group. In embodiments, when L10E is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L10E is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R11A (e.g., substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R11A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R11A is substituted, it is substituted with at least one substituent group. In embodiments, when R11A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R11A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R12A (e.g., substituted alkyl, substituted heteroalkyl, and/or substituted aryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R12A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R12A is substituted, it is substituted with at least one substituent group. In embodiments, when R12A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R12A is substituted, it is substituted with at least one lower substituent group.
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L1A is a bond or unsubstituted C1-C4 alkylene. In embodiments, R1A is a substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of tyrosine, a divalent form of phenylalanine, or a divalent form of tryptophan.
In embodiments,
is a divalent form of tyrosine. In embodiments, -L1A-R1A is
In embodiments, -L1A-R1A is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L2A is a bond or unsubstituted C1-C4 alkylene. In embodiments, R2A is a substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of phenylalanine, a divalent form of tyrosine, or a divalent form of tryptophan.
In embodiments,
is a divalent form of phenylalanine. In embodiments, -L2A-R2A is
In embodiments, -L2A-R2A is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L2A is a bond or unsubstituted C1-C4 alkylene. In embodiments, R2A is hydrogen, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments, R2D is an unsubstituted C1-C4 alkyl. In embodiments,
is a divalent form of an unnatural glycine derivative. In embodiments,
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L3A is a bond or unsubstituted C1-C4 alkylene. In embodiments, R3A is a substituted or unsubstituted alkyl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of valine, a divalent form of isoleucine, or a divalent form of leucine. In embodiments,
is a divalent form of valine. In embodiments, -L3A-R3A is
In embodiments, -L3A-R3A is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L3A is a bond or unsubstituted C1-C4 alkylene. In embodiments, R3A is a substituted or unsubstituted aryl. In embodiments, R3D is an unsubstituted C1-C4 alkyl. In embodiments,
is a divalent form of an unnatural phenylalanine derivative. In embodiments,
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L4A is a bond or unsubstituted C1-C4 alkylene. In embodiments, R4A is —C(O)NH2 or substituted or unsubstituted heteroalkyl. In embodiments
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of asparagine or a divalent form of glutamine. In embodiments,
is a divalent form of asparagine. In embodiments, -L4A-R4A is
In embodiments, -L4A-R4A is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L4A is a bond or unsubstituted C1-C4 alkylene. In embodiments, R4A is hydrogen, —C(O)NH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted aryl. In embodiments, R4D is an unsubstituted C1-C4 alkyl. In embodiments,
is a divalent form of an unnatural tyrosine derivative. In embodiments,
is a divalent form of an unnatural glycine derivative. In embodiments,
is a divalent form of a 2-aminobutyric acid derivative. In embodiments,
is a divalent form of an unnatural glutamic acid derivative. In embodiments,
In embodiments,
In embodiments,
In embodiments,
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L5A is a bond or unsubstituted C1-C4 alkylene. In embodiments, R5A is a substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments, R5A is a halogen-substituted aryl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of phenylalanine, a divalent form of tyrosine, or a divalent form of tryptophan. In embodiments,
is a divalent form of phenylalanine. In embodiments, -L5A-R5A is
In embodiments, -L5A-R5A is
In embodiments, -L5A-R5A is
In embodiments, -L5A-R5A is
In embodiments, -L5A-R5A is
In embodiments, -L5A-R5A is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L6A is a bond or unsubstituted C1-C6 alkylene. In embodiments, R6A is —NH2, —NHC(NH)NH2, or substituted or unsubstituted heteroalkyl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form
of arginine or a divalent form of lysine. In embodiments,
is a divalent form of arginine. In embodiments, -L6A-R6A is
In embodiments, -L6A-R6A is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L7A is a bond or unsubstituted C1-C4 alkylene. In embodiments, R7A is —C(O)NH2 or substituted or unsubstituted heteroalkyl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of asparagine or a divalent form of glutamine. In embodiments,
is a divalent form of asparagine. In embodiments, -L7A-R7A is
In embodiments, -L7A-R7A is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L8A is a bond or unsubstituted C1-C4 alkylene. In embodiments, R8A is a substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of phenylalanine, a divalent form of tyrosine, or a divalent form of tryptophan.
In embodiments,
is a divalent form of phenylalanine. In embodiments -L8A-R8A is
In embodiments, -L8A-R8A is
In embodiments, -L8A-R8A is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L8A is a bond or unsubstituted C1-C4 alkylene. In embodiments, R8A is hydrogen, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments, R8D is an unsubstituted C1-C4 alkyl. In embodiments,
is a divalent form of an unnatural glutamic acid derivative. In embodiments,
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L9A is a bond or unsubstituted C1-C6 alkylene. In embodiments, R9A is —NH2, —NHC(NH)NH2, or substituted or unsubstituted heteroalkyl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of arginine or a divalent form of lysine. In embodiments,
is a divalent form of arginine. In embodiments, -L9A-R9A is
In embodiments, -L9A-R9A is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments,
is a divalent form of 2,3-diaminoproprionic acid (Dap). In embodiments,
is a divalent form of citrulline (Cit). In embodiments, L10A is a bond or unsubstituted C1-C4 alkylene. In embodiments, R10A is —OH, —NH2, —NHC(O)NH2, —NHC(NH)NH2, substituted or unsubstituted alkyl, substituted or unsubstituted heterocycloalkyl, or substituted or unsubstituted heteroaryl. In embodiments, R10A is —OH, —NH2, —NHC(O)NH2, —NHC(NH)NH2, substituted or unsubstituted alkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments, -L10A-R10A is
In embodiments, -L10A-R10A is
In embodiments, -L10A-R10A is
In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of threonine, a divalent form of histidine, a divalent form of lysine, or a divalent form of arginine. In embodiments,
is a divalent form of threonine. In embodiments,
is a divalent form of histidine. In embodiments,
is a divalent form of lysine. In embodiments,
is a divalent form of arginine. In embodiments, -L10A-R10A is
In embodiments, -L10A-R10A is
In embodiments, -L10A-R10A is
In embodiments, -L10A-R10A is
In embodiments, -L10A-R10A is
In embodiments, -L10A-R10A is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L11A is a bond or unsubstituted C1-C4 alkylene. In embodiments, R11A is a substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of phenylalanine, a divalent form of tyrosine, or a divalent form of tryptophan. In embodiments,
is a divalent form of phenylalanine. In embodiments, -L11A-R11A is
In embodiments, -L11A-R11A is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L12A is a bond or unsubstituted C1-C6 alkylene. In embodiments, R12A is —NH2, —NHC(NH)NH2, or substituted or unsubstituted heteroalkyl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of arginine or a divalent form of lysine. In embodiments,
is a divalent form of arginine. In embodiments, -L12A-R12A is
In embodiments, -L12A-R12A is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L12A is a bond or unsubstituted C1-C6 alkylene. In embodiments, R12A is —NH2, —NHC(NH)NH2, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted aryl. In embodiments, R12D is an unsubstituted C1-C4 alkyl. In embodiments,
is a divalent form of an unnatural phenylalanine derivative. In embodiments,
In embodiments, R10A is independently hydrogen, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.
In embodiments, R10A is -L10D-L10E-E. L10D, L10E, and E are as described herein, including in embodiments.
In embodiments, L10D is independently a bond, —NH—, —O—, —C(O)—, —C(O)NH—, —NHC(O)NH—, —NHC(NH)NH—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene. In embodiments, L10D is independently a bond. In embodiments, L10D is independently —NH—. In embodiments, L10D is independently —O—. In embodiments, L10D is independently —C(O)—. In embodiments, L10D is independently —C(O)NH—. In embodiments, L10D is independently —NHC(O)NH—. In embodiments, L10D is independently substituted or unsubstituted alkylene. In embodiments, L10D is independently substituted or unsubstituted heteroalkylene. In embodiments, L10D is independently substituted or unsubstituted heterocycloalkylene. In embodiments, L10D is independently substituted or unsubstituted arylene. In embodiments, L10D is independently substituted or unsubstituted heteroarylene.
In embodiments, L10E is independently a bond, —NH—, —O—, —C(O)—, —C(O)NH—, —NHC(O)NH—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene. In embodiments, L10E is independently a bond. In embodiments, L10E is independently —NH—. In embodiments, L10E is independently —O—. In embodiments, L10E is independently —C(O)—. In embodiments, L10E is independently —C(O)NH—. In embodiments, L10E is independently —NHC(O)NH—. In embodiments, L10E is independently substituted or unsubstituted alkylene. In embodiments, L10E is independently substituted or unsubstituted heteroalkylene. In embodiments, L10E is independently substituted or unsubstituted heterocycloalkylene. In embodiments, L10E is independently substituted or unsubstituted arylene. In embodiments, L10E is independently substituted or unsubstituted heteroarylene.
In embodiments, E is an electrophilic moiety capable of forming a covalent bond with a cysteine, aspartate, lysine, arginine, histidine, leucine, tyrosine, methionine, serine, or glutamate residue.
In embodiments, E is an electrophilic moiety as described in Mukherjee et al. Curr. Opin. Chem. Biol. 44, 30-38 (2018), which is incorporated herein by reference in its entirety and for all purposes. In embodiments, E is an electrophilic moiety as described in Gehringer et al. J. Med. Chem. 62, 5673-5724 (2019), which is incorporated herein by reference in its entirety and for all purposes.
In embodiments, E is —SH, —SSR26,
R26, R27, and R28 are independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —C(O)OH, —C(O)NH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
X27 is independently —F, —Cl, —Br, or —I.
In embodiments, a substituted R26 (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R26 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R26 is substituted, it is substituted with at least one substituent group. In embodiments, when R26 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R26 is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R27 (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R27 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R27 is substituted, it is substituted with at least one substituent group. In embodiments, when R27 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R27 is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R28 (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R28 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R28 is substituted, it is substituted with at least one substituent group. In embodiments, when R28 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R28 is substituted, it is substituted with at least one lower substituent group.
In embodiments, E is
In embodiments, -L10A-R10A is
In embodiments, R3A and R9A are joined to form a bioconjugate linker.
In embodiments, R3A and R9A are joined to form a covalent linker having the formula -L18A-L18B-L18C-L18D-L18E-L18F-.
L18A, L18B, L18C, L18D, L18E, and L18F are independently bond, —SS—, —S(O)2—, —OS(O)2—, —S(O)2O—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkylene (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted arylene (e.g., C6-C10 or phenylene), or substituted or unsubstituted heteroarylene (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, a substituted L18A (e.g., substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L18A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L18A is substituted, it is substituted with at least one substituent group. In embodiments, when L18A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L18A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L18B (e.g., substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L18B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L18B is substituted, it is substituted with at least one substituent group. In embodiments, when L18B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L18B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L18C (e.g., substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L18C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L18C is substituted, it is substituted with at least one substituent group. In embodiments, when L18C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L18C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L18D (e.g., substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L18D is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L18D is substituted, it is substituted with at least one substituent group. In embodiments, when L18D is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L18D is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L18E (e.g., substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L18E is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L18E is substituted, it is substituted with at least one substituent group. In embodiments, when L18E is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L18E is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L18F (e.g., substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L18F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L18F is substituted, it is substituted with at least one substituent group. In embodiments, when L18F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L18F is substituted, it is substituted with at least one lower substituent group.
In embodiments, L18A is independently a bond or unsubstituted C1-C4 alkyl.
In embodiments, L18B is independently —SS— or unsubstituted heteroarylene. In embodiments, L18B is independently —SS—. In embodiments, L18B is independently an unsubstituted 3 to 8 membered heteroarylene. In embodiments, L18B is independently an unsubstituted triazolylene. In embodiments, L18B is independently
In embodiments, L18C is independently a bond or unsubstituted C1-C4 alkyl.
In embodiments, L18D is independently a bond or unsubstituted C1-C4 alkyl.
In embodiments, L18E is independently a bond or unsubstituted C1-C4 alkyl.
In embodiments, L18F is independently a bond or unsubstituted C1-C4 alkyl.
In embodiments, R3A and R9A are joined to form
In embodiments, R3A and R9A are joined to form
In embodiments, R3A and R9A are joined to form
In embodiments, the compound of formula (I) is a peptide of
is a divalent form of D-tyrosine;
is a divalent form of phenylalanine;
is a divalent form of valine;
is a divalent form of asparagine;
is a divalent form of phenylalanine;
is a divalent form of arginine;
is divalent form of asparagine;
is a divalent form of phenylalanine;
is a divalent form of
arginine;
is a divalent form of threonine;
is a divalent form of phenylalanine; and
is a divalent form of arginine. Where the compound of formula (I) is peptide 5 or 15 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). And for example, for peptide 15 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids).
In embodiments, the compound has the formula:
L16 is as described herein, including in embodiments.
In an aspect is provided a compound having the formula:
R1D, R2D, R3D, R4D, R5D, R6D, R7D, R8D, R9D, R10D, R11D, R12D, and L16 are as described herein, including in embodiments.
L1B, L2B, L3B, L4B, L5B, L6B, L7B, L8B, L9B, L10B, L11B, L12B, and L13B are independently a bond, substituted or unsubstituted alkylene (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), or substituted or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
R1B, R8B, and R10B are independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
R2B, R3B, R4B, R9B, and R11B are independently hydrogen, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), or substituted or unsubstituted aryl (e.g., C6-C10 or phenyl).
R5B is independently hydrogen, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), or substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
R6B is independently hydrogen, —OH, —COOH, —NO2, —SO3H, —OSO3H, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), or substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
R7B, R12B, and R13B are independently hydrogen, —NH2, —CONH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
Two substituents selected from R1B, R2B, R3B, R4B, R5B, R6B, L7B, R8B, R9B, R10B, R11B, R12B, and R13B may optionally be joined to form a covalent linker.
R13D is independently hydrogen or unsubstituted C1-C4 alkyl.
In embodiments, the compound has the formula:
L1B, L2B, L3B, L4B, L5B, L6B, L7B, L8B, L9B, L10B, L11B, L12B, L13B, L16, R1B, R2B, R3B, R4B, R5B, R6B, R7B, R8B, R9B, R10B, R11B, R12B, and R13B are as described herein, including in embodiments.
In embodiments, the compound has the formula:
L1B, L2B, L3B, L4B, L5B, L6B, L7B, L8B, L9B, L10B, L11B, L12B, L13B, L16, R1B, R2B, R3B, R4B, R5B, R6B, R7B, R8B, R9B, R10B, R11B, R12B, and R13B are as described herein, including in embodiments.
In embodiments, a substituted L1B (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L1B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L1B is substituted, it is substituted with at least one substituent group. In embodiments, when L1B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L1B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L2B (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L2B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L2B is substituted, it is substituted with at least one substituent group. In embodiments, when L2B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L2B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L3B (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L3B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L3B is substituted, it is substituted with at least one substituent group. In embodiments, when L3B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L3B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L4B (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L4B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L4B is substituted, it is substituted with at least one substituent group. In embodiments, when L4B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L4B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L5B (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L5B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L5B is substituted, it is substituted with at least one substituent group. In embodiments, when L5B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L5B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L6B (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L6B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L6B is substituted, it is substituted with at least one substituent group. In embodiments, when L6B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L6B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L7B (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L7B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L7B is substituted, it is substituted with at least one substituent group. In embodiments, when L7B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L7B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L8B (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L8B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L8B is substituted, it is substituted with at least one substituent group. In embodiments, when L8B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L8B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L9B (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L9B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L9B is substituted, it is substituted with at least one substituent group. In embodiments, when L9B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L9B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L10B (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L10B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L10B is substituted, it is substituted with at least one substituent group. In embodiments, when L10B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L10B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L11B (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L11B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L11B is substituted, it is substituted with at least one substituent group. In embodiments, when L11B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L11B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L12B (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L12B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L12B is substituted, it is substituted with at least one substituent group. In embodiments, when L12B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L12B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L13B (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L13B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L13B is substituted, it is substituted with at least one substituent group. In embodiments, when L13B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L13B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R1B (e.g., substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R1B is substituted, it is substituted with at least one substituent group. In embodiments, when R1B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R2B (e.g., substituted alkyl, substituted cycloalkyl, and/or substituted aryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R2B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R2B is substituted, it is substituted with at least one substituent group. In embodiments, when R2B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R2B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R3B (e.g., substituted alkyl, substituted cycloalkyl, and/or substituted aryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R3B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R3B is substituted, it is substituted with at least one substituent group. In embodiments, when R3B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R3B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R4B (e.g., substituted alkyl, substituted cycloalkyl, and/or substituted aryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R4B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R4B is substituted, it is substituted with at least one substituent group. In embodiments, when R4B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R4B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R5B (e.g., substituted alkyl and/or substituted heteroalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R5B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R5B is substituted, it is substituted with at least one substituent group. In embodiments, when R5B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R5B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R6B (e.g., substituted alkyl and/or substituted heteroalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R6B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R6B is substituted, it is substituted with at least one substituent group. In embodiments, when R6B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R6B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R7B (e.g., substituted alkyl, substituted heteroalkyl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R7B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R7B is substituted, it is substituted with at least one substituent group. In embodiments, when R7B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R7B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R8B (e.g., substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R8B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R8B is substituted, it is substituted with at least one substituent group. In embodiments, when R8B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R8B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R9B (e.g., substituted alkyl, substituted cycloalkyl, and/or substituted aryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R9B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R9B is substituted, it is substituted with at least one substituent group. In embodiments, when R9B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R9B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R10B (e.g., substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R10B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R10B is substituted, it is substituted with at least one substituent group. In embodiments, when R10B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R10B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R11B (e.g., substituted alkyl, substituted cycloalkyl, and/or substituted aryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R11B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R11B is substituted, it is substituted with at least one substituent group. In embodiments, when R11B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R11B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R12B (e.g., substituted alkyl, substituted heteroalkyl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R12B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R12B is substituted, it is substituted with at least one substituent group. In embodiments, when R12B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R12B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R13B (e.g., substituted alkyl, substituted heteroalkyl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R13B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R13B is substituted, it is substituted with at least one substituent group. In embodiments, when R13B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R13B is substituted, it is substituted with at least one lower substituent group.
In embodiments, H is a divalent form of an unnatural amino acid. In embodiments, L1B is a bond or unsubstituted C1-C4 alkylene. In embodiments, R1B is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of tyrosine, a divalent form of phenylalanine, or a divalent form of tryptophan.
In embodiments,
is a divalent form of tyrosine. In embodiments, -L1B-R1B is
In embodiments, -L1B-R1B is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L2B is a bond or unsubstituted C1-C4 alkylene. In embodiments, R2B is a substituted or unsubstituted alkyl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of isoleucine, a divalent form of leucine, or a divalent form of valine. In embodiments,
is a divalent form of isoleucine. In embodiments, -L2B-R2B is
In embodiments, -L2B-R2B is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L3B is a bond or unsubstituted C1-C4 alkylene. In embodiments, R3B is a substituted or unsubstituted alkyl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of isoleucine, a divalent form of leucine, or a divalent form of valine. In embodiments,
is a divalent form of isoleucine. In embodiments, -L3B-R3B is
In embodiments, -L3B-R3B is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L4B is a bond or unsubstituted C1-C4 alkylene. In embodiments, R4B is a substituted or unsubstituted alkyl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of valine, a divalent form of isoleucine, a divalent form of leucine, or a divalent form of alanine. In embodiments,
is a divalent form of valine. In embodiments,
is a divalent form of alanine. In embodiments, -L4B-R4B is
or —CH3. In embodiments, -L4B-R4B is
In embodiments, -L4B-R4B is —CH3.
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L5B is a bond or unsubstituted C1-C4 alkylene. In embodiments, R5B is —OH or substituted or unsubstituted alkyl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of threonine or a divalent form of serine. In embodiments,
is a divalent form of threonine. In embodiments, -L5B-R5B is
In embodiments, -L5B-R5B is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L6B is a bond or unsubstituted C1-C4 alkylene. In embodiments, R6B is —C(O)OH or substituted or unsubstituted heteroalkyl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of glutamic acid or a divalent form of aspartic acid. In embodiments,
is a divalent form of glutamic acid. In embodiments, -L6B-R6B is
In embodiments, -L6B-R6B is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L7B is a bond or unsubstituted C1-C6 alkylene. In embodiments, R7B is —NH2, —NHC(NH)NH2, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted heteroaryl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of lysine, a divalent form of arginine, or a divalent form of histidine. In embodiments,
is a divalent form of lysine. In embodiments, -L7B-R7B is
In embodiments, -L7B-R7B is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L8B is a bond or unsubstituted C1-C4 alkylene. In embodiments, R8B is a substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of phenylalanine, a divalent form of tyrosine, or a divalent form of tryptophan.
In embodiments,
is a divalent form of phenylalanine. In embodiments, -L8B-R8B is
In embodiments, -L8B-R8B is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L9B is a bond or unsubstituted C1-C4 alkylene. In embodiments, R9B is a substituted or unsubstituted alkyl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of isoleucine, a divalent form of leucine, or a divalent form of valine. In embodiments,
is a divalent form of isoleucine. In embodiments, -L9B-R9B is
In embodiments, -L9B-R9B is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L10B is a bond or unsubstituted C1-C4 alkylene. In embodiments, R10B is a substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of tryptophan, a divalent form of phenylalanine, or a divalent form of tyrosine. In embodiments,
is a divalent form of tryptophan. In embodiments, -L10B-R10B is
In embodiments, -L10B-R10B is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L11B is a bond or unsubstituted C1-C4 alkylene. In embodiments, R11B is a substituted or unsubstituted alkyl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of valine, a divalent form of isoleucine, or a divalent form of leucine. In embodiments,
is a divalent form of vane. In embodiments, -L11B-L11B is
In embodiments, -L11B-R11B is
In embodiments
is a divalent form of an unnatural amino acid. In embodiments, L12B is a bond or unsubstituted C1-C6 alkylene. In embodiments, R12B is —NH2, —NHC(NH)NH2, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted heteroaryl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of histidine, a divalent form of lysine, or a divalent form of arginine. In embodiments,
is a divalent form of histidine. In embodiments, -L12B-R12B is
In embodiments, -L12B-R12B is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L13B is a bond or unsubstituted C1-C6 alkylene. In embodiments, R13B is —NH2, —NHC(NH)NH2, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted heteroaryl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of histidine, a divalent form of lysine, or a divalent form of arginine. In embodiments,
is a divalent form of histidine. In embodiments, -L13B-L13B is
In embodiments, -L13B-R13B is
In embodiments, two substituents selected from R1B, R2B, R3B, R4B, R5B, R6B, L7B, R8B, R9B, R10B, R11B, R12B, and R13B may optionally be joined to form a bioconjugate linker. In embodiments, two substituents selected from R1B, R2B, R3B, R4B, R5B, R6B, L7B, R8B, R9B, R10B, R11B, R12B, and R13B may optionally be joined to form a covalent linker having the formula -L18A-L18B-L18C-L18D-L18E-L18F-, L18A, L18B, L18C, L18D, L18E, and L18F are as described herein, including in embodiments.
In embodiments, the compound of formula (II) is a peptide of
is a divalent form of D-tyrosine;
is a divalent form of isoleucine;
is a divalent form of isoleucine;
is a divalent form of valine;
is a divalent form of threonine;
is a divalent form of glutamic acid;
is a divalent form of lysine;
is a divalent form of phenylalanine;
is a divalent form of isoleucine;
is a divalent form of tryptophan;
is a divalent form of valine;
is a divalent form of histidine; and
is a divalent form of histidine. Where the compound of formula (II) is peptide 7, 8, 9, 10, 11, 12, 13, 14, 16, or 19 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 8 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids).
For example, for peptide 9 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 10 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 11 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 12 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 13 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 14 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 16 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 19 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids).
In embodiments, the compound has the formula:
L16 is as described herein, including in embodiments.
In an aspect is provided a compound having the formula:
R1D, R2D, R3D, R4D, R5D, R6D, R7D, R8D, R9D, R10D, R11D, R12D, R13D, and L16 are as described herein, including in embodiments.
In an aspect is provided a compound having the formula:
R1D, R2D, R3D, R4D, R5D, R6D, R7D, R8D, R9D, R10D, R11D, R12D, R13D, and L16 are as described herein, including in embodiments.
L1C, L2C, L3C, L4C, L5C, L6C, L7C, L8C, L9C, L10C, L11C, L12C, L13C, L14C, and L15C are independently a bond, substituted or unsubstituted alkylene (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), or substituted or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
R1C is independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
R2C is independently hydrogen, —OH, —NO2, —CN, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), or substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
L3 is independently a bond or
R3C is independently hydrogen, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
L4 is independently a bond or
R4C is independently hydrogen, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), or substituted or unsubstituted aryl (e.g., C6-C10 or phenyl).
L5 is independently a bond or
R5C is independently substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
L6 is independently a bond,
R6C is independently hydrogen, —CN, —NH2, —C(O)NH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), or substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
R7C and R8C are independently hydrogen, —CN, —NH2, —C(O)NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
L9 is independently a bond,
R9C is independently hydrogen, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), or substituted or unsubstituted aryl (e.g., C6-C10 or phenyl).
L10 is independently a bond,
R10C is independently hydrogen, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
L11 is independently a bond or
R11C is independently hydrogen, —CN, —OH, —C(O)OH, —NO2, —SO3H, —OSO3H, —NH2, —C(O)NH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), or substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
R12C is independently hydrogen, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
L13 is independently
R13C is independently hydrogen, —OH, —NH2, —C(O)OH, —C(O)NH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), or substituted or unsubstituted aryl (e.g., C6-C10 or phenyl).
L14 is independently a bond or
R14C is independently hydrogen, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
L15 is independently a bond or
R15C is independently hydrogen, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
Two substituents selected from R1C, R2C, R3C, R4C, R5C, R6C, R7C, R8C, R9C, R10C, R11C, R12C, R13C, R14C, and R15C may optionally be joined to form a covalent linker.
R14D and R15D are independently hydrogen or unsubstituted C1-C4 alkyl.
In embodiments, the compound has the formula:
L1C, L2C, L3, L4, L5, L6, L7C, L8C, L9, L10, L11, L12C, L13, L14, L15, L16, R1C, R2C, R7C, R8C, and R12C are as described herein, including in embodiments.
In embodiments, the compound has the formula:
L1C, L2C, L3, L4, L5, L6, L7C, L8C, L9, L10, L11, L12C, L13, L14, L15, L16, R1C, R2C, R7C, R8C, and R12C are as described herein, including in embodiments.
In embodiments, the compound has the formula:
L1C, L2C, L3, L4, L5, L6, L7C, L8C, L9, L10, L11, L12C, L13, L14, L15, L16, R1C, R2C, R7C, R8C, and R12C are as described herein, including in embodiments.
In embodiments, the compound has the formula:
L1C, L2C, L3, L4, L5, L6, L7C, L8C, L9, L10, L11, L12C, L13, L14, L15, L16, R1C, R2C, R7C, R8C, and R12C are as described herein, including in embodiments.
In embodiments, a substituted L1C (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L1C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L1C is substituted, it is substituted with at least one substituent group. In embodiments, when L1C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L1C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L2C (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L2C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L2C is substituted, it is substituted with at least one substituent group. In embodiments, when L2C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L2C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L3C (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L3C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L3C is substituted, it is substituted with at least one substituent group. In embodiments, when L3C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L3C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L4C (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L4C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L4C is substituted, it is substituted with at least one substituent group. In embodiments, when L4C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L4C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L5C (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L5C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L5C is substituted, it is substituted with at least one substituent group. In embodiments, when L5C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L5C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L6C (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L6C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L6C is substituted, it is substituted with at least one substituent group. In embodiments, when L6C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L6C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L7C (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L7C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L7C is substituted, it is substituted with at least one substituent group. In embodiments, when L7C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L7C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L8C (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L8C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L8C is substituted, it is substituted with at least one substituent group. In embodiments, when L8C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L8C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L9C (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L9C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L9C is substituted, it is substituted with at least one substituent group. In embodiments, when L9C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L9C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L10C (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L10C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L10C is substituted, it is substituted with at least one substituent group. In embodiments, when L10C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L10C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L11C (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L11C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L11C is substituted, it is substituted with at least one substituent group. In embodiments, when L11C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L11C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L12C (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L12C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L12C is substituted, it is substituted with at least one substituent group. In embodiments, when L12C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L12C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L13C (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L13C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L13C is substituted, it is substituted with at least one substituent group. In embodiments, when L13C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L13C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L14C (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L14C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L14C is substituted, it is substituted with at least one substituent group. In embodiments, when L14C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L14C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L15C (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L15C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L15C is substituted, it is substituted with at least one substituent group. In embodiments, when L15C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L15C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R1C (e.g., substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R1C is substituted, it is substituted with at least one substituent group. In embodiments, when R1C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R2C (e.g., substituted alkyl and/or substituted heteroalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R2C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R2C is substituted, it is substituted with at least one substituent group. In embodiments, when R2C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R2C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R3C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R3C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R3C is substituted, it is substituted with at least one substituent group. In embodiments, when R3C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R3C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R4C (e.g., substituted alkyl, substituted cycloalkyl, and/or substituted aryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R4C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R4C is substituted, it is substituted with at least one substituent group. In embodiments, when R4C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R4C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R5C (e.g., substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R5C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R5C is substituted, it is substituted with at least one substituent group. In embodiments, when R5C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R5C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R6C (e.g., substituted alkyl and/or substituted heteroalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R6C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R6C is substituted, it is substituted with at least one substituent group. In embodiments, when R6C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R6C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R7C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R7C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R7C is substituted, it is substituted with at least one substituent group. In embodiments, when R7C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R7C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R8C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R8C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R8C is substituted, it is substituted with at least one substituent group. In embodiments, when R8C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R8C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R9C (e.g., substituted alkyl, substituted cycloalkyl, and/or substituted aryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R9C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R9C is substituted, it is substituted with at least one substituent group. In embodiments, when R9C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R9C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R10C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R10C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R10C is substituted, it is substituted with at least one substituent group. In embodiments, when R10C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R10C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R11C (e.g., substituted alkyl and/or substituted heteroalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R11C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R11C is substituted, it is substituted with at least one substituent group. In embodiments, when R11C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R11C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R12C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R12C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R12C is substituted, it is substituted with at least one substituent group. In embodiments, when R12C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R12C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R13C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, and/or substituted aryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R13C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R13C is substituted, it is substituted with at least one substituent group. In embodiments, when R13C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R13C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R14C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R14C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R14C is substituted, it is substituted with at least one substituent group. In embodiments, when R14C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R14C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R15C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R15C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R15C is substituted, it is substituted with at least one substituent group. In embodiments, when R15C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R15C is substituted, it is substituted with at least one lower substituent group.
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L1C is a bond or unsubstituted C1-C4 alkylene. In embodiments, R1C is a substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of tyrosine, a divalent form of phenylalanine, or a divalent form of tryptophan.
In embodiments,
is a divalent form of tyrosine. In embodiments, -L1C-R1C is
In embodiments, -L1C-R1C is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L2C is a bond or unsubstituted C1-C6 alkylene. In embodiments, R2C is —C(O)OH, —C(O)NH2, —NHC(NH)NH2, or substituted or unsubstituted heteroalkyl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of asparagine, a divalent form of glutamine, a divalent form of aspartic acid, or a divalent form of arginine. In embodiments,
is a divalent form of asparagine. In embodiments,
is a divalent form of glutamine. In embodiments,
is a divalent form of aspartic acid. In embodiments,
is a divalent form of arginine. In embodiments, -L2C-R2C is
In embodiments, -L2C-R2C is
In embodiments, -L2C-R2C is
In embodiments, -L2C-R2C is
In embodiments, -L2C-R2C is
In embodiments, L3 is independently a bond or
In embodiments, L3 is independently a bond or
In embodiments, L3 is independently a bond or
In embodiments, L3 is independently a bond. In embodiments, L3 is independently
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L3C is a bond or unsubstituted C1-C4 alkylene. In embodiments, R3C is a —C(O)NH2, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of tyrosine, a divalent form of phenylalanine, a divalent form of tryptophan, a divalent form of asparagine, or a divalent form of glutamine. In embodiments,
is a divalent form of tyrosine. In embodiments,
is a divalent form of asparagine. In embodiments, -L3C-R3C is
In embodiments, -L3C-R3C is
In embodiments, -L3C-R3C is
In embodiments, L4 is independently a bond or
In embodiments, L4 is independently a bond or
In embodiments, L4 is independently a bond or
In embodiments, L4 is independently a bond. In embodiments, L4 is independently
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L4C is a bond or unsubstituted C1-C4 alkylene. In embodiments, R4C is a substituted or unsubstituted alkyl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of leucine, a divalent form of isoleucine, or a divalent form of valine. In embodiments,
is a divalent form of leucine. In embodiments,
is a divalent form of isoleucine. In embodiments, -L4C-R4C is
In embodiments, -L4C-R4C is
In embodiments, -L4C-R4C is
In embodiments, L5 is independently a bond or
In embodiments, L5 is independently a bond or
In embodiments, L5 is independently a bond or
In embodiments, L5 is independently a bond. In embodiments, L5 is independently
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L5C is a bond or unsubstituted C1-C4 alkylene. In embodiments, R5C is a substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of tyrosine, a divalent form of phenylalanine, or a divalent form of tryptophan. In embodiments,
is a divalent form of tyrosine. In embodiments, -L5C-R5C is
In embodiments, -L5C-R5C is OH.
In embodiments, L6 is independently a bond,
In embodiments, L6 is independently a bond,
In embodiments, L6 is independently a bond,
In embodiments, L6 is independently a bond. In embodiments, L6 is independently
In embodiments, L6 is independently
In embodiments, L6 is independently a divalent form of proline. In embodiments, L6 is independently
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L6C is a bond or unsubstituted C1-C6 alkylene. In embodiments, R6C is —NHC(NH)NH2 or substituted or unsubstituted heteroalkyl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of arginine. In embodiments, -L6C-R6C is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L7C is a bond or unsubstituted C1-C4 alkylene. In embodiments, R7C is a substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of tyrosine, a divalent form of phenylalanine, or a divalent form of tryptophan.
In embodiments,
is a divalent form of tyrosine. In embodiments,
is a divalent form of tryptophan. In embodiments, -L7C-R7C is
In embodiments, -L7C-R7C is
In embodiments, -L7C-R7C is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L8C is a bond or unsubstituted C1-C6 alkylene. In embodiments, R8C is —NH2, —NHC(NH)NH2, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of arginine, a divalent form of histidine, a divalent form of lysine, a divalent form of phenylalanine, or a divalent form of tyrosine. In embodiments,
is a divalent form of arginine. In embodiments,
is a divalent form of histidine. In embodiments,
is a divalent form of tyrosine. In embodiments, -L8C-R8C is
In embodiments, -L8C-R8C is
In embodiments, -L8C-R8C is
In embodiments, -L8C-R8C is
In embodiments, L9 is independently a bond,
In embodiments, L9 is independently a bond,
In embodiments, L9 is independently a bond,
In embodiments, L9 is independently a bond. In embodiments, L9 is independently
In embodiments, L9 is independently
In embodiments, L9 is independently
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments,
is a divalent form of a natural amino acid.
In embodiments, L10 is independently a bond,
In embodiments, L10 is independently a bond,
In embodiments, L10 is independently a bond,
In embodiments, L10 is independently a bond. In embodiments, L10 is independently
In embodiments, L10 is independently
In embodiments, L10 is independently
In embodiments
is a divalent form of an unnatural amino acid. In embodiments, L10C is a bond or unsubstituted C1-C4 alkylene. In embodiments, R10C is a substituted or unsubstituted alkyl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of alanine, a divalent form of valine, a divalent form of leucine, or a divalent form of isoleucine. In embodiments,
is a divalent form of alanine. In embodiments,
is a divalent form of valine. In embodiments,
is a divalent form of leucine. In embodiments, -L10C-R10C is —CH3,
In embodiments, -L10C-R10C is —CH3. In embodiments, -L10C-R10C is
In embodiments, -L10C-R10C is
In embodiments, L11 is independently a bond or
In embodiments, L11 is independently a bond or
In embodiments, L11 is independently a bond or
In embodiments, L11 is independently a bond. In embodiments,
L11 is independently
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L11C is a bond or unsubstituted C1-C4 alkylene. In embodiments, R11C is —C(O)OH or substituted or unsubstituted heteroalkyl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of glutamic acid or a divalent form of aspartic acid. In embodiments,
is a divalent form of glutamic acid. In embodiments, -L11C-R11C is
In embodiments, -L11C-R11C is
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L12C is a bond or unsubstituted C1-C4 alkylene. In embodiments, R12C is a substituted or unsubstituted alkyl or a substituted or unsubstituted aryl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of leucine, a divalent form of isoleucine, a divalent form of valine, a divalent form of phenylalanine, or a divalent form of tyrosine. In embodiments,
is a divalent form of leucine. In embodiments,
is a divalent form of isoleucine. In embodiments,
is a divalent form of phenylalanine. In embodiments, -L12C-R12C is
In embodiments, -L12C-R12C is
In embodiments, -L12C-R12C is
In embodiments, -L12C-R12C is
In embodiments, L13 is independently
In embodiments, L13 is independently
In embodiments, L13 is independently
In embodiments, L13 is independently
In embodiments, L13 is independently
In embodiments, L13 is independently
In embodiments, L13C is a bond or unsubstituted C1-C4 alkylene. In embodiments, R13C is hydrogen, —OH, or substituted or unsubstituted alkyl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of glycine, a divalent form of alanine, a divalent form of leucine, or a divalent form of serine. In embodiments,
is a divalent form of glycine. In embodiments,
is a divalent form of leucine. In embodiments,
is a divalent form of serine. In embodiments, -L13C-R13C is —H, —CH3,
In embodiments, -L13C-R13C is —H. In embodiments, -L13C-R13C is
In embodiments, -L13C-R13C is
In embodiments, L14 is independently a bond or
In embodiments, L14 is independently a bond or
In embodiments, L14 is independently a bond or
In embodiments, L14 is independently a bond. In embodiments, L14 is independently
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L14C is a bond or unsubstituted C1-C4 alkylene. In embodiments, R14C is a substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of tryptophan, a divalent form of phenylalanine, or a divalent form of tyrosine. In embodiments,
is a divalent form of tryptophan. In embodiments,
is a divalent form of tyrosine. In embodiments, -L14C-R14C is
In embodiments, -L14C-R14C is
In embodiments, -L14C-R14C is
In embodiments, L15 is independently a bond or
In embodiments, L15 is independently a bond or
In embodiments, L15 is independently a bond or
In embodiments, L15 is independently a bond. In embodiments, L15 is independently
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments, L15C is a bond or unsubstituted C1-C4 alkylene. In embodiments, R15C is a substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In embodiments,
is a divalent form of a natural amino acid. In embodiments,
is a divalent form of tyrosine, a divalent form of phenylalanine, or a divalent form of tryptophan. In embodiments,
is a divalent form of tyrosine. In embodiments,
is a divalent form of tryptophan. In embodiments, -L15C-R15C is
In embodiments, -L15C-R15C is
In embodiments, -L15C-R15C is
In embodiments, two substituents selected from R1C, R2C, R3C, R4C, R5C, R6C, R7C, R8C, R9C, R10C, R11C, R12C, R13C, R14C, and R15C may optionally be joined to form a bioconjugate linker. In embodiments, two substituents selected from R1C, R2C, R3C, R4C, R5C, R6C, R7C, R8C, R9C, R10C, R11C, R12C, R13C, R14C, and R15C may optionally be joined to form a covalent linker having the formula -L18A-L18B-L18C-L18D-L18E-L18F; L18A, L18B, L18C, L18D, L18E, and L18F are as described herein, including in embodiments.
In embodiments, the compound of formula (III) is a peptide of
is a divalent form of D-tyrosine;
is a divalent form of asparagine; L3 and L4 are a bond;
is a divalent form of tyrosine; L6 is
is a divalent form of tyrosine;
is a divalent form of arginine; L9 is
is a divalent form of leucine;
is a divalent form of glutamic acid;
is a divalent form of leucine;
is a divalent form of glycine;
is a divalent form of tryptophan; and
is a divalent form of tyrosine. Where the compound of formula (III) is peptide 3, 4, 6, 18, or 20 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids).
For example, for peptide 4 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 6 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 18 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 20 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids).
In embodiments, the compound has the formula:
L16 is as described herein, including in embodiments.
In an aspect is provided a compound having the formula:
R1D, R2D, R3D, R4D, R5D, R6D, R7D, R8D, R9D, R10D, R11D, R12D, R13D, R14D, R15D, and L16 are as described herein, including in embodiments.
L1F, L2F, L3F, L4F, L5F, L6F, L7F, L8F, L9F, L10F, L11F, L12F, L13F, L14F, and L15F are independently a bond, substituted or unsubstituted alkylene (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), or substituted or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
R1F is substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
R2F is hydrogen, —OH, —NO2, —CN, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), or substituted or unsubstituted aryl (e.g., C6-C10 or phenyl).
L23 is a bond or
R3F is hydrogen, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
L24 is a bond or
R4F is hydrogen, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), or substituted or unsubstituted aryl (e.g., C6-C10 or phenyl).
L25 is a bond or
R5F is —OH, —NO2, —CN, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
L26 is a bond,
R6F is hydrogen, —OH, —NO2, —CN, —NH2, —C(O)OH, —C(O)NH2, —SH—, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), or substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
R7F and R8F are independently hydrogen, —OH, —NO2, —CN, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
L29 is a bond,
R9F is hydrogen, —OH, —NO2, —CN, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
L30 is a bond,
R10F is hydrogen, —OH, —NO2, —CN, —NH2, —C(O)OH, —C(O)NH2, —SH, SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
L31 is a bond,
R11F is hydrogen, —CN, —OH, —C(O)OH, —NO2, —SO3H, —OSO3H, —NH2, —C(O)NH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), or substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered).
R12F is hydrogen, —OH, —NO2, —CN, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
L33 is
R13F is hydrogen, —OH, —NH2, —C(O)OH, —C(O)NH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
L34 is a bond or
R14F is hydrogen, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
L35 is a bond or
R15F is hydrogen, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
Two substituents selected from R1F, R2F, R3F, R4F, R5F, R6F, R7F, R8F, R9F, R10F, R11F, R12F, R13F, R14F, and R15F may optionally be joined to form a covalent linker.
In embodiments, the compound has the formula:
L1F, L2F, L23, L24, L25, L26, L7F, L8F, L29, L30, L31, L12F, L33, L34, L35, L16, R1F, R2F, R7F, R8F, and R12F are as described herein, including in embodiments.
In embodiments, the compound has the formula:
L1F, L2F, L23, L24, L25, L26, L7F, L8F, L29, L30, L31, L12F, L33, L34, L35, L16, R1F, R2F, R7F, R8F, and R12F are as described herein, including in embodiments.
In embodiments, a substituted L1F (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L1F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L1F is substituted, it is substituted with at least one substituent group. In embodiments, when L1F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L1F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L2F (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L2F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L2F is substituted, it is substituted with at least one substituent group. In embodiments, when L2F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L2F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L3F (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L3F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L3F is substituted, it is substituted with at least one substituent group. In embodiments, when L3F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L3F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L4F (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L4F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L4F is substituted, it is substituted with at least one substituent group. In embodiments, when L4F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L4F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L5F (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L5F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L5F is substituted, it is substituted with at least one substituent group. In embodiments, when L5F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L5F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L6F (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L6F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L6F is substituted, it is substituted with at least one substituent group. In embodiments, when L6F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L6F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L7F (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L7F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L7F is substituted, it is substituted with at least one substituent group. In embodiments, when L7F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L7F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L8F (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L8F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L8F is substituted, it is substituted with at least one substituent group. In embodiments, when L8F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L8F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L9F (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L9F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L9F is substituted, it is substituted with at least one substituent group. In embodiments, when L9F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L9F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L10F (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L10F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L10F is substituted, it is substituted with at least one substituent group. In embodiments, when L10F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L10F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L11F (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L11F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L11F is substituted, it is substituted with at least one substituent group. In embodiments, when L11F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L11F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L12F (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L12F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L12F is substituted, it is substituted with at least one substituent group. In embodiments, when L12F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L12F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L13F (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L13F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L13F is substituted, it is substituted with at least one substituent group. In embodiments, when L13F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L13F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L14F (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L14F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L14F is substituted, it is substituted with at least one substituent group. In embodiments, when L14F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L14F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L15F (e.g., substituted alkylene and/or substituted heteroalkylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L15F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L15F is substituted, it is substituted with at least one substituent group. In embodiments, when L15F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L15F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R1F (e.g., substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R1F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R1F is substituted, it is substituted with at least one substituent group. In embodiments, when R1F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R1F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R2F (e.g., substituted alkyl, substituted heteroalkyl, and/or substituted aryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R2F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R2F is substituted, it is substituted with at least one substituent group. In embodiments, when R2F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R2F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R3F (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R3F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R3F is substituted, it is substituted with at least one substituent group. In embodiments, when R3F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R3F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R4F (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, and/or substituted aryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R4F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R4F is substituted, it is substituted with at least one substituent group. In embodiments, when R4F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R4F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R5F (e.g., substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R5F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R5F is substituted, it is substituted with at least one substituent group. In embodiments, when R5F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R5F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R6F (e.g., substituted alkyl and/or substituted heteroalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R6F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R6F is substituted, it is substituted with at least one substituent group. In embodiments, when R6F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R6F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R7F (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R7F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R7F is substituted, it is substituted with at least one substituent group. In embodiments, when R7F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R7F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R8F (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R8F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R8F is substituted, it is substituted with at least one substituent group. In embodiments, when R8F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R8F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R9F (e.g., substituted alkyl, substituted cycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R9F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R9F is substituted, it is substituted with at least one substituent group. In embodiments, when R9F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R9F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R10F (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R10F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R10F is substituted, it is substituted with at least one substituent group. In embodiments, when R10F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R10F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R11F (e.g., substituted alkyl and/or substituted heteroalkyl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R11F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R11F is substituted, it is substituted with at least one substituent group. In embodiments, when R11F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R11F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R12F (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R12F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R12F is substituted, it is substituted with at least one substituent group. In embodiments, when R12F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R12F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R13F (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R13F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R13F is substituted, it is substituted with at least one substituent group. In embodiments, when R13F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R13F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R14F (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R14F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R14F is substituted, it is substituted with at least one substituent group. In embodiments, when R14F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R14F is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted R15F (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R15F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R15F is substituted, it is substituted with at least one substituent group. In embodiments, when R15F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R15F is substituted, it is substituted with at least one lower substituent group.
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments,
is a divalent form of a natural amino acid.
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments,
is a divalent form of a natural amino acid.
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments,
is a divalent form of a natural amino acid.
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments,
is a divalent form of a natural amino acid.
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments,
is a divalent form of a natural amino acid.
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments,
is a divalent form of a natural amino acid.
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments,
is a divalent form of a natural amino acid.
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments,
is a divalent form of a natural amino acid.
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments,
is a divalent form of a natural amino acid.
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments,
is a divalent form of a natural amino acid.
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments,
is a divalent form of a natural amino acid.
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments,
is a divalent form of a natural amino acid.
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments,
is a divalent form of a natural amino acid.
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments,
is a divalent form of a natural amino acid.
In embodiments,
is a divalent form of an unnatural amino acid. In embodiments,
is a divalent form of a natural amino acid.
In embodiments, the compound of formula (IV) is a peptide of
is a divalent form of D-tyrosine;
is a divalent form of cysteine;
L23, L24, and L25 are a bond; L26 is
is a divalent form of phenylalanine;
is a divalent form of threonine;
is a divalent form of tryptophan;
is a divalent form of leucine;
is a divalent form of threonine;
is a divalent form of cysteine;
is a divalent form of leucine;
is a divalent form of tyrosine; and
is a divalent form of lysine. Where the compound of formula (IV) is peptide 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 3 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 4 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 5 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 6 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 7 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 8 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 9 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 10 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 11 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 12 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 13 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 14 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 15 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 16 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 17 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 18 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 19 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids). For example, for peptide 20 of
is a divalent form of D-tyrosine (with the same exemplification of the remaining amino acids).
In embodiments, R1D is independently hydrogen. In embodiments, R1D is independently unsubstituted methyl. In embodiments, R2D is independently hydrogen. In embodiments, R2D is independently unsubstituted methyl. In embodiments, R3D is independently hydrogen. In embodiments, R3D is independently unsubstituted methyl. In embodiments, R4D is independently hydrogen. In embodiments, R4D is independently unsubstituted methyl. In embodiments, R5D is independently hydrogen. In embodiments, R5D is independently unsubstituted methyl. In embodiments, R6D is independently hydrogen. In embodiments, R6D is independently unsubstituted methyl. In embodiments, R7D is independently hydrogen. In embodiments, R7D is independently unsubstituted methyl. In embodiments, R8D is independently hydrogen. In embodiments, R8D is independently unsubstituted methyl. In embodiments, R9D is independently hydrogen. In embodiments, R9D is independently unsubstituted methyl. In embodiments, R10D is independently hydrogen. In embodiments, R10D is independently unsubstituted methyl. In embodiments, R1D is independently hydrogen. In embodiments, R1D is independently unsubstituted methyl. In embodiments, R12D is independently hydrogen. In embodiments, R12D is independently unsubstituted methyl. In embodiments, R13D is independently hydrogen. In embodiments, R13D is independently unsubstituted methyl. In embodiments, R14D is independently hydrogen. In embodiments, R14D is independently unsubstituted methyl. In embodiments, R15D is independently hydrogen. In embodiments, R15D is independently unsubstituted methyl.
In embodiments, R1D is independently hydrogen. In embodiments, R1D is independently unsubstituted methyl. In embodiments, R1D is independently unsubstituted ethyl. In embodiments, R1D is independently unsubstituted propyl. In embodiments, R1D is independently unsubstituted butyl. In embodiments, R1D is independently unsubstituted pentyl. In embodiments, R1D is independently unsubstituted isopentyl. In embodiments, R2D is independently hydrogen. In embodiments, R2D is independently unsubstituted methyl. In embodiments, R2D is independently unsubstituted ethyl. In embodiments, R2D is independently unsubstituted propyl. In embodiments, R2D is independently unsubstituted butyl. In embodiments, R2D is independently unsubstituted pentyl. In embodiments, R2D is independently unsubstituted isopentyl. In embodiments, R3D is independently hydrogen. In embodiments, R3D is independently unsubstituted methyl. In embodiments, R3D is independently unsubstituted ethyl. In embodiments, R3D is independently unsubstituted propyl. In embodiments, R3D is independently unsubstituted butyl. In embodiments, R3D is independently unsubstituted pentyl. In embodiments, R3D is independently unsubstituted isopentyl. In embodiments, R4D is independently hydrogen. In embodiments, R4D is independently unsubstituted methyl. In embodiments, R4D is independently unsubstituted ethyl. In embodiments, R4D is independently unsubstituted propyl. In embodiments, R4D is independently unsubstituted butyl. In embodiments, R4D is independently unsubstituted pentyl. In embodiments, R4D is independently unsubstituted isopentyl. In embodiments, R5D is independently hydrogen. In embodiments, R5D is independently unsubstituted methyl. In embodiments, R5D is independently unsubstituted ethyl. In embodiments, R5D is independently unsubstituted propyl. In embodiments, R5D is independently unsubstituted butyl. In embodiments, R5D is independently unsubstituted pentyl. In embodiments, R5D is independently unsubstituted isopentyl. In embodiments, R6D is independently hydrogen. In embodiments, R6D is independently unsubstituted methyl. In embodiments, R6D is independently unsubstituted ethyl. In embodiments, R6D is independently unsubstituted propyl. In embodiments, R6D is independently unsubstituted butyl. In embodiments, R6D is independently unsubstituted pentyl. In embodiments, R6D is independently unsubstituted isopentyl. In embodiments, R7D is independently hydrogen. In embodiments, R7D is independently unsubstituted methyl. In embodiments, R7D is independently unsubstituted ethyl. In embodiments, R7D is independently unsubstituted propyl. In embodiments, R7D is independently unsubstituted butyl. In embodiments, R7D is independently unsubstituted pentyl. In embodiments, R7D is independently unsubstituted isopentyl. In embodiments, R8D is independently hydrogen. In embodiments, R8D is independently unsubstituted methyl. In embodiments, R8D is independently unsubstituted ethyl. In embodiments, R8D is independently unsubstituted propyl. In embodiments, R8D is independently unsubstituted butyl. In embodiments, R8D is independently unsubstituted pentyl. In embodiments, R8D is independently unsubstituted isopentyl. In embodiments, R9D is independently hydrogen. In embodiments, R9D is independently unsubstituted methyl. In embodiments, R9D is independently unsubstituted ethyl. In embodiments, R9D is independently unsubstituted propyl. In embodiments, R9D is independently unsubstituted butyl. In embodiments, R9D is independently unsubstituted pentyl. In embodiments, R9D is independently unsubstituted isopentyl. In embodiments, R10D is independently hydrogen. In embodiments, R10D is independently unsubstituted methyl. In embodiments, R10D is independently unsubstituted ethyl. In embodiments, R10D is independently unsubstituted propyl. In embodiments, R10D is independently unsubstituted butyl. In embodiments, R10D is independently unsubstituted pentyl. In embodiments, R10D is independently unsubstituted isopentyl. In embodiments, R11D is independently hydrogen. In embodiments, R11D is independently unsubstituted methyl. In embodiments, R11D is independently unsubstituted ethyl. In embodiments, R11D is independently unsubstituted propyl. In embodiments, R11D is independently unsubstituted butyl. In embodiments, R11D is independently unsubstituted pentyl. In embodiments, R11D is independently unsubstituted isopentyl. In embodiments, R12D is independently hydrogen. In embodiments, R12D is independently unsubstituted methyl. In embodiments, R12D is independently unsubstituted ethyl. In embodiments, R12D is independently unsubstituted propyl. In embodiments, R12D is independently unsubstituted butyl. In embodiments, R12D is independently unsubstituted pentyl. In embodiments, R12D is independently unsubstituted isopentyl. In embodiments, R13D is independently hydrogen. In embodiments, R13D is independently unsubstituted methyl. In embodiments, R13D is independently unsubstituted ethyl. In embodiments, R13D is independently unsubstituted propyl. In embodiments, R13D is independently unsubstituted butyl. In embodiments, R13D is independently unsubstituted pentyl. In embodiments, R13D is independently unsubstituted isopentyl. In embodiments, R14D is independently hydrogen. In embodiments, R14D is independently unsubstituted methyl. In embodiments, R14D is independently unsubstituted ethyl. In embodiments, R14D is independently unsubstituted propyl. In embodiments, R14D is independently unsubstituted butyl. In embodiments, R14D is independently unsubstituted pentyl. In embodiments, R14D is independently unsubstituted isopentyl. In embodiments, R15D is independently hydrogen. In embodiments, R15D is independently unsubstituted methyl. In embodiments, R15D is independently unsubstituted ethyl. In embodiments, R15D is independently unsubstituted propyl. In embodiments, R15D is independently unsubstituted butyl. In embodiments, R15D is independently unsubstituted pentyl. In embodiments, R15D is independently unsubstituted isopentyl.
In embodiments, L16 is a bioconjugate linker. In embodiments, L16 is a substituted or unsubstituted divalent amino acid. In embodiments, L16 is a substituted or unsubstituted divalent δ-amino acid.
In embodiments, a substituted L16 (e.g., substituted divalent amino acid and/or substituted divalent δ-amino acid) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L16 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L16 is substituted, it is substituted with at least one substituent group. In embodiments, when L16 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L16 is substituted, it is substituted with at least one lower substituent group.
In embodiments, L16 is -L16A-L16B-L16C-L16D-L16E-L16F-.
L16A, L16B, L16C, L16D, L16E, and L16F are independently bond, —SS—, —S(O)2—, —OS(O)2—, —S(O)2O—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkylene (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted arylene (e.g., C6-C10 or phenylene), or substituted or unsubstituted heteroarylene (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
In embodiments, a substituted L16A (e.g., substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L16A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L16A is substituted, it is substituted with at least one substituent group. In embodiments, when L16A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L16A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L16B (e.g., substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L16B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L16B is substituted, it is substituted with at least one substituent group. In embodiments, when L16B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L16B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L16C (e.g., substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L16C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L16C is substituted, it is substituted with at least one substituent group. In embodiments, when L16C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L16C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L16D (e.g., substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L16D is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L16D is substituted, it is substituted with at least one substituent group. In embodiments, when L16D is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L16D is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L16E (e.g., substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L16E is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L16E is substituted, it is substituted with at least one substituent group. In embodiments, when L16E is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L16E is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L16F (e.g., substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L16F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L16F is substituted, it is substituted with at least one substituent group. In embodiments, when L16F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L16F is substituted, it is substituted with at least one lower substituent group.
In embodiments, L16A is independently bond, —SS—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, or substituted or unsubstituted heteroarylene. In embodiments, L16A is independently bond. In embodiments, L16A is independently —SS—. In embodiments, L16A is independently substituted or unsubstituted C1-C4 alkylene. In embodiments, L16A is independently substituted or unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L16A is independently substituted or unsubstituted 3 to 6 membered heteroarylene. In embodiments, L16A is independently unsubstituted triazolylene. In embodiments, L16A is independently
In embodiments, L16B is independently bond, —SS—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, or substituted or unsubstituted heteroarylene. In embodiments, L16B is independently bond. In embodiments, L16B is independently —SS—. In embodiments, L16B is independently substituted or unsubstituted C1-C4 alkylene. In embodiments, L16B is independently substituted or unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L16B is independently substituted or unsubstituted 3 to 6 membered heteroarylene. In embodiments, L16B is independently unsubstituted triazolylene. In embodiments, L16B is independently
In embodiments, L16C is independently bond, —SS—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, or substituted or unsubstituted heteroarylene. In embodiments, L16C is independently bond. In embodiments, L16C is independently —SS—. In embodiments, L16C is independently substituted or unsubstituted C1-C4 alkylene. In embodiments, L16C is independently substituted or unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L16C is independently substituted or unsubstituted 3 to 6 membered heteroarylene. In embodiments, L16C is independently unsubstituted triazolylene. In embodiments, L16C is independently
In embodiments, L16D is independently bond, —SS—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, or substituted or unsubstituted heteroarylene. In embodiments, L16D is independently bond. In embodiments, L16D is independently —SS—. In embodiments, L16D is independently substituted or unsubstituted C1-C4 alkylene. In embodiments, L16D is independently substituted or unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L16D is independently substituted or unsubstituted 3 to 6 membered heteroarylene. In embodiments, L16D is independently unsubstituted triazolylene. In embodiments, L16D is independently
In embodiments, L16E is independently bond, —SS—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, or substituted or unsubstituted heteroarylene. In embodiments, L16E is independently bond. In embodiments, L16E is independently —SS—. In embodiments, L16E is independently substituted or unsubstituted C1-C4 alkylene. In embodiments, L16E is independently substituted or unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L16E is independently substituted or unsubstituted 3 to 6 membered heteroarylene. In embodiments, L16E is independently unsubstituted triazolylene. In embodiments, L16E is independently
In embodiments, L16F is independently bond, —SS—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, or substituted or unsubstituted heteroarylene. In embodiments, L16F is independently bond. In embodiments, L16F is independently —SS—. In embodiments, L16F is independently substituted or unsubstituted C1-C4 alkylene. In embodiments, L16F is independently substituted or unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L16F is independently substituted or unsubstituted 3 to 6 membered heteroarylene. In embodiments, L16F is independently unsubstituted triazolylene. In embodiments, L16F is independently
In embodiments, -L16B-L16C-L16D- is —SS—,
In embodiments, L16 is —NH-L16B-L16C-L16D-L16E-C(O)—.
In embodiments, L16B is
L17 is -L17A-L17B-L17C-L17D-L17E-L17F-.
L17A, L17B, L17C, L17D, L17E, and L17F are independently bond, —SS—, —S(O)2—, —OS(O)2—, —S(O)2O—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkylene (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkylene (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkylene (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted arylene (e.g., C6-C10 or phenylene), or substituted or unsubstituted heteroarylene (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered).
R17 is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —C(O)OH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered), a monovalent nucleic acid, a monovalent protein, a detectable moiety, or a drug moiety.
In embodiments, L16 is a bond,
L17 and R17 are as described herein, including in embodiments. In embodiments, L16 is a bond. In embodiments, L16 is
L17 and R17 are as described herein, including in embodiments. In embodiments, L16 is
L17 and R17 are as described herein, including in embodiments. In embodiments, L16 is
L17 and R17 are as described herein, including in embodiments. In embodiments, L16 is
L17 and R17 are as described herein, including in embodiments. In embodiments, L16 is
L17 and R17 are as described herein, including in embodiments. In embodiments, L16 is
L17 and R17 are as described herein, including in embodiments. In embodiments, L16 is
L17 and R17 are as described herein, including in embodiments.
In embodiments, L16 is
L17 and R17 are as described herein, including in embodiments.
In embodiments, a substituted L17A (e.g., substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L17A is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L17A is substituted, it is substituted with at least one substituent group. In embodiments, when L17A is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L17A is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L17B (e.g., substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L17B is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L17B is substituted, it is substituted with at least one substituent group. In embodiments, when L17B is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L17B is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L17C (e.g., substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L17C is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L17C is substituted, it is substituted with at least one substituent group. In embodiments, when L17C is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L17C is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L17D (e.g., substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L17D is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L17D is substituted, it is substituted with at least one substituent group. In embodiments, when L17D is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L17D is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L17E (e.g., substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L17E is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L17E is substituted, it is substituted with at least one substituent group. In embodiments, when L17E is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L17E is substituted, it is substituted with at least one lower substituent group.
In embodiments, a substituted L17F (e.g., substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and/or substituted heteroarylene) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted L17F is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when L17F is substituted, it is substituted with at least one substituent group. In embodiments, when L17F is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when L17F is substituted, it is substituted with at least one lower substituent group.
In embodiments, L17A is a bond, unsubstituted alkylene, or unsubstituted heteroalkylene. In embodiments, L17A is a bond, unsubstituted C1-C6 alkylene, or unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L17A is a bond. In embodiments, L17A is unsubstituted C1-C6 alkylene. In embodiments, L17A is unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L17A is
n is independently an integer from 1 to 100. In embodiments, n is independently an integer from 1 to 5.
In embodiments, L17B is a bond, —NHC(O)—, —C(O)NH—, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene. In embodiments, L17B is a bond, —NHC(O)—, —C(O)NH—, substituted or unsubstituted C1-C6 alkylene, or substituted or unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L17B is a bond. In embodiments, L17B is —NHC(O)—. In embodiments, L17B is —C(O)NH—. In embodiments, L17B is substituted or unsubstituted C1-C6 alkylene. In embodiments, L17B is substituted or unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L17B is
n is independently an integer from 1 to 100. In embodiments, n is independently an integer from 1 to 5.
In embodiments, L17C is a bond, unsubstituted alkylene, or unsubstituted heteroalkylene. In embodiments, L17C is a bond, unsubstituted C1-C6 alkylene, or unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L17C is a bond. In embodiments, L17C is unsubstituted C1-C6 alkylene. In embodiments, L17C is unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L17c is
n is independently an integer from 1 to 100. In embodiments, n is independently an integer from 1 to 5.
In embodiments, L17D is a bond, —O—, unsubstituted alkylene, or unsubstituted heteroalkylene. In embodiments, L17D is a bond, —O—, unsubstituted C1-C8 alkylene, or unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L17D is a bond. In embodiments, L17D is —O—. In embodiments, L17D is unsubstituted C1-C8 alkylene. In embodiments, L17D is unsubstituted 2 to 6 membered heteroalkylene.
In embodiments, L17E is a bond, unsubstituted alkylene, or unsubstituted heteroalkylene. In embodiments, L17E is a bond, unsubstituted C1-C8 alkylene, or unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L17E is a bond. In embodiments, L17E is unsubstituted C1-C8 alkylene. In embodiments, L17E is unsubstituted 2 to 6 membered heteroalkylene.
In embodiments, L17F is a bond, unsubstituted alkylene, or unsubstituted heteroalkylene. In embodiments, L17F is a bond, unsubstituted C1-C8 alkylene, or unsubstituted 2 to 6 membered heteroalkylene. In embodiments, L17F is a bond. In embodiments, L17F is unsubstituted C1-C8 alkylene. In embodiments, L17F is unsubstituted 2 to 6 membered heteroalkylene.
In embodiments, n is independently 1. In embodiments, n is independently 2. In embodiments, n is independently 3. In embodiments, n is independently 4. In embodiments, n is independently 5.
In embodiments, L17 is a divalent form of puromycin. In embodiments, L17 is -L7A-(divalent form of puromycin)-L17E-L17F-; L7A, L17E, and L17F are as described herein, including in embodiments. In embodiments, L17 is
In embodiments, L17 is
In embodiments, L17 is
In embodiments, L17 is
In embodiments, -L17B-L17C-L17D- is a divalent form of puromycin. In embodiments, -L17B-L17C-L17D- is
In embodiments, -L17B-L17C-L17D- is
In embodiments, -L17B-L17C-L17D- is
In embodiments, -L17B, L17C-L17D- is
In embodiments, a substituted R17 (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and/or substituted heteroaryl) is substituted with at least one substituent group, size-limited substituent group, or lower substituent group; wherein if the substituted R17 is substituted with a plurality of groups selected from substituent groups, size-limited substituent groups, and lower substituent groups; each substituent group, size-limited substituent group, and/or lower substituent group may optionally be different. In embodiments, when R17 is substituted, it is substituted with at least one substituent group. In embodiments, when R17 is substituted, it is substituted with at least one size-limited substituent group. In embodiments, when R17 is substituted, it is substituted with at least one lower substituent group.
In embodiments, R17 is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —C(O)OH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2 to 8 membered, 2 to 6 membered, 4 to 6 membered, 2 to 3 membered, or 4 to 5 membered), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3 to 8 membered, 3 to 6 membered, 4 to 6 membered, 4 to 5 membered, or 5 to 6 membered), substituted or unsubstituted aryl (e.g., C6-C10 or phenyl), substituted or unsubstituted heteroaryl (e.g., 5 to 10 membered, 5 to 9 membered, or 5 to 6 membered), a monovalent nucleic acid, a monovalent protein, or a detectable moiety.
In embodiments, R17 is hydrogen. In embodiments, R17 is —F. In embodiments, R17 is —Cl. In embodiments, R17 is —Br. In embodiments, R17 is —I. In embodiments, R17 is —CCl3. In embodiments, R17 is —CBr3. In embodiments, R17 is —CF3. In embodiments, R17 is —CI3. In embodiments, R17 is —CHCl2. In embodiments, R17 is —CHBr2. In embodiments, R17 is —CHF2. In embodiments, R17 is —CHI2. In embodiments, R17 is —CH2Cl. In embodiments, R17 is —CH2Br. In embodiments, R17 is —CH2F. In embodiments, R17 is —CH2I. In embodiments, R17 is —OH. In embodiments, R17 is —NH2. In embodiments, R17 is substituted or unsubstituted alkyl. In embodiments, R17 is substituted or unsubstituted heteroalkyl. In embodiments, R17 is substituted or unsubstituted cycloalkyl. In embodiments, R17 is substituted or unsubstituted heterocycloalkyl. In embodiments, R17 is substituted or unsubstituted aryl. In embodiments, R17 is substituted or unsubstituted heteroaryl. In embodiments, R17 is a monovalent nucleic acid. In embodiments, R17 is a monovalent protein. In embodiments, R17 is a detectable moiety. In embodiments, R17 is a drug moiety. In embodiments, R17 is a monovalent form of thalidomide.
In embodiments, -L17-R17 is
In embodiments, -L17-R17 is
In embodiments, L16 is —SS—,
In embodiments, L16 is a bond,
In embodiments, L16 is a bond. In embodiments, L16 is
In embodiments, L16 is
In embodiments, L16 is
In embodiments, L16 is
In embodiments, L16 is
In embodiments, L16 is
In embodiments, L16 is
In embodiments, L16 is
In embodiments, the compound has the formula:
L17 and R17 are as described herein, including in embodiments.
In embodiments, the compound has the formula:
L17 and R17 are as described herein, including in embodiments.
In embodiments, the compound has the formula:
L17 and R17 are as described herein, including in embodiments.
In embodiments, the compound has the formula:
In embodiments, the compound has the formula:
In embodiments, the compound has the formula:
In embodiments, the compound has the formula:
In embodiments, the compound has the formula:
In embodiments, when R1A is substituted, R1A is substituted with one or more first substituent groups denoted by R1A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R1A.1 substituent group is substituted, the R1A.1 substituent group is substituted with one or more second substituent groups denoted by R1A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R1A.2 substituent group is substituted, the R1A.2 substituent group is substituted with one or more third substituent groups denoted by R1A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R1A, R1A.1, R1A.2, and R1A.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R1A, R1A.1, R1A.2 and R1A.3, respectively.
In embodiments, when R1B is substituted, R1B is substituted with one or more first substituent groups denoted by R1B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R1B.1 substituent group is substituted, the R1B.1 substituent group is substituted with one or more second substituent groups denoted by R1B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R1B.2 substituent group is substituted, the R1B.2 substituent group is substituted with one or more third substituent groups denoted by R1B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R1B, R1B.1, R1B.2, and R1B.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R1B, R1B.1, R1B.2, and R1B.3, respectively.
In embodiments, when R1C is substituted, R1C is substituted with one or more first substituent groups denoted by R1C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R1C.1 substituent group is substituted, the R1C.1 substituent group is substituted with one or more second substituent groups denoted by R1C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R1C.2 substituent group is substituted, the R1C.2 substituent group is substituted with one or more third substituent groups denoted by R1C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R1C, R1C.1, R1C.2, and R1C.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R1C, R1C.1, R1C.2, and R1C.3, respectively.
In embodiments, when R1F is substituted, R1F is substituted with one or more first substituent groups denoted by R1F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R1F.1 substituent group is substituted, the R1F.1 substituent group is substituted with one or more second substituent groups denoted by R1F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R1F.2 substituent group is substituted, the R1F.2 substituent group is substituted with one or more third substituent groups denoted by R1F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R1F, R1F.1, R1F.2, and R1F.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R1F, R1F.1, R1F.2, and R1F.3, respectively.
In embodiments, when R2A is substituted, R2A is substituted with one or more first substituent groups denoted by R2A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R2A.1 substituent group is substituted, the R2A.1 substituent group is substituted with one or more second substituent groups denoted by R2A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R2A.2 substituent group is substituted, the R2A.2 substituent group is substituted with one or more third substituent groups denoted by R2A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R2A, R2A.1, R2A.2, and R2A.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R2A, R2A.1, R2A.2, and R2A.3, respectively.
In embodiments, when R2B is substituted, R2B is substituted with one or more first substituent groups denoted by R2B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R2B.1 substituent group is substituted, the R2B.1 substituent group is substituted with one or more second substituent groups denoted by R2B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R2B.2 substituent group is substituted, the R2B.2 substituent group is substituted with one or more third substituent groups denoted by R2B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R2B, R2B.1, R2B.2, and R2B.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R2B, R2B.1, R2B.2, and R2B.3, respectively.
In embodiments, when R2C is substituted, R2C is substituted with one or more first substituent groups denoted by R2C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R2C.1 substituent group is substituted, the R2C.1 substituent group is substituted with one or more second substituent groups denoted by R2C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R2C.2 substituent group is substituted, the R2C.2 substituent group is substituted with one or more third substituent groups denoted by R2C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R2C, R2C.1, R2C.2, and R2C.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R2C, R2C.1, R2C.2, and R2C.3, respectively.
In embodiments, when R2F is substituted, R2F is substituted with one or more first substituent groups denoted by R2F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R2F.1 substituent group is substituted, the R2F.1 substituent group is substituted with one or more second substituent groups denoted by R2F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R2F.2 substituent group is substituted, the R2F.2 substituent group is substituted with one or more third substituent groups denoted by R2F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R2F, R2F.1, R2F.2, and R2F.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R2F, R2F.1, R2F.2, and R2F.3, respectively.
In embodiments, when R3A is substituted, R3A is substituted with one or more first substituent groups denoted by R3A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R3A.1 substituent group is substituted, the R3A.1 substituent group is substituted with one or more second substituent groups denoted by R3A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R3A.2 substituent group is substituted, the R3A.2 substituent group is substituted with one or more third substituent groups denoted by R3A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R3A, R3A.1, R3A.2, and R3A.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R3A, R3A.1, R3A.2 and R3A.3, respectively.
In embodiments, when R3B is substituted, R3B is substituted with one or more first substituent groups denoted by R3B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R3B.1 substituent group is substituted, the R3B.1 substituent group is substituted with one or more second substituent groups denoted by R3B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R3B.2 substituent group is substituted, the R3B.2 substituent group is substituted with one or more third substituent groups denoted by R3B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R3B, R3B.1, R3B.2, and R3B.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R3B, R3B.1, R3B.2, and R3B.3, respectively.
In embodiments, when R3C is substituted, R3C is substituted with one or more first substituent groups denoted by R3C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R3C.1 substituent group is substituted, the R3C.1 substituent group is substituted with one or more second substituent groups denoted by R3C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R3C.2 substituent group is substituted, the R3C.2 substituent group is substituted with one or more third substituent groups denoted by R3C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R3C, R3C.1, R3C.2, and R3C.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R3C, R3C.1, R3C.2, and R3C.3, respectively.
In embodiments, when R3F is substituted, R3F is substituted with one or more first substituent groups denoted by R3F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R3F.1 substituent group is substituted, the R3F.1 substituent group is substituted with one or more second substituent groups denoted by R3F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R3F.2 substituent group is substituted, the R3F.2 substituent group is substituted with one or more third substituent groups denoted by R3F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R3F, R3F.1, R3F.2, and R3F.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R3F, R3F.1, R3F.2, and R3F.3, respectively.
In embodiments, when R4A is substituted, R4A is substituted with one or more first substituent groups denoted by R4A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R4A.1 substituent group is substituted, the R4A.1 substituent group is substituted with one or more second substituent groups denoted by R4A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R4A.2 substituent group is substituted, the R4A.2 substituent group is substituted with one or more third substituent groups denoted by R4A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R4A, R4A.1, R4A.2, and R4A.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R4A, R4A.1, R4A.2, and R4A.3, respectively.
In embodiments, when R4B is substituted, R4B is substituted with one or more first substituent groups denoted by R4B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R4B.1 substituent group is substituted, the R4B.1 substituent group is substituted with one or more second substituent groups denoted by R4B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R4B.2 substituent group is substituted, the R4B.2 substituent group is substituted with one or more third substituent groups denoted by R4B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R4B, R4B.1, R4B.2, and R4B.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R4B, R4B.1, R4B.2, and R4B.3, respectively.
In embodiments, when R4C is substituted, R4C is substituted with one or more first substituent groups denoted by R4C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R4C.1 substituent group is substituted, the R4C.1 substituent group is substituted with one or more second substituent groups denoted by R4C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R4C.2 substituent group is substituted, the R4C.2 substituent group is substituted with one or more third substituent groups denoted by R4C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R4C, R4C.1, R4C.2, and R4C.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R4C, R4C.1, R4C.2, and R4C.3, respectively.
In embodiments, when R4F is substituted, R4F is substituted with one or more first substituent groups denoted by R4F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R4F.1 substituent group is substituted, the R4F.1 substituent group is substituted with one or more second substituent groups denoted by R4F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R4F.2 substituent group is substituted, the R4F.2 substituent group is substituted with one or more third substituent groups denoted by R4F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R4F, R4F.1, R4F.2, and R4F.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R4F, R4F.1, R4F.2, and R4F.3, respectively.
In embodiments, when R5A is substituted, R5A is substituted with one or more first substituent groups denoted by R5A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R5A.1 substituent group is substituted, the R5A.1 substituent group is substituted with one or more second substituent groups denoted by R5A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R5A.2 substituent group is substituted, the R5A.2 substituent group is substituted with one or more third substituent groups denoted by R5A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R5A, R5A.1, R5A.2, and R5A.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R5A, R5A.1, R5A.2 and R5A.3, respectively.
In embodiments, when R5B is substituted, R5B is substituted with one or more first substituent groups denoted by R5B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R5B.1 substituent group is substituted, the R5B.1 substituent group is substituted with one or more second substituent groups denoted by R5B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R5B.2 substituent group is substituted, the R5B.2 substituent group is substituted with one or more third substituent groups denoted by R5B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R5B, R5B.1, R5B.2, and R5B.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R5B, R5B.1, R5B.2, and R5B.3, respectively.
In embodiments, when R5C is substituted, R5C is substituted with one or more first substituent groups denoted by R5C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R5C.1 substituent group is substituted, the R5C.1 substituent group is substituted with one or more second substituent groups denoted by R5C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R5C.2 substituent group is substituted, the R5C.2 substituent group is substituted with one or more third substituent groups denoted by R5C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R5C, R5C.1, R5C.2, and R5C.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R5C, R5C.1, R5C.2, and R5C.3, respectively.
In embodiments, when R5F is substituted, R5F is substituted with one or more first substituent groups denoted by R5F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R5F.1 substituent group is substituted, the R5F.1 substituent group is substituted with one or more second substituent groups denoted by R5F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R5F.2 substituent group is substituted, the R5F.2 substituent group is substituted with one or more third substituent groups denoted by R5F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R5F, R5F.1, R5F.2, and R5F.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R5F, R5F.1, R5F.2, and R5F.3, respectively.
In embodiments, when R6A is substituted, R6A is substituted with one or more first substituent groups denoted by R6A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R6A.1 substituent group is substituted, the R6A.1 substituent group is substituted with one or more second substituent groups denoted by R6A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R6A.2 substituent group is substituted, the R6A.2 substituent group is substituted with one or more third substituent groups denoted by R6A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R6A, R6A.1, R6A.2, and R6A.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R6A, R6A.1, R6A.2, and R6A.3, respectively.
In embodiments, when R6B is substituted, R6B is substituted with one or more first substituent groups denoted by R6B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R6B.1 substituent group is substituted, the R6B.1 substituent group is substituted with one or more second substituent groups denoted by R6B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R6B.2 substituent group is substituted, the R6B.2 substituent group is substituted with one or more third substituent groups denoted by R6B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R6B, R6B.1, R6B.2, and R6B.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R6B, R6B.1, R6B.2, and R6B.3, respectively.
In embodiments, when R6C is substituted, R6C is substituted with one or more first substituent groups denoted by R6C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R6C.1 substituent group is substituted, the R6C.1 substituent group is substituted with one or more second substituent groups denoted by R6C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R6C.2 substituent group is substituted, the R6C.2 substituent group is substituted with one or more third substituent groups denoted by R6C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R6C, R6C.1, R6C.2, and R6C.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R6C, R6C.1, R6C.2, and R6C.3, respectively.
In embodiments, when R6F is substituted, R6F is substituted with one or more first substituent groups denoted by R6F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R6F.1 substituent group is substituted, the R6F.1 substituent group is substituted with one or more second substituent groups denoted by R6F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R6F.2 substituent group is substituted, the R6F.2 substituent group is substituted with one or more third substituent groups denoted by R6F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R6F, R6F.1, R6F.2, and R6F.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R6F, R6F.1, R6F.2, and R6F.3, respectively.
In embodiments, when R7A is substituted, R7A is substituted with one or more first substituent groups denoted by R7A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R7A.1 substituent group is substituted, the R7A.1 substituent group is substituted with one or more second substituent groups denoted by R7A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R7A.2 substituent group is substituted, the R7A.2 substituent group is substituted with one or more third substituent groups denoted by R7A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R7A, R7A.1, R7A.2, and R7A.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R7A, R7A.1, R7A.2, and R7A.3, respectively.
In embodiments, when R7B is substituted, R7B is substituted with one or more first substituent groups denoted by R7B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R7B.1 substituent group is substituted, the R7B.1 substituent group is substituted with one or more second substituent groups denoted by R7B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R7B.2 substituent group is substituted, the R7B.2 substituent group is substituted with one or more third substituent groups denoted by R7B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R7B, R7B.1, R7B.2, and R7B.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R7B, R7B.1, R7B.2, and R7B.3, respectively.
In embodiments, when R7C is substituted, R7C is substituted with one or more first substituent groups denoted by R7C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R7C.1 substituent group is substituted, the R7C.1 substituent group is substituted with one or more second substituent groups denoted by R7C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R7C.2 substituent group is substituted, the R7C.2 substituent group is substituted with one or more third substituent groups denoted by R7C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R7C, R7C.1, R7C.2, and R7C.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R7C, R7C.1, R7C.2, and R7C.3, respectively.
In embodiments, when R7F is substituted, R7F is substituted with one or more first substituent groups denoted by R7F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R7F.1 substituent group is substituted, the R7F.1 substituent group is substituted with one or more second substituent groups denoted by R7F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R7F.2 substituent group is substituted, the R7F.2 substituent group is substituted with one or more third substituent groups denoted by R7F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R7F, R7F.1, R7F.2, and R7F.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R7F, R7F.1, R7F.2, and R7F.3, respectively.
In embodiments, when R8A is substituted, R8A is substituted with one or more first substituent groups denoted by R8A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R8A.1 substituent group is substituted, the R8A.1 substituent group is substituted with one or more second substituent groups denoted by R8A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R8A.2 substituent group is substituted, the R8A.2 substituent group is substituted with one or more third substituent groups denoted by R8A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R8A, R8A.1, R8A.2, and R8A.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R8A, R8A.1, R8A.2, and R8A.3, respectively.
In embodiments, when R8B is substituted, R8B is substituted with one or more first substituent groups denoted by R8B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R8B.1 substituent group is substituted, the R8B.1 substituent group is substituted with one or more second substituent groups denoted by R8B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R8B.2 substituent group is substituted, the R8B.2 substituent group is substituted with one or more third substituent groups denoted by R8B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R8B, R8B.1, R8B.2, and R8B.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R8B, R8B.1, R8B.2, and R8B.3, respectively.
In embodiments, when R8C is substituted, R5C is substituted with one or more first substituent groups denoted by R8C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R8C.1 substituent group is substituted, the R8C.1 substituent group is substituted with one or more second substituent groups denoted by R8C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R8C.2 substituent group is substituted, the R8C.2 substituent group is substituted with one or more third substituent groups denoted by R8C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R8C, R8C.1, R8C.2, and R8C.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R8C, R8C.1, R8C.2, and R8C.3, respectively.
In embodiments, when R8F is substituted, R8F is substituted with one or more first substituent groups denoted by R8F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R8F.1 substituent group is substituted, the R8F.1 substituent group is substituted with one or more second substituent groups denoted by R8F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R8F.2 substituent group is substituted, the R8F.2 substituent group is substituted with one or more third substituent groups denoted by R8F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R8F, R8F.1, R8F.2, and R8F.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R8F, R8F.1, R8F.2, and R8F.3, respectively.
In embodiments, when R9A is substituted, R9A is substituted with one or more first substituent groups denoted by R9A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R9A.1 substituent group is substituted, the R9A.1 substituent group is substituted with one or more second substituent groups denoted by R9A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R9A.2 substituent group is substituted, the R9A.2 substituent group is substituted with one or more third substituent groups denoted by R9A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R9A, R9A.1, R9A.2, and R9A.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R9A, R9A.1, R9A.2 and R9A.3, respectively.
In embodiments, when R9B is substituted, R9B is substituted with one or more first substituent groups denoted by R9B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R9B.1 substituent group is substituted, the R9B.1 substituent group is substituted with one or more second substituent groups denoted by R9B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R9B.2 substituent group is substituted, the R9B.2 substituent group is substituted with one or more third substituent groups denoted by R9B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R9B, R9B.1, R9B.2, and R9B.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R9B, R9B.1, R9B.2, and R9B.3, respectively.
In embodiments, when R9C is substituted, R9C is substituted with one or more first substituent groups denoted by R9C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R9C.1 substituent group is substituted, the R9C.1 substituent group is substituted with one or more second substituent groups denoted by R9C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R9C.2 substituent group is substituted, the R9C.2 substituent group is substituted with one or more third substituent groups denoted by R9C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R9C, R9C.1, R9C.2, and R9C.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R9C, R9C.1, R9C.2, and R9C.3, respectively.
In embodiments, when R9F is substituted, R9F is substituted with one or more first substituent groups denoted by R9F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R9F.1 substituent group is substituted, the R9F.1 substituent group is substituted with one or more second substituent groups denoted by R9F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R9F.2 substituent group is substituted, the R9F.2 substituent group is substituted with one or more third substituent groups denoted by R9F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R9F, R9F.1, R9F.2, and R9F.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R9F, R9F.1, R9F.2, and R9F.3, respectively.
In embodiments, when R10A is substituted, R10A is substituted with one or more first substituent groups denoted by R10A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R10A.1 substituent group is substituted, the R10A.1 substituent group is substituted with one or more second substituent groups denoted by R10A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R10A.2 substituent group is substituted, the R10A.2 substituent group is substituted with one or more third substituent groups denoted by R10A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R10A, R10A.1, R10A.2, and R10A.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R10A, R10A.1, R10A.2, and R10A.3, respectively.
In embodiments, when R10B is substituted, R10B is substituted with one or more first substituent groups denoted by R10B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R10B substituent group is substituted, the R10B.1 substituent group is substituted with one or more second substituent groups denoted by R10B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R10B.2 substituent group is substituted, the R10B.2 substituent group is substituted with one or more third substituent groups denoted by R10B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R10B, R10B.1, R10B.2, and R10B.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R10B, R10B.1, R10B.2, and R10B.3, respectively.
In embodiments, when R10C is substituted, R10C is substituted with one or more first substituent groups denoted by R10C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R10C.1 substituent group is substituted, the R10C.1 substituent group is substituted with one or more second substituent groups denoted by R10C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R10C.2 substituent group is substituted, the R10C.2 substituent group is substituted with one or more third substituent groups denoted by R10C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R10C, R10C.1, R10C.2, and R10C.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R10C, R10C.1, R10C.2, and R10C.3, respectively.
In embodiments, when R10F is substituted, R10F is substituted with one or more first substituent groups denoted by R10F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R10F.1 substituent group is substituted, the R10F.1 substituent group is substituted with one or more second substituent groups denoted by R10F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R10F.2 substituent group is substituted, the R10F.2 substituent group is substituted with one or more third substituent groups denoted by R10F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R10F, R10F.1, R10F.2, and R10F.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R10F, R10F.1, R10F.2, and R10F.3, respectively.
In embodiments, when R11A is substituted, R11A is substituted with one or more first substituent groups denoted by R11A as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R11A.1 substituent group is substituted, the R11A.1 substituent group is substituted with one or more second substituent groups denoted by R11A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R11A.2 substituent group is substituted, the R11A.2 substituent group is substituted with one or more third substituent groups denoted by R11A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R11A, R11A.1, R11A.2, and R11A.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R11A, R11A.1, R11A.2, and R11A.3, respectively.
In embodiments, when R11B is substituted, R11B is substituted with one or more first substituent groups denoted by R11B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R11B.1 substituent group is substituted, the R11B.1 substituent group is substituted with one or more second substituent groups denoted by R11B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R11B.2 substituent group is substituted, the R11B.2 substituent group is substituted with one or more third substituent groups denoted by R11B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R11B, R11B.1, R11B.2, and R11B.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R11B, R11B.1, R11B.2, and R11B.3, respectively.
In embodiments, when R11C is substituted, R11C is substituted with one or more first substituent groups denoted by R11C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R11C.1 substituent group is substituted, the R11C.1 substituent group is substituted with one or more second substituent groups denoted by R11C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R11C.2 substituent group is substituted, the R11C.2 substituent group is substituted with one or more third substituent groups denoted by R11C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R11C, R11C.1, R11C.2, and R11C.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R11C, R11C.1, R11C.2, and R11C.3, respectively.
In embodiments, when R11F is substituted, R11F is substituted with one or more first substituent groups denoted by R11F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R11F.1 substituent group is substituted, the R11F.1 substituent group is substituted with one or more second substituent groups denoted by R11F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R11F.2 substituent group is substituted, the R11F.2 substituent group is substituted with one or more third substituent groups denoted by R11F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R11F, R11F.1, R11F.2, and R11F.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R11F, R11F.1, R11F.2, and R11F.3, respectively.
In embodiments, when R12A is substituted, R12A is substituted with one or more first substituent groups denoted by R12A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R12A.1 substituent group is substituted, the R12A.1 substituent group is substituted with one or more second substituent groups denoted by R12A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R12A.2 substituent group is substituted, the R12A.2 substituent group is substituted with one or more third substituent groups denoted by R12A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R12A, R12A.1, R12A.2, and R12A.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R12A, R12A.1, R12A.2, and R12A.3, respectively.
In embodiments, when R12B is substituted, R12B is substituted with one or more first substituent groups denoted by R12B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R12B.1 substituent group is substituted, the R12B.1 substituent group is substituted with one or more second substituent groups denoted by R12B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R12B.2 substituent group is substituted, the R12B.2 substituent group is substituted with one or more third substituent groups denoted by R12B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R12B, R12B.1, R12B.2, and R12B.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R12B, R12B.1, R12B.2, and R12B.3, respectively.
In embodiments, when R12C is substituted, R12C is substituted with one or more first substituent groups denoted by R12C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R12C.1 substituent group is substituted, the R12C.1 substituent group is substituted with one or more second substituent groups denoted by R12C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R12C.2 substituent group is substituted, the R12C.2 substituent group is substituted with one or more third substituent groups denoted by R12C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R12C, R12C.1, R12C.2, and R12C.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R12C, R12C.1, R12C.2, and R12C.3, respectively.
In embodiments, when R12F is substituted, R12F is substituted with one or more first substituent groups denoted by R12F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R12F.1 substituent group is substituted, the R12F.1 substituent group is substituted with one or more second substituent groups denoted by R12F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R12F.2 substituent group is substituted, the R12F.2 substituent group is substituted with one or more third substituent groups denoted by R12F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R12F, R12F.1, R12F.2, and R12F.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R12F, R12F.1, R12F.2, and R12F.3, respectively.
In embodiments, when R13B is substituted, R13B is substituted with one or more first substituent groups denoted by R13B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R13B.1 substituent group is substituted, the R13B.1 substituent group is substituted with one or more second substituent groups denoted by R13B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R13B.2 substituent group is substituted, the R13B.2 substituent group is substituted with one or more third substituent groups denoted by R13B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R13B, R13B.1, R13B.2, and R13B.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R13B, R13B.1, R13B.2, and R13B.3, respectively.
In embodiments, when R13C is substituted, R13C is substituted with one or more first substituent groups denoted by R13C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R13C.1 substituent group is substituted, the R13C.1 substituent group is substituted with one or more second substituent groups denoted by R13C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R13C.2 substituent group is substituted, the R13C.2 substituent group is substituted with one or more third substituent groups denoted by R13C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R13C, R13C.1, R13C.2, and R13C.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R13C, R13C.1, R13C.2, and R13C.3, respectively.
In embodiments, when R13F is substituted, R13F is substituted with one or more first substituent groups denoted by R3F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R3F.1 substituent group is substituted, the R3F.1 substituent group is substituted with one or more second substituent groups denoted by R13F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R13F.2 substituent group is substituted, the R13F.2 substituent group is substituted with one or more third substituent groups denoted by R13F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R13F, R13F.1, R13F.2, and R13F.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R13F, R13F.1, R13F.2, and R13F.3, respectively.
In embodiments, when R14C is substituted, R14C is substituted with one or more first substituent groups denoted by R14C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R14C.1 substituent group is substituted, the R14C.1 substituent group is substituted with one or more second substituent groups denoted by R14C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R14C.2 substituent group is substituted, the R14C.2 substituent group is substituted with one or more third substituent groups denoted by R14C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R14C, R14C.1, R14C.2, and R14C.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R14C, R14C.1, R14C.2, and R14C.3, respectively.
In embodiments, when R14F is substituted, R14F is substituted with one or more first substituent groups denoted by R14F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R14F.1 substituent group is substituted, the R14F.1 substituent group is substituted with one or more second substituent groups denoted by R14F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R14F.2 substituent group is substituted, the R14F.2 substituent group is substituted with one or more third substituent groups denoted by R14F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R14F, R14F.1, R14F.2, and R14F.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R14F, R14F.1, R14F.2, and R14F.3, respectively.
In embodiments, when R15C is substituted, R15C is substituted with one or more first substituent groups denoted by R15C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R15C.1 substituent group is substituted, the R15C.1 substituent group is substituted with one or more second substituent groups denoted by R15C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R15C.2 substituent group is substituted, the R15C.2 substituent group is substituted with one or more third substituent groups denoted by R15C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R15C, R15C.1, R15C.2, and R15C.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R15C, R15C.1, R15C.2, and R15C.3, respectively.
In embodiments, when R15F is substituted, R15F is substituted with one or more first substituent groups denoted by R15F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R15F.1 substituent group is substituted, the R15F.1 substituent group is substituted with one or more second substituent groups denoted by R15F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R15F.2 substituent group is substituted, the R15F.2 substituent group is substituted with one or more third substituent groups denoted by R15F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R15F, R15F.1, R15F.2, and R15F.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R15F, R15F.1, R15F.2, and R15F.3, respectively.
In embodiments, when R17 is substituted, R17 is substituted with one or more first substituent groups denoted by R17.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R17.1 substituent group is substituted, the R17.1 substituent group is substituted with one or more second substituent groups denoted by R17.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R17.2 substituent group is substituted, the R17.2 substituent group is substituted with one or more third substituent groups denoted by R17.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R17, R17.1, R17.2, and R17.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R17, R17.1, R17.2, and R17.3, respectively.
In embodiments, when R26 is substituted, R26 is substituted with one or more first substituent groups denoted by R26.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R26.1 substituent group is substituted, the R26.1 substituent group is substituted with one or more second substituent groups denoted by R26.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R26.2 substituent group is substituted, the R26.2 substituent group is substituted with one or more third substituent groups denoted by R26.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R26, R26.1, R26.2, and R26.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R26, R26.1, R26.2, and R26.3, respectively.
In embodiments, when R27 is substituted, R27 is substituted with one or more first substituent groups denoted by R27.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R27.1 substituent group is substituted, the R27.1 substituent group is substituted with one or more second substituent groups denoted by R27.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R27.2 substituent group is substituted, the R27.2 substituent group is substituted with one or more third substituent groups denoted by R27.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R27, R27.1, R27.2, and R27.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R27, R27.1, R27.2, and R27.3, respectively.
In embodiments, when R28 is substituted, R28 is substituted with one or more first substituent groups denoted by R28.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R28.1 substituent group is substituted, the R28.1 substituent group is substituted with one or more second substituent groups denoted by R28.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an R28.2 substituent group is substituted, the R28.2 substituent group is substituted with one or more third substituent groups denoted by R28.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, R28, R28.1, R28.2, and R28.3 have values corresponding to the values of RWW, RWW.1, RWW.2, and RWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein RWW, RWW.1, RWW.2, and RWW.3 correspond to R28, R28.1, R28.2, and R28.3, respectively.
In embodiments, when L1A is substituted, L1A is substituted with one or more first substituent groups denoted by RL1A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL1A.1 substituent group is substituted, the RL1A.1 substituent group is substituted with one or more second substituent groups denoted by RL1A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL1A.2 substituent group is substituted, the RL1A.2 substituent group is substituted with one or more third substituent groups denoted by RL1A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L1A, RL1A.1, RL1A.2, and RL1A.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2 and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L1A, RL1A.1, RL1A.2 and RL1A.3, respectively.
In embodiments, when L1B is substituted, L1B is substituted with one or more first substituent groups denoted by RL1B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL1B.1 substituent group is substituted, the RL1B.1 substituent group is substituted with one or more second substituent groups denoted by RL1B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL1B.2 substituent group is substituted, the RL1B.2 substituent group is substituted with one or more third substituent groups denoted by RL1B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L1B, RL1B.1, RL1B.2, and RL1B.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L1B, RL1B.1, RL1B.2, and RL1B.3, respectively.
In embodiments, when LC is substituted, L1C is substituted with one or more first substituent groups denoted by RL1C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL1C.1 substituent group is substituted, the RL1C.1 substituent group is substituted with one or more second substituent groups denoted by RL1C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL1C.2 substituent group is substituted, the RL1C.2 substituent group is substituted with one or more third substituent groups denoted by RL1C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L1C, RL1C.1, RL1C.2, and RL1C.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L1C, RL1C.1, RL1C.2, and RL1C.3, respectively.
In embodiments, when L1F is substituted, L1F is substituted with one or more first substituent groups denoted by RL1F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL1F.1 substituent group is substituted, the RL1F.1 substituent group is substituted with one or more second substituent groups denoted by RL1F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL1F.2 substituent group is substituted, the RL1F.2 substituent group is substituted with one or more third substituent groups denoted by RL1F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L1F, RL1F.1, RL1F.2, and RL1F.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2 and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L1F, RL1F.1, RL1F.2, and RL1F.3, respectively.
In embodiments, when L2A is substituted, L2A is substituted with one or more first substituent groups denoted by RL2A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL2A.1 substituent group is substituted, the RL2A.1 substituent group is substituted with one or more second substituent groups denoted by RL2A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL2A.2 substituent group is substituted, the RL2A.2 substituent group is substituted with one or more third substituent groups denoted by RL2A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L2A, RL2A.1, RL2A.2, and RL2A.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L2A, RL2A.1, RL2A.2, and RL2A.3, respectively.
In embodiments, when L2B is substituted, L2B is substituted with one or more first substituent groups denoted by RL2B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL2B.1 substituent group is substituted, the RL2B.1 substituent group is substituted with one or more second substituent groups denoted by RL2B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL2B.2 substituent group is substituted, the RL2B.2 substituent group is substituted with one or more third substituent groups denoted by RL2B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L2B, RL2B.1, RL2B.2, and RL2B.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L2B, RL2B.1, RL2B.2, and RL2B.3, respectively.
In embodiments, when L2C is substituted, L2C is substituted with one or more first substituent groups denoted by RL2C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL2C.1 substituent group is substituted, the RL2C.1 substituent group is substituted with one or more second substituent groups denoted by RL2C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL2C.2 substituent group is substituted, the RL2C.2 substituent group is substituted with one or more third substituent groups denoted by RL2C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L2C, RL2C.1, RL2C.2, and RL2C.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L2C, RL2C.1, RL2C.2, and RL2C.3, respectively.
In embodiments, when L2F is substituted, L2F is substituted with one or more first substituent groups denoted by RL2F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL2F.1 substituent group is substituted, the RL2F.1 substituent group is substituted with one or more second substituent groups denoted by RL2F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL2F.2 substituent group is substituted, the RL2F.2 substituent group is substituted with one or more third substituent groups denoted by RL2F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L2F, RL2F.1, RL2F.2, and RL2F.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L2F, RL2F.1, RL2F.2, and RL2F.3, respectively.
In embodiments, when L3A is substituted, L3A is substituted with one or more first substituent groups denoted by RL3A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL3A.1 substituent group is substituted, the RL3A.1 substituent group is substituted with one or more second substituent groups denoted by RL3A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL3A.2 substituent group is substituted, the RL3A.2 substituent group is substituted with one or more third substituent groups denoted by RL3A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L3A, RL3A.1, RL3A.2, and RL3A.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L3A, RL3A.1, RL3A.2 and RL3A.3, respectively.
In embodiments, when L3B is substituted, L3B is substituted with one or more first substituent groups denoted by RL3B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL3B.1 substituent group is substituted, the RL3B.1 substituent group is substituted with one or more second substituent groups denoted by RL3B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL3B.2 substituent group is substituted, the RL3B.2 substituent group is substituted with one or more third substituent groups denoted by RL3B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L3B, RL3B.1, RL3B.2, and RL3B.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L3B, RL3B.1, RL3B.2, and RL3B.3, respectively.
In embodiments, when L3C is substituted, L3C is substituted with one or more first substituent groups denoted by RL3C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL3C.1 substituent group is substituted, the RL3C.1 substituent group is substituted with one or more second substituent groups denoted by RL3C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL3C.2 substituent group is substituted, the RL3C.2 substituent group is substituted with one or more third substituent groups denoted by RL3C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L3C, RL3C.1, RL3C.2, and RL3C.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L3C, RL3C.1, RL3C.2, and RL3C.3, respectively.
In embodiments, when L3F is substituted, L3F is substituted with one or more first substituent groups denoted by RL3F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL3F.1 substituent group is substituted, the RL3F.1 substituent group is substituted with one or more second substituent groups denoted by RL3F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL3F.2 substituent group is substituted, the RL3F.2 substituent group is substituted with one or more third substituent groups denoted by RL3F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L3F, RL3F.1, RL3F.2, and RL3F.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2 and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L3F, RL3F.1, RL3F.2, and RL3F.3, respectively.
In embodiments, when L4A is substituted, L4A is substituted with one or more first substituent groups denoted by RL4A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL4A.1 substituent group is substituted, the RL4A.1 substituent group is substituted with one or more second substituent groups denoted by RL4A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL4A.2 substituent group is substituted, the RL4A.2 substituent group is substituted with one or more third substituent groups denoted by RL4A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L4A, RL4A.1, RL4A.2, and RL4A.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L4A, RL4A.1, RL4A.2, and RL4A.3, respectively.
In embodiments, when L4B is substituted, L4B is substituted with one or more first substituent groups denoted by RL4B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL4B.1 substituent group is substituted, the RL4B.1 substituent group is substituted with one or more second substituent groups denoted by RL4B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL4B.2 substituent group is substituted, the RL4B.2 substituent group is substituted with one or more third substituent groups denoted by RL4B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L4B, RL4B.1, RL4B.2, and RL4B.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L4B, RL4B.1, RL4B.2, and RL4B.3, respectively.
In embodiments, when L4C is substituted, L4C is substituted with one or more first substituent groups denoted by RL4C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL4C.1 substituent group is substituted, the RL4C.1 substituent group is substituted with one or more second substituent groups denoted by RL4C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL4C.2 substituent group is substituted, the RL4C.2 substituent group is substituted with one or more third substituent groups denoted by RL4C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L4C, RL4C.1, RL4C.2, and RL4C.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L4C, RL4C.1, RL4C.2, and RL4C.3, respectively.
In embodiments, when L4F is substituted, L4F is substituted with one or more first substituent groups denoted by RL4F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL4F.1 substituent group is substituted, the RL4F.1 substituent group is substituted with one or more second substituent groups denoted by RL4F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL4F.2 substituent group is substituted, the RL4F.2 substituent group is substituted with one or more third substituent groups denoted by RL4F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L4F, RL4F.1, RL4F.2, and RL4F.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L4F, RL4F.1, RL4F.2, and RL4F.3, respectively.
In embodiments, when L5A is substituted, L5A is substituted with one or more first substituent groups denoted by RL5A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL5A.1 substituent group is substituted, the RL5A.1 substituent group is substituted with one or more second substituent groups denoted by RL5A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL5A.2 substituent group is substituted, the RL5A.2 substituent group is substituted with one or more third substituent groups denoted by RL5A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L5A, RL5A.1, RL5A.2, and RL5A.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L5A, RL5A.1, RL5A.2 and RL5A.3, respectively.
In embodiments, when L5B is substituted, L5B is substituted with one or more first substituent groups denoted by RL5B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL5B.1 substituent group is substituted, the RL5B.1 substituent group is substituted with one or more second substituent groups denoted by RL5B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL5B.2 substituent group is substituted, the RL5B.2 substituent group is substituted with one or more third substituent groups denoted by RL5B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L5B, RL5B.1, RL5B.2, and RL5B.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L5B, RL5B.1, RL5B.2, and RL5B.3, respectively.
In embodiments, when L5C is substituted, L5C is substituted with one or more first substituent groups denoted by RL5C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL5C.1 substituent group is substituted, the RL5C.1 substituent group is substituted with one or more second substituent groups denoted by RL5C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL5C.2 substituent group is substituted, the RL5C.2 substituent group is substituted with one or more third substituent groups denoted by RL5C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L5C, RL5C.1, RL5C.2, and RL5C.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L5C, RL5C.1, RL5C.2, and RL5C.3, respectively.
In embodiments, when L5F is substituted, L5F is substituted with one or more first substituent groups denoted by RL5F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL5F.1 substituent group is substituted, the RL5F.1 substituent group is substituted with one or more second substituent groups denoted by RL5F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL5F.2 substituent group is substituted, the RL5F.2 substituent group is substituted with one or more third substituent groups denoted by RL5F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L5F, RL5F.1, RL5F.2, and RL5F.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2 and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L5F, RL5F.1, RL5F.2, and RL5F.3, respectively.
In embodiments, when L6A is substituted, L6A is substituted with one or more first substituent groups denoted by RL6A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL6A.1 substituent group is substituted, the RL6A.1 substituent group is substituted with one or more second substituent groups denoted by RL6A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL6A.2 substituent group is substituted, the RL6A.2 substituent group is substituted with one or more third substituent groups denoted by RL6A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L6A, RL6A.1, RL6A.2, and RL6A.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L6A, RL6A.1, RL6A.2, and RL6A.3, respectively.
In embodiments, when L6B is substituted, L6B is substituted with one or more first substituent groups denoted by RL6B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL6B.1 substituent group is substituted, the RL6B.1 substituent group is substituted with one or more second substituent groups denoted by RL6B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL6B.2 substituent group is substituted, the RL6B.2 substituent group is substituted with one or more third substituent groups denoted by RL6B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L6B, RL6B.1, RL6B.2, and RL6B.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L6B, RL6B.1, RL6B.2, and RL6B.3, respectively.
In embodiments, when L6C is substituted, L6C is substituted with one or more first substituent groups denoted by RL6C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL6C.1 substituent group is substituted, the RL6C.1 substituent group is substituted with one or more second substituent groups denoted by RL6C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL6C.2 substituent group is substituted, the RL6C.2 substituent group is substituted with one or more third substituent groups denoted by RL6C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L6C, RL6C.1, RL6C.2, and RL6C.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L6C, RL6C.1, RL6C.2, and RL6C.3, respectively.
In embodiments, when L6F is substituted, L6F is substituted with one or more first substituent groups denoted by RL6F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL6F.1 substituent group is substituted, the RL6F.1 substituent group is substituted with one or more second substituent groups denoted by RL6F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL6F.2 substituent group is substituted, the RL6F.2 substituent group is substituted with one or more third substituent groups denoted by RL6F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L6F, RL6F.1, RL6F.2, and RL6F.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L6F, RL6F.1, RL6F.2, and RL6F.3, respectively.
In embodiments, when L7A is substituted, L7A is substituted with one or more first substituent groups denoted by RL7A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL7A.1 substituent group is substituted, the RL7A.1 substituent group is substituted with one or more second substituent groups denoted by RL7A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL7A.2 substituent group is substituted, the RL7A.2 substituent group is substituted with one or more third substituent groups denoted by RL7A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L7A, RL7A.1, RL7A.2, and RL7A.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L7A, RL7A.1, RL7A.2 and RL7A.3, respectively.
In embodiments, when L7B is substituted, L7B is substituted with one or more first substituent groups denoted by RL7B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL7B.1 substituent group is substituted, the RL7B.1 substituent group is substituted with one or more second substituent groups denoted by RL7B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL7B.2 substituent group is substituted, the RL7B.2 substituent group is substituted with one or more third substituent groups denoted by RL7B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L7B, RL7B.1, RL7B.2, and RL7B.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L7B, RL7B.1, RL7B.2, and RL7B.3, respectively.
In embodiments, when L7C is substituted, L7C is substituted with one or more first substituent groups denoted by RL7C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL7C.1 substituent group is substituted, the RL7C.1 substituent group is substituted with one or more second substituent groups denoted by RL7C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL7C.2 substituent group is substituted, the RL7C.2 substituent group is substituted with one or more third substituent groups denoted by RL7C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L7C, RL7C.1, RL7C.2, and RL7C.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L7C, RL7C.1, RL7C.2, and RL7C.3, respectively.
In embodiments, when L7F is substituted, L7F is substituted with one or more first substituent groups denoted by RL7F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL7F.1 substituent group is substituted, the RL7F.1 substituent group is substituted with one or more second substituent groups denoted by RL7F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL7F.2 substituent group is substituted, the RL7F.2 substituent group is substituted with one or more third substituent groups denoted by RL7F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L7F, RL7F.1, RL7F.2, and RL7F.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2 and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L7F, RL7F.1, RL7F.2, and RL7F.3, respectively.
In embodiments, when L8A is substituted, L8A is substituted with one or more first substituent groups denoted by RL8A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL8A.1 substituent group is substituted, the RL8A.1 substituent group is substituted with one or more second substituent groups denoted by RL8A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL8A.2 substituent group is substituted, the RL8A.2 substituent group is substituted with one or more third substituent groups denoted by RL8A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L8A, RL8A.1, RL8A.2, and RL8A.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L8A, RL8A.1, RL8A.2, and RL8A.3, respectively.
In embodiments, when L8B is substituted, L8B is substituted with one or more first substituent groups denoted by RL8B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL8B.1 substituent group is substituted, the RL8B.1 substituent group is substituted with one or more second substituent groups denoted by RL8B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL8B.2 substituent group is substituted, the RL8B.2 substituent group is substituted with one or more third substituent groups denoted by RL8B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L8B, RL8B.1, RL8B.2, and RL8B.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L8B, RL8B.1, RL8B.2, and RL8B.3, respectively.
In embodiments, when L8C is substituted, L8C is substituted with one or more first substituent groups denoted by RL8C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL1C.1 substituent group is substituted, the RL8C.1 substituent group is substituted with one or more second substituent groups denoted by RL8C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL8C.2 substituent group is substituted, the RL8C.2 substituent group is substituted with one or more third substituent groups denoted by RL8C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L8C, RL8C.1, RL8C.2, and RL8C.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L8C, RL8C.1, RL8C.2, and RL8C.3, respectively.
In embodiments, when L8F is substituted, L8F is substituted with one or more first substituent groups denoted by RL8F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL8F.1 substituent group is substituted, the RL8F.1 substituent group is substituted with one or more second substituent groups denoted by RL8F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL8F.2 substituent group is substituted, the RL8F.2 substituent group is substituted with one or more third substituent groups denoted by RL8F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L8F, RL8F.1, RL8F.2, and RL8F.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L8F, RL8F.1, RL8F.2, and RL8F.3, respectively.
In embodiments, when L9A is substituted, L9A is substituted with one or more first substituent groups denoted by RL9A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL9A.1 substituent group is substituted, the RL9A.1 substituent group is substituted with one or more second substituent groups denoted by RL9A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL9A.2 substituent group is substituted, the RL9A.2 substituent group is substituted with one or more third substituent groups denoted by RL9A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L9A, RL9A.1, RL9A.2, and RL9A.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L9A, RL9A.1, RL9A.2 and RL9A.3, respectively.
In embodiments, when L9B is substituted, L9B is substituted with one or more first substituent groups denoted by RL9B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL9B.1 substituent group is substituted, the RL9B.1 substituent group is substituted with one or more second substituent groups denoted by RL9B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL9B.2 substituent group is substituted, the RL9B.2 substituent group is substituted with one or more third substituent groups denoted by RL9B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L9B, RL9B.1, RL9B.2, and RL9B.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L9B, RL9B.1, RL9B.2, and RL9B.3, respectively.
In embodiments, when L9C is substituted, L9C is substituted with one or more first substituent groups denoted by RL9C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL9C.1 substituent group is substituted, the RL9C.1 substituent group is substituted with one or more second substituent groups denoted by RL9C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL9C.2 substituent group is substituted, the RL9C.2 substituent group is substituted with one or more third substituent groups denoted by RL9C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L9C, RL9C.1, RL9C.2, and RL9C.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L9C, RL9C.1, RL9C.2, and RL9C.3, respectively.
In embodiments, when L9F is substituted, L9F is substituted with one or more first substituent groups denoted by RL9F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL9F.1 substituent group is substituted, the RL9F.1 substituent group is substituted with one or more second substituent groups denoted by RL9F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL9F.2 substituent group is substituted, the RL9F.2 substituent group is substituted with one or more third substituent groups denoted by RL9F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L9F, RL9F.1, RL9F.2, and RL9F.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2 and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L9F, RL9F.1, RL9F.2, and RL9F.3, respectively.
In embodiments, when L10A is substituted, L10A is substituted with one or more first substituent groups denoted by RL10A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL10A.1 substituent group is substituted, the RL10A.1 substituent group is substituted with one or more second substituent groups denoted by RL10A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL10A.2 substituent group is substituted, the RL10A.2 substituent group is substituted with one or more third substituent groups denoted by RL10A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L10A, RL10A.1, RL10A.2, and RL10A.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L10A, RL10A.1, RL10A.2, and RL10A.3, respectively.
In embodiments, when L10B is substituted, L10B is substituted with one or more first substituent groups denoted by RL10B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL10B.1 substituent group is substituted, the RL10B.1 substituent group is substituted with one or more second substituent groups denoted by RL10B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL10B.2 substituent group is substituted, the RL10B.2 substituent group is substituted with one or more third substituent groups denoted by RL10B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L10B, RL10B.1, RL10B.2 and RL10B.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2 and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L10B, RL10B.1, RL10B.2, and RL10B.3, respectively.
In embodiments, when L10C is substituted, L10C is substituted with one or more first substituent groups denoted by RL10C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL10C.1 substituent group is substituted, the RL10C.1 substituent group is substituted with one or more second substituent groups denoted by RL10C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL10C.2 substituent group is substituted, the RL10C.2 substituent group is substituted with one or more third substituent groups denoted by RL10C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L10C, RL10C.1, RL10C.2, and RL10C.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2 and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L10C, RL10C.1, RL10C.2, and RL10C.3, respectively.
In embodiments, when L10D is substituted, L10D is substituted with one or more first substituent groups denoted by RL10D.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL10D.1 substituent group is substituted, the RL10D.1 substituent group is substituted with one or more second substituent groups denoted by RL10D.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL10D.2 substituent group is substituted, the RL10D.2 substituent group is substituted with one or more third substituent groups denoted by RL10D.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L10D, RL10D.1, RL10D.2, and RL10D.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L10D, RL10D.1, RL10D.2, and RL10D.3, respectively.
In embodiments, when L10E is substituted, L10E is substituted with one or more first substituent groups denoted by RL10E.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL10E.1 substituent group is substituted, the RL10E.1 substituent group is substituted with one or more second substituent groups denoted by RL10E.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL10E.2 substituent group is substituted, the RL10E.2 substituent group is substituted with one or more third substituent groups denoted by RL10E.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L10E, RL10E.1, RL10E.2, and RL10E.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L10E, RL10E.1, RL10E.2 and RL10E.3, respectively.
In embodiments, when L10F is substituted, L10F is substituted with one or more first substituent groups denoted by RL10F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL10F.1 substituent group is substituted, the RL10F.1 substituent group is substituted with one or more second substituent groups denoted by RL10F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL10F.2 substituent group is substituted, the RL10F.2 substituent group is substituted with one or more third substituent groups denoted by RL10F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L10F, RL10F.1, RL10F.2, and RL10F.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L10F, RL10F.1, RL10F.2 and RL10F.3, respectively.
In embodiments, when L11A is substituted, L11A is substituted with one or more first substituent groups denoted by RL11A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL11A.1 substituent group is substituted, the RL11A.1 substituent group is substituted with one or more second substituent groups denoted by RL11A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL11A.2 substituent group is substituted, the RL11A.2 substituent group is substituted with one or more third substituent groups denoted by RL11A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L11A, RL11A.1, RL11A.2, and RL11A.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2 and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L11A, RL11A.1, RL11A.2, and RL11A.3, respectively.
In embodiments, when L11B is substituted, L11B is substituted with one or more first substituent groups denoted by RL11B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL11B.1 substituent group is substituted, the RL11B.1 substituent group is substituted with one or more second substituent groups denoted by RL11B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL11B.2 substituent group is substituted, the RL11B.2 substituent group is substituted with one or more third substituent groups denoted by RL11B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L11B, RL11B.1, RL11B.2, and RL11B.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L11B, RL11B.1, RL11B.2, and RL11B.3, respectively.
In embodiments, when L11C is substituted, L11C is substituted with one or more first substituent groups denoted by RL11C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL11C.1 substituent group is substituted, the RL11C.1 substituent group is substituted with one or more second substituent groups denoted by RL11C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL11C.2 substituent group is substituted, the RL11C.2 substituent group is substituted with one or more third substituent groups denoted by RL11C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L11C, RL11C.1, RL11C.2, and RL11C.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L11C, R11C.1, RL11C.2 and RL11C.3, respectively.
In embodiments, when L11F is substituted, L11F is substituted with one or more first substituent groups denoted by RL11F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL11F.1 substituent group is substituted, the RL11F.1 substituent group is substituted with one or more second substituent groups denoted by RL11F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL11F.2 substituent group is substituted, the RL11F.2 substituent group is substituted with one or more third substituent groups denoted by RL11F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L11F, RL11F.1, RL11F.2, and RL11F.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2 and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L11F, RL11F.1, RL11F.2, and RL11F.3, respectively.
In embodiments, when L12A is substituted, L12A is substituted with one or more first substituent groups denoted by RL12A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL12A.1 substituent group is substituted, the RL12A.1 substituent group is substituted with one or more second substituent groups denoted by RL12A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL12A.2 substituent group is substituted, the RL12A.2 substituent group is substituted with one or more third substituent groups denoted by RL12A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L12A, RL12A.1, RL12A.2, and RL12A.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L12A, RL12A.1, RL12A.2, and RL12A.3, respectively.
In embodiments, when L12B is substituted, L12B is substituted with one or more first substituent groups denoted by RL12B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL12B.1 substituent group is substituted, the RL12B.1 substituent group is substituted with one or more second substituent groups denoted by RL12B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL12B.2 substituent group is substituted, the RL12B.2 substituent group is substituted with one or more third substituent groups denoted by RL12B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L12B, RL12B.1, RL12B.2, and RL12B.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2 and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L12B, RL12B.1, RL12B.2, and RL12B.3, respectively.
In embodiments, when L12C is substituted, L12C is substituted with one or more first substituent groups denoted by RL12C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL12C.1 substituent group is substituted, the RL12C.1 substituent group is substituted with one or more second substituent groups denoted by RL12C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL12C.2 substituent group is substituted, the RL12C.2 substituent group is substituted with one or more third substituent groups denoted by RL12C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L12C, RL12C.1, RL12C.2, and RL12C.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L12c, RL12C.1, RL12C.2, and RL12C.3, respectively.
In embodiments, when L12F is substituted, L12F is substituted with one or more first substituent groups denoted by RL12F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL12F.1 substituent group is substituted, the RL12F.1 substituent group is substituted with one or more second substituent groups denoted by RL12F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL12F.2 substituent group is substituted, the RL12F.2 substituent group is substituted with one or more third substituent groups denoted by RL12F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L12F, RL12F.1, RL12F.2, and RL12F.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L12F, RL12F.1, RL12F.2 and RL12F.3, respectively.
In embodiments, when L13B is substituted, L13B is substituted with one or more first substituent groups denoted by RL13B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL13B.1 substituent group is substituted, the RL13B.1 substituent group is substituted with one or more second substituent groups denoted by RL13B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL13B.2 substituent group is substituted, the RL13B.2 substituent group is substituted with one or more third substituent groups denoted by RL13B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L13B, RL13B.1, RL13B.2, and RL13B.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L13B, RL13B.1, RL13B.2, and RL13B.3, respectively.
In embodiments, when L13C is substituted, L13C is substituted with one or more first substituent groups denoted by RL13C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL13C.1 substituent group is substituted, the RL13C.1 substituent group is substituted with one or more second substituent groups denoted by RL13C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL13C.2 substituent group is substituted, the RL13C.2 substituent group is substituted with one or more third substituent groups denoted by RL13C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L13C, RL13C.1, RL13C.2, and RL13C.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2 and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L13C, RL13C.1, RL13C.2, and RL13C.3, respectively.
In embodiments, when L13F is substituted, L13F is substituted with one or more first substituent groups denoted by RL13F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL13F.1 substituent group is substituted, the RL13F.1 substituent group is substituted with one or more second substituent groups denoted by RL13F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL13F.2 substituent group is substituted, the RL13F.2 substituent group is substituted with one or more third substituent groups denoted by RL13F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L13F, RL13F.1, RL13F.2, and RL13F.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2 and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L13F, RL13F.1, RL13F.2 and RL13F.3, respectively.
In embodiments, when L14C is substituted, L14C is substituted with one or more first substituent groups denoted by RL14C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL14C.1 substituent group is substituted, the RL14C.1 substituent group is substituted with one or more second substituent groups denoted by RL14C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL14C.2 substituent group is substituted, the RL14C.2 substituent group is substituted with one or more third substituent groups denoted by RL14C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L14C, RL14C.1, RL14C.2, and RL14C.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L14C, RL14C.1, RL14C.2, and RL14C.3, respectively.
In embodiments, when L14F is substituted, L14F is substituted with one or more first substituent groups denoted by RL14F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL14F.1 substituent group is substituted, the RL14F.1 substituent group is substituted with one or more second substituent groups denoted by RL14F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL14F.2 substituent group is substituted, the RL14F.2 substituent group is substituted with one or more third substituent groups denoted by RL14F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L14F, RL14F.1, RL14F.2, and RL14F.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L14F, RL14F.1, RL14F.2, and RL14F.3, respectively.
In embodiments, when L15C is substituted, L15C is substituted with one or more first substituent groups denoted by RL15C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL15C.1 substituent group is substituted, the RL15C.1 substituent group is substituted with one or more second substituent groups denoted by RL15C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL15C.2 substituent group is substituted, the RL15C.2 substituent group is substituted with one or more third substituent groups denoted by RL15C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L15C, RL15C.1, RL15C.2, and RL15C.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2 and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L15C, RL15C.1, RL15C.2, and RL15C.3, respectively.
In embodiments, when L15F is substituted, L15F is substituted with one or more first substituent groups denoted by RL15F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL15F.1 substituent group is substituted, the RL15F.1 substituent group is substituted with one or more second substituent groups denoted by RL15F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL15F.2 substituent group is substituted, the RL15F.2 substituent group is substituted with one or more third substituent groups denoted by RL15F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L15F, RL15F.1, RL15F.2, and RL15F.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2 and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L15F, RL15F.1, RL15F.2 and RL15F.3, respectively.
In embodiments, when L16 is substituted, L16 is substituted with one or more first substituent groups denoted by RL16.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL16.1 substituent group is substituted, the RL16.1 substituent group is substituted with one or more second substituent groups denoted by RL16.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL16.2 substituent group is substituted, the RL16.2 substituent group is substituted with one or more third substituent groups denoted by RL16.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L16, RL16.1, RL16.2, and RL16.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2 and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L16, RL16.1, RL16.2, and RL16.3, respectively.
In embodiments, when L16A is substituted, L16A is substituted with one or more first substituent groups denoted by RL16A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL16A.1 substituent group is substituted, the RL16A.1 substituent group is substituted with one or more second substituent groups denoted by RL16A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL16A.2 substituent group is substituted, the RL16A.2 substituent group is substituted with one or more third substituent groups denoted by RL16A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L16A, RL16A.1, RL16A.2, and RL16A.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L16A, RL16A.1, RL16A.2, and RL16A.3, respectively.
In embodiments, when L16B is substituted, L16B is substituted with one or more first substituent groups denoted by RL16B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL16B.1 substituent group is substituted, the RL16B.1 substituent group is substituted with one or more second substituent groups denoted by RL16B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL16B.2 substituent group is substituted, the RL16B.2 substituent group is substituted with one or more third substituent groups denoted by RL16B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L16B, RL16B.1, RL16B.2, and RL16B.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L16B, RL16B.1, RL16B.2, and RL16B.3, respectively.
In embodiments, when L16C is substituted, L16C is substituted with one or more first substituent groups denoted by RL16C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL16C.1 substituent group is substituted, the RL16C.1 substituent group is substituted with one or more second substituent groups denoted by RL16C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL16C.2 substituent group is substituted, the RL16C.2 substituent group is substituted with one or more third substituent groups denoted by RL16C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L16C, RL16C.1, RL16C.2, and RL16C.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2 and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L16c, RL16C.1, RL16C.2, and RL16C.3, respectively.
In embodiments, when L16D is substituted, L16D is substituted with one or more first substituent groups denoted by RL16D.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL16D.1 substituent group is substituted, the RL16D.1 substituent group is substituted with one or more second substituent groups denoted by RL16D.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL16D.2 substituent group is substituted, the RL16D.2 substituent group is substituted with one or more third substituent groups denoted by RL16D.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L16D, RL16D.1, RL16D.2, and RL16D.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L16D, RL16D.1, RL16D.2, and RL16D.3, respectively.
In embodiments, when L16E is substituted, L16E is substituted with one or more first substituent groups denoted by RL16E.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL16E.1 substituent group is substituted, the RL16E.1 substituent group is substituted with one or more second substituent groups denoted by RL16E.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL16E.2 substituent group is substituted, the RL16E.2 substituent group is substituted with one or more third substituent groups denoted by RL16E.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L16E, RL16E.1, RL16E.2, and RL16E.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L16E, RL16E.1, RL16E.2 and RL16E.3, respectively.
In embodiments, when L16F is substituted, L16F is substituted with one or more first substituent groups denoted by RL16F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL16F.1 substituent group is substituted, the RL16F.1 substituent group is substituted with one or more second substituent groups denoted by RL16F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL16F.2 substituent group is substituted, the RL16F.2 substituent group is substituted with one or more third substituent groups denoted by RL16F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L16F, RL16F.1, RL16F.2 and RL16F.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L16F, RL16F.1, RL16F.2, and RL16F.3, respectively.
In embodiments, when L17A is substituted, L17A is substituted with one or more first substituent groups denoted by RL17A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL17A.1 substituent group is substituted, the RL17A.1 substituent group is substituted with one or more second substituent groups denoted by RL17A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL17A.2 substituent group is substituted, the RL17A.2 substituent group is substituted with one or more third substituent groups denoted by RL17A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L17A, RL17A.1, RL17A.2, and RL17A.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L17A, RL17A.1, RL17A.2, and RL17A.3, respectively.
In embodiments, when L17B is substituted, L17B is substituted with one or more first substituent groups denoted by RL17B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL17B.1 substituent group is substituted, the RL17B.1 substituent group is substituted with one or more second substituent groups denoted by RL17B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL17B.2 substituent group is substituted, the RL17B.2 substituent group is substituted with one or more third substituent groups denoted by RL17B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L17B, RL17B.1, RL17B.2, and RL17B.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L17B, RL17B.1, RL17B.2, and RL17B.3, respectively.
In embodiments, when L17C is substituted, L17C is substituted with one or more first substituent groups denoted by RL17C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL17C.1 substituent group is substituted, the RL17C.1 substituent group is substituted with one or more second substituent groups denoted by RL17C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL17C.2 substituent group is substituted, the RL17C.2 substituent group is substituted with one or more third substituent groups denoted by RL17C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L17C, RL17C.1, RL17C.2, and RL17C.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L17c, RL17C.1, RL17C.2, and RL17C.3, respectively.
In embodiments, when L17D is substituted, L17D is substituted with one or more first substituent groups denoted by RL17D.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL17D.1 substituent group is substituted, the RL17D.1 substituent group is substituted with one or more second substituent groups denoted by RL17D.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL17D.2 substituent group is substituted, the RL17D.2 substituent group is substituted with one or more third substituent groups denoted by RL17D.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L17D, RL17D.1, RL17D.2, and RL17D.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L17D, RL17D.1, RL17D.2, and RL17D.3, respectively.
In embodiments, when L17E is substituted, L17E is substituted with one or more first substituent groups denoted by RL17E.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL17E.1 substituent group is substituted, the RL17E.1 substituent group is substituted with one or more second substituent groups denoted by RL17E.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL17E.2 substituent group is substituted, the RL17E.2 substituent group is substituted with one or more third substituent groups denoted by RL17E.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L17E, RL17E.1, RL17E.2, and RL17E.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L17E, RL17E.1, RL17E.2 and RL17E.3, respectively.
In embodiments, when L17F is substituted, L17F is substituted with one or more first substituent groups denoted by RL17F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL17F.1 substituent group is substituted, the RL17F.1 substituent group is substituted with one or more second substituent groups denoted by RL17F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL17F.2 substituent group is substituted, the RL17F.2 substituent group is substituted with one or more third substituent groups denoted by RL17F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L17F, RL17F.1, RL17F.2, and RL17F.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L17F, RL17F.1, RL17F.2, and RL17F.3, respectively.
In embodiments, when L18A is substituted, L18A is substituted with one or more first substituent groups denoted by RL18A.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL18A.1 substituent group is substituted, the RL18A.1 substituent group is substituted with one or more second substituent groups denoted by RL18A.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL18A.2 substituent group is substituted, the RL1A.2 substituent group is substituted with one or more third substituent groups denoted by RL18A.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L18A, RL18A.1, RL18A.2, and RL1A.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L18A, RL18A.1, RL18A.2, and RL1A.3, respectively.
In embodiments, when L18B is substituted, L18B is substituted with one or more first substituent groups denoted by RL18B.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL18B.1 substituent group is substituted, the RL18B.1 substituent group is substituted with one or more second substituent groups denoted by RL18B.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL18B.2 substituent group is substituted, the RL18B.2 substituent group is substituted with one or more third substituent groups denoted by RL18B.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L18B, RL18B.1, RL18B.2, and RL18B.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L18B, RL18B.1, RL18B.2, and RL18B.3, respectively.
In embodiments, when L18C is substituted, L18C is substituted with one or more first substituent groups denoted by RL18C.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL18C.1 substituent group is substituted, the RL18C.1 substituent group is substituted with one or more second substituent groups denoted by RL18C.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL18C.2 substituent group is substituted, the RL18C.2 substituent group is substituted with one or more third substituent groups denoted by RL18C.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L18C, RL18C.1, RL18C.2, and RL18C.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L18C, RL18C.1, RL18C.2, and RL18C.3, respectively.
In embodiments, when L18D is substituted, L18D is substituted with one or more first substituent groups denoted by RL18D.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL18D.1 substituent group is substituted, the RL18D.1 substituent group is substituted with one or more second substituent groups denoted by RL18D.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL18D.2 substituent group is substituted, the RL18D.2 substituent group is substituted with one or more third substituent groups denoted by RL18D.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L18D, RL18D.1, RL18D.2, and RL18D.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L18D, RL18D.1, RL18D.2, and RL18D.3, respectively.
In embodiments, when L18E is substituted, L18E is substituted with one or more first substituent groups denoted by RL18E.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL18E.1 substituent group is substituted, the RL18E.1 substituent group is substituted with one or more second substituent groups denoted by RL18E.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL18E.2 substituent group is substituted, the RL18E.2 substituent group is substituted with one or more third substituent groups denoted by RL18E.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L18E, RL18E.1, RL18E.2, and RL18E.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L18E, RL18E.1, RL18E.2, and RL18E.3, respectively.
In embodiments, when L18F is substituted, L18F is substituted with one or more first substituent groups denoted by RL18F.1 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL18F.1 substituent group is substituted, the RL18F.1 substituent group is substituted with one or more second substituent groups denoted by RL18F.2 as explained in the definitions section above in the description of “first substituent group(s)”. In embodiments, when an RL18F.2 substituent group is substituted, the RL18F.2 substituent group is substituted with one or more third substituent groups denoted by RL18F.3 as explained in the definitions section above in the description of “first substituent group(s)”. In the above embodiments, L18F, RL18F.1, RL18F.2, and RL18F.3 have values corresponding to the values of LWW, RLWW.1, RLWW.2, and RLWW.3, respectively, as explained in the definitions section above in the description of “first substituent group(s)”, wherein LWW, RLWW.1, RLWW.2, and RLWW.3 are L18F, RL18F.1, RL18F.2 and RL18F.3, respectively.
In embodiments, the compound contacts the Switch 2 groove of human K-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to G60, Q61, D69, D92, H95, Y96, or Q99 of human K-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to G60 of human K-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to Q61 of human K-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to D69 of human K-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to D92 of human K-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to H95 of human K-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to Y96 of human K-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to Q99 of human K-Ras protein.
In embodiments, the compound contacts the Switch 2 groove of human H-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to G60, Q61, D69, D92, Q95, Y96, or Q99 of human H-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to G60 of human H-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to Q61 of human H-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to D69 of human H-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to D92 of human H-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to Q95 of human H-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to Y96 of human H-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to Q99 of human H-Ras protein.
In embodiments, the compound contacts the Switch 2 groove of human N-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to G60, Q61, D69, D92, L95, Y96, or Q99 of human N-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to G60 of human N-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to Q61 of human N-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to D69 of human N-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to D92 of human N-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to L95 of human N-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to Y96 of human N-Ras protein. In embodiments, the compound contacts a Switch 2 groove amino acid corresponding to Q99 of human N-Ras protein.
In embodiments, the compound binds a human K-Ras protein-GTP complex more strongly than the compound binds a human K-Ras protein-GDP complex under identical conditions. In embodiments, the compound binds a human K-Ras protein-GTP complex at least 2-fold stronger than the compound binds a human K-Ras protein-GDP complex under identical conditions. In embodiments, the compound binds a human K-Ras protein-GTP complex at least 5-fold stronger than the compound binds a human K-Ras protein-GDP complex under identical conditions. In embodiments, the compound binds a human K-Ras protein-GTP complex at least 10-fold stronger than the compound binds a human K-Ras protein-GDP complex under identical conditions. In embodiments, the compound binds a human K-Ras protein-GTP complex at least 20-fold stronger than the compound binds a human K-Ras protein-GDP complex under identical conditions. In embodiments, the compound binds a human K-Ras protein-GTP complex at least 40-fold stronger than said compound binds a human K-Ras protein-GDP complex under identical conditions. In embodiments, the compound binds a human K-Ras protein-GTP complex at least 60-fold stronger than the compound binds a human K-Ras protein-GDP complex under identical conditions. In embodiments, the compound binds a human K-Ras protein-GTP complex at least 80-fold stronger than the compound binds a human K-Ras protein-GDP complex under identical conditions. In embodiments, the compound binds a human K-Ras protein-GTP complex at least 100-fold stronger than said compound binds a human K-Ras protein-GDP complex under identical conditions. In embodiments, the compound binds a human K-Ras protein-GTP complex at least 500-fold stronger than the compound binds a human K-Ras protein-GDP complex under identical conditions.
In embodiments, the compound of formula (I), (II), or (III) binds a human K-Ras protein-GTP complex more strongly than the compound binds a human K-Ras protein-GDP complex under identical conditions. In embodiments, the compound of formula (I), (II), or (III) binds a human K-Ras protein-GTP complex at least 2-fold stronger than the compound binds a human K-Ras protein-GDP complex under identical conditions. In embodiments, the compound of formula (I), (II), or (III) binds a human K-Ras protein-GTP complex at least 5-fold stronger than the compound binds a human K-Ras protein-GDP complex under identical conditions. In embodiments, the compound of formula (I), (II), or (III) binds a human K-Ras protein-GTP complex at least 10-fold stronger than the compound binds a human K-Ras protein-GDP complex under identical conditions. In embodiments, the compound of formula (I), (II), or (III) binds a human K-Ras protein-GTP complex at least 20-fold stronger than the compound binds a human K-Ras protein-GDP complex under identical conditions. In embodiments, the compound of formula (I), (II), or (III) binds a human K-Ras protein-GTP complex at least 40-fold stronger than the compound binds a human K-Ras protein-GDP complex under identical conditions. In embodiments, the compound of formula (I), (II), or (III) binds a human K-Ras protein-GTP complex at least 60-fold stronger than the compound binds a human K-Ras protein-GDP complex under identical conditions. In embodiments, the compound of formula (I), (II), or (III) binds a human K-Ras protein-GTP complex at least 80-fold stronger than the compound binds a human K-Ras protein-GDP complex under identical conditions. In embodiments, the compound of formula (I), (II), or (III) binds a human K-Ras protein-GTP complex at least 100-fold stronger than the compound binds a human K-Ras protein-GDP complex under identical conditions. In embodiments, the compound of formula (I), (II), or (III) binds a human K-Ras protein-GTP complex at least 500-fold stronger than the compound binds a human K-Ras protein-GDP complex under identical conditions.
In embodiments, the compound of formula (IV) binds a human K-Ras protein-GDP complex more strongly than the compound binds a human K-Ras protein-GTP complex under identical conditions. In embodiments, the compound of formula (IV) binds a human K-Ras protein-GDP complex at least 2-fold stronger than the compound binds a human K-Ras protein-GTP complex under identical conditions. In embodiments, the compound of formula (IV) binds a human K-Ras protein-GDP complex at least 5-fold stronger than the compound binds a human K-Ras protein-GTP complex under identical conditions. In embodiments, the compound of formula (IV) binds a human K-Ras protein-GDP complex at least 10-fold stronger than the compound binds a human K-Ras protein-GTP complex under identical conditions. In embodiments, the compound of formula (IV) binds a human K-Ras protein-GDP complex at least 20-fold stronger than the compound binds a human K-Ras protein-GTP complex under identical conditions. In embodiments, the compound of formula (IV) binds a human K-Ras protein-GDP complex at least 40-fold stronger than the compound binds a human K-Ras protein-GTP complex under identical conditions. In embodiments, the compound of formula (IV) binds a human K-Ras protein-GDP complex at least 60-fold stronger than the compound binds a human K-Ras protein-GTP complex under identical conditions. In embodiments, the compound of formula (IV) binds a human K-Ras protein-GDP complex at least 80-fold stronger than the compound binds a human K-Ras protein-GTP complex under identical conditions. In embodiments, the compound of formula (IV) binds a human K-Ras protein-GDP complex at least 100-fold stronger than the compound binds a human K-Ras protein-GTP complex under identical conditions. In embodiments, the compound of formula (IV) binds a human K-Ras protein-GDP complex at least 500-fold stronger than the compound binds a human K-Ras protein-GTP complex under identical conditions.
In embodiments, the compound binds a human K-Ras G12D protein more strongly than the compound binds a human K-Ras wildtype protein under identical conditions. In embodiments, the compound binds a human K-Ras G12D protein at least 2-fold stronger than the compound binds a human K-Ras wildtype protein under identical conditions. In embodiments, the compound binds a human K-Ras G12D protein at least 5-fold stronger than the compound binds a human K-Ras wildtype protein under identical conditions. In embodiments, the compound binds a human K-Ras G12D protein at least 10-fold stronger than the compound binds a human K-Ras wildtype protein under identical conditions. In embodiments, the compound binds a human K-Ras G12D protein at least 20-fold stronger than the compound binds a human K-Ras wildtype protein under identical conditions. In embodiments, the compound binds a human K-Ras G12D protein at least 40-fold stronger than the compound binds a human K-Ras wildtype protein under identical conditions. In embodiments, the compound binds a human K-Ras G12D protein at least 60-fold stronger than the compound binds a human K-Ras wildtype protein under identical conditions. In embodiments, the compound binds a human K-Ras G12D protein at least 80-fold stronger than the compound binds a human K-Ras wildtype protein under identical conditions. In embodiments, the compound binds a human K-Ras G12D protein at least 100-fold stronger than the compound binds a human K-Ras wildtype protein under identical conditions. In embodiments, the compound binds a human K-Ras G12D protein at least 500-fold stronger than the compound binds a human K-Ras wildtype protein under identical conditions.
In embodiments, the compound is capable of binding a water molecule and wherein the water molecule simultaneously binds a D12 residue of a human K-Ras G12D protein.
In embodiments, the compound binds (e.g., covalently binds) a S12 residue of a human K-Ras G12S protein. In embodiments, the compound binds (e.g., covalently binds) a C12 residue of a human K-Ras G12C protein. In embodiments, the compound binds (e.g., covalently binds) a D12 residue of a human K-Ras G12D protein. In embodiments, the compound binds (e.g., covalently binds) a R12 residue of a human K-Ras G12R protein.
In embodiments, the compound binds (e.g., covalently binds) a K61 residue of a human K-Ras Q61K protein. In embodiments, the compound binds (e.g., covalently binds) a R61 residue of a human K-Ras Q61R protein. In embodiments, the compound binds (e.g., covalently binds) a H61 residue of a human K-Ras Q61H protein.
In embodiments, the compound binds (e.g., covalently binds) a K61 residue of a human H-Ras Q61K protein. In embodiments, the compound binds (e.g., covalently binds) a R61 residue of a human H-Ras Q61R protein. In embodiments, the compound binds (e.g., covalently binds) a H61 residue of a human H-Ras Q61H protein.
In embodiments, the compound binds (e.g., covalently binds) a K61 residue of a human N-Ras Q61K protein. In embodiments, the compound binds (e.g., covalently binds) a R61 residue of a human N-Ras Q61R protein. In embodiments, the compound binds (e.g., covalently binds) a H61 residue of a human N-Ras Q61H protein.
In embodiments, the compound binds a human K-Ras G12D protein and wherein the shortest average distance between the compound and the D12 residue of the human K-Ras protein is from 1.5 Å to 6.0 Å. In embodiments, the compound binds a human K-Ras G12D protein and wherein the shortest average distance between the compound and the D12 residue of the human K-Ras protein is from about 1.5 Å to about 6.0 Å. In embodiments, the compound binds a human K-Ras G12D protein and wherein the shortest average distance between the compound and the D12 residue of the human K-Ras protein is less than 1.5 Å. In embodiments, the compound binds a human K-Ras G12D protein and wherein the shortest average distance between the compound and the D12 residue of the human K-Ras protein is less than 2.0 Å. In embodiments, the compound binds a human K-Ras G12D protein and wherein the shortest average distance between the compound and the D12 residue of the human K-Ras protein is less than 3.0 Å. In embodiments, the compound binds a human K-Ras G12D protein and wherein the shortest average distance between the compound and the D12 residue of the human K-Ras protein is less than 4.0 Å. In embodiments, the compound binds a human K-Ras G12D protein and wherein the shortest average distance between the compound and the D12 residue of the human K-Ras protein is less than 5.0 Å. In embodiments, the compound binds a human K-Ras G12D protein and wherein the shortest average distance between the compound and the D12 residue of the human K-Ras protein is less than 6.0 Å.
In embodiments, the compound binds a human K-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human K-Ras protein-GTP complex is from 1.5 Å to 10.0 Å. In embodiments, the compound binds a human K-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human K-Ras protein-GTP complex is from about 1.5 Å to about 10.0 Å. In embodiments, the compound binds a human K-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human K-Ras protein-GTP complex is from 3.0 Å to 10.0 Å. In embodiments, the compound binds a human K-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human K-Ras protein-GTP complex is from about 3.0 Å to about 10.0 Å. In embodiments, the compound binds a human K-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human K-Ras protein-GTP complex is less than 1.5 Å. In embodiments, the compound binds a human K-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human K-Ras protein-GTP complex is less than 2.0 Å. In embodiments, the compound binds a human K-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human K-Ras protein-GTP complex is less than 3.0 Å. In embodiments, the compound binds a human K-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human K-Ras protein-GTP complex is less than 4.0 Å. In embodiments, the compound binds a human K-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human K-Ras protein-GTP complex is less than 5.0 Å. In embodiments, the compound binds a human K-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human K-Ras protein-GTP complex is less than 6.0 Å. In embodiments, the compound binds a human K-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human K-Ras protein-GTP complex is less than 7.0 Å. In embodiments, the compound binds a human K-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human K-Ras protein-GTP complex is less than 8.0 Å. In embodiments, the compound binds a human K-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human K-Ras protein-GTP complex is less than 9.0 Å. In embodiments, the compound binds a human K-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human K-Ras protein-GTP complex is less than 10.0 Å.
In embodiments, the compound binds a human H-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human H-Ras protein-GTP complex is from 1.5 Å to 10.0 Å. In embodiments, the compound binds a human H-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human H-Ras protein-GTP complex is from about 1.5 Å to about 10.0 Å. In embodiments, the compound binds a human H-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human H-Ras protein-GTP complex is from 3.0 Å to 10.0 Å. In embodiments, the compound binds a human H-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human H-Ras protein-GTP complex is from about 3.0 Å to about 10.0 Å. In embodiments, the compound binds a human H-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human H-Ras protein-GTP complex is less than 1.5 Å. In embodiments, the compound binds a human H-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human H-Ras protein-GTP complex is less than 2.0 Å. In embodiments, the compound binds a human H-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human H-Ras protein-GTP complex is less than 3.0 Å. In embodiments, the compound binds a human H-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human H-Ras protein-GTP complex is less than 5.0 Å. In embodiments, the compound binds a human H-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human H-Ras protein-GTP complex is less than 10.0 Å.
In embodiments, the compound binds a human N-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human N-Ras protein-GTP complex is from 1.5 Å to 10.0 Å. In embodiments, the compound binds a human N-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human N-Ras protein-GTP complex is from about 1.5 Å to about 10.0 Å. In embodiments, the compound binds a human N-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human N-Ras protein-GTP complex is from 3.0 Å to 10.0 Å. In embodiments, the compound binds a human N-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human N-Ras protein-GTP complex is from about 3.0 Å to about 10.0 Å. In embodiments, the compound binds a human N-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human N-Ras protein-GTP complex is less than 1.5 Å. In embodiments, the compound binds a human N-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human N-Ras protein-GTP complex is less than 2.0 Å. In embodiments, the compound binds a human N-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human N-Ras protein-GTP complex is less than 3.0 Å. In embodiments, the compound binds a human N-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human N-Ras protein-GTP complex is less than 5.0 Å. In embodiments, the compound binds a human N-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of the human N-Ras protein-GTP complex is less than 10.0 Å.
In embodiments, the compound is useful as a comparator compound. In embodiments, the comparator compound can be used to assess the activity of a test compound as set forth in an assay described herein (e.g., in the examples section, figures, or tables).
In embodiments, the compound is a compound as described herein, including in embodiments. In embodiments the compound is a compound described herein (e.g., in the examples section, figures, tables, or claims).
In an aspect is provided a pharmaceutical composition including a compound described herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
In embodiments, the pharmaceutical composition includes an effective amount of the compound. In embodiments, the pharmaceutical composition includes a therapeutically effective amount of the compound.
In embodiments, the pharmaceutical composition includes an effective amount of a second agent, wherein the second agent is an anti-cancer agent. In embodiments, the anti-cancer agent is a MEK inhibitor (e.g., XL518, CI-1040, PD035901, selumetinib/AZD6244, GSK1120212/trametinib, GDC-0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS703026, or BAY 869766) or an EGFR inhibitor (e.g., gefitinib (Iressa™), erlotinib (Tarceva™), cetuximab (Erbitux™), lapatinib (Tykerb™) panitumumab (Vectibix™), vandetanib (Caprelsa™), afatinib/BIBW2992, CI-1033/canertinib, neratinib/HKI-272, CP-724714, TAK-285, AST-1306, ARRY334543, ARRY-380, AG-1478, dacomitinib/PF299804, OSI-420/desmethyl erlotinib, AZD8931, AEE788, pelitinib/EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, or BMS-599626).
In an aspect is provided a method of treating a cancer in a patient in need of such treatment, the method including administering a therapeutically effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof, to the patient.
In embodiments, the cancer is breast cancer, pancreatic cancer, prostate cancer, colorectal cancer, lung cancer, leukemia, bladder cancer, thyroid cancer, salivary duct carcinoma, epithelial carcinoma, or kidney cancer.
In an aspect is provided a method of modulating (e.g., reducing) the activity of a human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein, the method including contacting the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein with an effective amount of a compound described herein, or a pharmaceutically acceptable salt thereof. In embodiments, the activity of Ras (e.g., K-Ras, H-Ras, or N-Ras) is reduced by about 1.5-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 25-, 30-, 35-, 40-, 45-, 50-, 60-, 70-, 80-, 90-, 100-, 150-, 200-, 250-, 300-, 350-, 400-, 450-, 500-, 600-, 700-, 800-, 900-, or 1000-fold. In embodiments, the activity of Ras (e.g., K-Ras, H-Ras, or N-Ras) is reduced by at least 1.5-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 25-, 30-, 35-, 40-, 45-, 50-, 60-, 70-, 80-, 90-, 100-, 150-, 200-, 250-, 300-, 350-, 400-, 450-, 500-, 600-, 700-, 800-, 900-, or 1000-fold.
In embodiments, the human Ras protein is a human K-Ras protein. In embodiments, the activity of K-Ras is reduced by about 1.5-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 25-, 30-, 35-, 40-, 45-, 50-, 60-, 70-, 80-, 90-, 100-, 150-, 200-, 250-, 300-, 350-, 400-, 450-, 500-, 600-, 700-, 800-, 900-, or 1000-fold. In embodiments, the activity of K-Ras is reduced by at least 1.5-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 25-, 30-, 35-, 40-, 45-, 50-, 60-, 70-, 80-, 90-, 100-, 150-, 200-, 250-, 300-, 350-, 400-, 450-, 500-, 600-, 700-, 800-, 900-, or 1000-fold.
In embodiments, the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is a human Ras (e.g., K-Ras, H-Ras, or N-Ras) G12D protein, a human Ras (e.g., K-Ras, H-Ras, or N-Ras) G12C protein, a human Ras (e.g., K-Ras, H-Ras, or N-Ras) G12S protein, a human Ras (e.g., K-Ras, H-Ras, or N-Ras) G12V protein, or a human Ras (e.g., K-Ras, H-Ras, or N-Ras) G12R protein. In embodiments, the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is a human Ras (e.g., K-Ras, H-Ras, or N-Ras) G12D protein. In embodiments, the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is a human Ras (e.g., K-Ras, H-Ras, or N-Ras) G12C protein. In embodiments, the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is a human Ras (e.g., K-Ras, H-Ras, or N-Ras) G12S protein. In embodiments, the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is a human Ras (e.g., K-Ras, H-Ras, or N-Ras) G12V protein. In embodiments, the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is a human Ras (e.g., K-Ras, H-Ras, or N-Ras) G12R protein.
In embodiments, the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is a human Ras (e.g., K-Ras, H-Ras, or N-Ras) Q61L protein, a human Ras (e.g., K-Ras, H-Ras, or N-Ras) Q61K protein, a human Ras (e.g., K-Ras, H-Ras, or N-Ras) Q61R protein, or a human Ras (e.g., K-Ras, H-Ras, or N-Ras) Q61H protein. In embodiments, the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is a human Ras (e.g., K-Ras, H-Ras, or N-Ras) Q61L protein. In embodiments, the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is a human Ras (e.g., K-Ras, H-Ras, or N-Ras) Q61K protein. In embodiments, the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is a human Ras (e.g., K-Ras, H-Ras, or N-Ras) Q61R protein. In embodiments, the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is a human Ras (e.g., K-Ras, H-Ras, or N-Ras) Q61H protein.
In embodiments, the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein includes a Q61 mutation. In embodiments, the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein includes a Q61L mutation. In embodiments, the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein includes a Q61K mutation. In embodiments, the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein includes a Q61R mutation. In embodiments, the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein includes a Q61H mutation.
In embodiments, the activity of the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is GTPase activity, nucleotide exchange, GDP binding, GTP binding, differential GDP or GTP binding, effector protein binding, Ras (e.g., K-Ras, H-Ras, or N-Ras) binding to Raf, effector protein activation, guanine exchange factor (GEF) binding, GEF-facilitated nucleotide exchange, phosphate release, nucleotide release, nucleotide binding, Ras (e.g., K-Ras, H-Ras, or N-Ras) subcellular localization, Ras (e.g., K-Ras, H-Ras, or N-Ras) post-translational processing, or Ras (e.g., K-Ras, H-Ras, or N-Ras) post-translational modifications. In embodiments, the activity of the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is GTPase activity. In embodiments, the activity of the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is nucleotide exchange. In embodiments, the activity of the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is GDP binding. In embodiments, the activity of the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is GTP binding. In embodiments, the activity of the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is differential GDP or GTP binding. In embodiments, the activity of the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is effector protein binding. In embodiments, the activity of the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is Ras (e.g., K-Ras, H-Ras, or N-Ras) binding to Raf. In embodiments, the activity of the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is effector protein activation. In embodiments, the activity of the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is guanine exchange factor (GEF) binding. In embodiments, the activity of the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is GEF-facilitated nucleotide exchange. In embodiments, the activity of the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is phosphate release. In embodiments, the activity of the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is nucleotide release. In embodiments, the activity of the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is nucleotide binding. In embodiments, the activity of the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is K-Ras subcellular localization. In embodiments, the activity of the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is Ras (e.g., K-Ras, H-Ras, or N-Ras) post-translational processing. In embodiments, the activity of the human Ras (e.g., K-Ras, H-Ras, or N-Ras) protein is Ras (e.g., K-Ras, H-Ras, or N-Ras) post-translational modifications.
In embodiments, the human Ras protein is a human H-Ras protein. In embodiments, the activity of H-Ras is reduced by about 1.5-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 25-, 30-, 35-, 40-, 45-, 50-, 60-, 70-, 80-, 90-, 100-, 150-, 200-, 250-, 300-, 350-, 400-, 450-, 500-, 600-, 700-, 800-, 900-, or 1000-fold. In embodiments, the activity of H-Ras is reduced by at least 1.5-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 25-, 30-, 35-, 40-, 45-, 50-, 60-, 70-, 80-, 90-, 100-, 150-, 200-, 250-, 300-, 350-, 400-, 450-, 500-, 600-, 700-, 800-, 900-, or 1000-fold.
In embodiments, the human Ras protein is a human N-Ras protein. In embodiments, the activity of N-Ras is reduced by about 1.5-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 25-, 30-, 35-, 40-, 45-, 50-, 60-, 70-, 80-, 90-, 100-, 150-, 200-, 250-, 300-, 350-, 400-, 450-, 500-, 600-, 700-, 800-, 900-, or 1000-fold. In embodiments, the activity of N-Ras is reduced by at least 1.5-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 15-, 20-, 25-, 30-, 35-, 40-, 45-, 50-, 60-, 70-, 80-, 90-, 100-, 150-, 200-, 250-, 300-, 350-, 400-, 450-, 500-, 600-, 700-, 800-, 900-, or 1000-fold.
Embodiment P1. A compound having the formula:
wherein
L1A, L2A, L3A, L4A, L5A, L6A, L7A, L8A, L9A, L10A, L11A, and L12A are independently a bond, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene;
R1A, R2A, R2A, R8A, and R11A are independently substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R3A is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted aryl;
R4A and R7A are independently hydrogen, —NH2, —COOH, —CONH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl;
R6A, R9A, and R12A are independently hydrogen, —CN, —NH2, —CONH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHOH, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl;
R3A and R9A may optionally be joined to form a covalent linker;
R10A is independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —COOH, —C(O)NH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, -L10DL10E-E, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L10D is independently a bond, —S(O)2—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
L10E is independently a bond, —S(O)2—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted heteroalkylene, substituted or unsubstituted heterocycloalkylene, or substituted or unsubstituted heteroarylene;
E is an electrophilic moiety;
R1D, R2D, R3D, R4D, RSD, R6D, R7D, R8D, R9D, R10D, R11D, and R12D are independently hydrogen or unsubstituted C1-C4 alkyl; and
L16 is a covalent linker.
Embodiment P2. The compound of embodiment P1, having the formula:
Embodiment P3. The compound of embodiment P1, having the formula:
Embodiment P4. The compound of one of embodiments P1 to P3, wherein R10A is independently hydrogen, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.
Embodiment P5. The compound of one of embodiments P1 to P3, wherein R10A is -L10D-L10E-E;
L10D is independently a bond, —S(O)2—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
L10E is independently a bond, —NH—, —O—, —C(O)—, —C(O)NH—, —NHC(O)NH—, —NHC(NH)NH—, substituted or unsubstituted heteroalkylene, substituted or unsubstituted heterocycloalkylene, or substituted or unsubstituted heteroarylene;
E is an electrophilic moiety capable of forming a covalent bond with a cysteine, aspartate, lysine, arginine, histidine, leucine, tyrosine, methionine, serine, or glutamate residue.
Embodiment P6. The compound of one of embodiments P1 to P3, wherein R10A is -L10D-L10E-E;
L10D is independently a bond, —S(O)2—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
L10E is independently a bond, —S(O)2—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; E is —SH, —SSR26,
R26, R27, and R28 are independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —C(O)OH, —C(O)NH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
X27 is independently —F, —Cl, —Br, or —I.
Embodiment P7. The compound of one of embodiments P1 to P3, wherein R10A is -L10D-L10E-E;
L10D is independently a bond;
L10E is independently —NH—; and
Embodiment P8. The compound of one of embodiments P1 to P3, wherein
-L10A-R10A is
Embodiment P9. The compound of one of embodiments P1 to P8, wherein R3A and R9A are joined to form a bioconjugate linker.
Embodiment P10. The compound of one of embodiments P1 to P8, wherein R3A and R9A are joined to form a covalent linker having the formula -L18A-L18B-L18C-L18D-L18E-L18F-;
L18A, L18B, L18C, L18D, L18E, and L18F are independently bond, —SS—, —S(O)2—, —OS(O)2—, —S(O)2O—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
Embodiment P11. The compound of one of embodiments P1 to P8, wherein R3A and R9A are joined to form
Embodiment P12. The compound of one of embodiments P1 to P3, having the formula:
Embodiment P13. A compound having the formula:
wherein
L1B, L2B, L3B, L4B, L5B, L6B, L7B, L8B, L9B, L10B, L11B, L12B, and L13B are independently a bond, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene;
R1B, R8B, and R10B are independently substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2B, R3B, R4B, R9B, and R11B are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted aryl;
R5B is independently hydrogen, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl;
R6B is independently hydrogen, —OH, —COOH, —NO2, —SO3H, —OSO3H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl;
R7B, R12B, and R13B are independently hydrogen, —NH2, —CONH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted heteroaryl; two substituents selected from R1B, R2B, R3B, R4B, R5B, R6B, L7B, R8B, R9B, R10B, R11B, R12B, and R13B may optionally be joined to form a covalent linker;
R1D, R2D, R3D, R4D, RSD, R6D, R7D, R8D, R9D, R10D, R11D, R12D, and R13D are independently hydrogen or unsubstituted C1-C4 alkyl; and
L16 is a covalent linker.
Embodiment P14. The compound of embodiment P13, having the formula:
Embodiment P15. The compound of embodiment P13, having the formula:
Embodiment P16. The compound of embodiment P13, having the formula:
Embodiment P17. A compound having the formula:
wherein
L1C, L2C, L3C, L4C, L5C, L6C, L7C, L8C, L9C, L10C, L11C, L12C, L13C, L14C, and L15C are independently a bond, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene;
R1C is independently substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2C is independently hydrogen, —OH, —NO2, —CN, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl;
L3 is independently a bond or
R3C is independently hydrogen, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L4 is independently a bond or
R4C is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted aryl;
L5 is independently a bond or
R5C is independently substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L6 is independently a bond,
R6C is independently hydrogen, —CN, —NH2, —C(O)NH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHOH, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl;
R7C and R8C are independently hydrogen, —CN, —NH2, —C(O)NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHOH, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L9 is independently a bond,
R9C is independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted aryl;
L10 is independently a bond,
R10C is independently hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L11 is independently a bond or
R11C is independently hydrogen, —CN, —OH, —C(O)OH, —NO2, —SO3H, —OSO3H, —NH2, —C(O)NH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl;
R12C is independently hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L13 is independently
R13C is independently hydrogen, —OH, —NH2, —C(O)OH, —C(O)NH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted aryl;
L14 is independently a bond or
R14C is independently hydrogen, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L15 is independently a bond or
R15C is independently hydrogen, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
two substituents selected from R1C, R2C, R3C, R4C, R5C, R6C, R7C, R8C, R9C, R10C, R11C, R12C, R13C, R14C, and R15C may optionally be joined to form a covalent linker;
R1D, R2D, R3D, R4D, R5D, R6D, R7D, R8D, R9D, R10D, R11D, R12D, R13D, R14D, and R15D are independently hydrogen or unsubstituted C1-C4 alkyl; and
L16 is a covalent linker.
Embodiment P18. The compound of embodiment P17, having the formula:
wherein
R3D, R4D, R5D, R6D, R9D, R10D, R11D, R13D, R14D, and R15D are independently hydrogen.
Embodiment P19. The compound of embodiment P18, having the formula:
Embodiment P20. The compound of embodiment P18, having the formula:
Embodiment P21. The compound of one of embodiments P1 to P20, wherein L16 is a bioconjugate linker.
Embodiment P22. The compound of one of embodiments P1 to P20, wherein L16 is a substituted or unsubstituted divalent amino acid.
Embodiment P23. The compound of embodiment P22, wherein L16 is a substituted or unsubstituted divalent δ-amino acid.
Embodiment P24. The compound of one of embodiments P1 to P20, wherein
L16 is -L16A-L16B-L16C-L16D-L16E-L16F-; and
L16A, L16B, L16C, L16D, L16E, and L16F are independently bond, —SS—, —S(O)2—, —OS(O)2—, —S(O)2O—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
Embodiment P25. The compound of embodiment P24, wherein
L16 is —NH-L16B-L16C-L16D-L16E-C(O)—;
L16C, L16D, and L16E are independently bond, —SS—, —S(O)2—, —OS(O)2—, —S(O)2O—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
L17 is -L17A-L17B-L17C-L17D-L17E-L17F-;
L17A, L17B, L17C, L17D, L17E, and L17F are independently bond, —SS—, —S(O)2—, —OS(O)2—, —S(O)2O—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
R17 is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a monovalent nucleic acid, a monovalent protein a detectable moiety, or a drug moiety.
Embodiment P26. The compound of embodiment P24, wherein L16 is a bond,
L17 is -L17A-L17B-L17C-L17D-L17E-L17F-;
L17A, L17B, L17C, L17D, L17E, and L17F are independently bond, —SS—, —S(O)2—, —OS(O)2—, —S(O)2O—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
R17 is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —C(O)OH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, a monovalent nucleic acid, a monovalent protein, a detectable moiety, or a drug moiety.
Embodiment P27. The compound of embodiment P24, wherein L16 is a bond,
Embodiment P28. A compound having the formula:
wherein
L17 is -L17A-L17B-L17C-L17D-L17E-L17F-;
L17A, L17B, L17C, L17D, L17E, and L17F are independently bond, —SS—, —S(O)2—, —OS(O)2—, —S(O)2O—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
R17 is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —C(O)OH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a monovalent nucleic acid, a monovalent protein, a detectable moiety, or a drug moiety.
Embodiment P29. A compound having the formula:
wherein
L17 is -L17A-L17B-L17C-L17D-L17E-L17F-;
L17A, L17B, L17C, L17D, L17E, and L17F are independently bond, —SS—, —S(O)2—, —OS(O)2—, —S(O)2O—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
R17 is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —C(O)OH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a monovalent nucleic acid, a monovalent protein, a detectable moiety, or a drug moiety.
Embodiment P30. A compound having the formula:
wherein
L17 is -L17A-L17B-L17C-L17D-L17E-L17F-.
L17A, L17B, L17C, L17D, L17E, and L17F are independently bond, —SS—, —S(O)2—, —OS(O)2—, —S(O)2O—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
R17 is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —C(O)OH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a monovalent nucleic acid, a monovalent protein, a detectable moiety, or a drug moiety.
Embodiment P31. A compound having the formula:
Embodiment P32. The compound of one of embodiments P1 to P31, wherein said compound contacts the Switch 2 groove of human K-Ras protein.
Embodiment P33. The compound of one of embodiments P1 to P31, wherein said compound contacts a Switch 2 groove amino acid corresponding to G60, Q61, D69, D92, H95, Y96, or Q99 of human K-Ras protein.
Embodiment P34. The compound of one of embodiments P1 to P31, wherein said compound binds a human K-Ras protein-GTP complex more strongly than said compound binds a human K-Ras protein-GDP complex under identical conditions.
Embodiment P35. The compound of embodiment P34, wherein said compound binds a human K-Ras protein-GTP complex at least 2-fold stronger than said compound binds a human K-Ras protein-GDP complex under identical conditions.
Embodiment P36. The compound of embodiment P34, wherein said compound binds a human K-Ras protein-GTP complex at least 5-fold stronger than said compound binds a human K-Ras protein-GDP complex under identical conditions.
Embodiment P37. The compound of embodiment P34, wherein said compound binds a human K-Ras protein-GTP complex at least 40-fold stronger than said compound binds a human K-Ras protein-GDP complex under identical conditions.
Embodiment P38. The compound of embodiment P34, wherein said compound binds a human K-Ras protein-GTP complex at least 100-fold stronger than said compound binds a human K-Ras protein-GDP complex under identical conditions.
Embodiment P39. The compound of one of embodiments P1 to P38, wherein said compound binds a human K-Ras G12D protein more strongly than said compound binds a human K-Ras wildtype protein under identical conditions.
Embodiment P40. The compound of one of embodiments P1 to P38, wherein said compound binds a human K-Ras G12D protein at least 2-fold stronger than said compound binds a human K-Ras wildtype protein under identical conditions.
Embodiment P41. The compound of one of embodiments P1 to P38, wherein said compound binds a human K-Ras G12D protein at least 10-fold stronger than said compound binds a human K-Ras wildtype protein under identical conditions.
Embodiment P42. The compound of one of embodiments P1 to P38, wherein said compound binds a human K-Ras G12D protein at least 100-fold stronger than said compound binds a human K-Ras wildtype protein under identical conditions.
Embodiment P43. The compound of one of embodiments P1 to P42, wherein said compound is capable of binding a water molecule and wherein said water molecule simultaneously binds a D12 residue of a human K-Ras G12D protein.
Embodiment P44. The compound of one of embodiments P1 to P42, wherein said compound binds a human K-Ras G12D protein and wherein the shortest average distance between the compound and the D12 residue of said human K-Ras protein is from 1.5 Å to 6.0 Å.
Embodiment P45. The compound of one of embodiments P1 to P42, wherein said compound binds a human K-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of said human K-Ras protein-GTP complex is from 1.5 Å to 10.0 Å.
Embodiment P46. A pharmaceutical composition comprising the compound of any one of embodiments P1 to P45, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
Embodiment P47. A method of treating a cancer in a patient in need of such treatment, said method comprising administering a therapeutically effective amount of a compound of any one of embodiments P1 to P45 to said patient.
Embodiment P48. A method of modulating the activity of a human K-Ras protein, said method comprising contacting said human K-Ras protein with an effective amount of a compound of any one of embodiments P1 to P45.
Embodiment P49. The method of embodiment P48, wherein said human K-Ras protein is a human K-Ras G12D protein, a human K-Ras G12C protein, a human K-Ras G12S protein, a human K-Ras G12V protein, or a human K-Ras G12R protein.
Embodiment P50. The method of embodiment P48, wherein said human K-Ras protein comprises a Q61 mutation.
Embodiment P51. The method of one of embodiments P48 to P50, wherein the activity of the human K-Ras protein is GTPase activity, nucleotide exchange, GDP binding, GTP binding, differential GDP or GTP binding, effector protein binding, K-Ras binding to Raf, effector protein activation, guanine exchange factor (GEF) binding, GEF-facilitated nucleotide exchange, phosphate release, nucleotide release, nucleotide binding, K-Ras subcellular localization, K-Ras post-translational processing, or K-Ras post-translational modifications.
Embodiment P52. The method of one of embodiments P48 to P50, wherein the activity of the human K-Ras protein is K-Ras binding to Raf.
Embodiment P53. A method of modulating the activity of a human H-Ras protein, said method comprising contacting said human H-Ras protein with an effective amount of a compound of any one of embodiments P1 to P45.
Embodiment P54. A method of modulating the activity of a human N-Ras protein, said method comprising contacting said human N-Ras protein with an effective amount of a compound of any one of embodiments P1 to P45.
Embodiment 1. A compound having the formula:
wherein
L1A, L2A, L3A, L4A, L5A, L6A, L7A, L8A, L9A, L10A, L11A, and L12A are independently a bond, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene;
R1A, R2A, R5A, R8A, and R11A are independently substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R3A is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted aryl;
R4A and R7A are independently hydrogen, —NH2, —COOH, —CONH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl;
R6A, R9A, and R12A are independently hydrogen, —CN, —NH2, —CONH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHOH, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl;
R3A and R9A may optionally be joined to form a covalent linker;
R10A is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —COOH, —C(O)NH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, -L10D-L10E-E, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L10D is a bond, —S(O)2—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
L10E is a bond, —S(O)2—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted heteroalkylene, substituted or unsubstituted heterocycloalkylene, or substituted or unsubstituted heteroarylene;
E is an electrophilic moiety;
R1D, R2D, R3D, R4D, R5D, R6D, R7D, R8D, R9D, R10D, R11D, and R12D are independently hydrogen or unsubstituted C1-C4 alkyl; and
L16 is a covalent linker.
Embodiment 2. The compound of embodiment 1, having the formula:
Embodiment 3. The compound of embodiment 1, having the formula:
Embodiment 4. The compound of one of embodiments 1 to 3, wherein R10A is hydrogen, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl.
Embodiment 5. The compound of one of embodiments 1 to 3, wherein R10A is -L10D-L10E-E;
L10D is a bond, —S(O)2—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; L10E is a bond, —NH—, —O—, —C(O)—, —C(O)NH—, —NHC(O)NH—, —NHC(NH)NH—, substituted or unsubstituted heteroalkylene, substituted or unsubstituted heterocycloalkylene, or substituted or unsubstituted heteroarylene; and
E is an electrophilic moiety capable of forming a covalent bond with a cysteine, aspartate, lysine, arginine, histidine, leucine, tyrosine, methionine, serine, or glutamate residue.
Embodiment 6. The compound of one of embodiments 1 to 3, wherein R10A is -L10D-L10E-E;
L10D is a bond, —S(O)2—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
L10E is a bond, —S(O)2—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
R26, R27, and R28 are independently hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —C(O)OH, —C(O)NH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
Embodiment 7. The compound of one of embodiments 1 to 3, wherein
R10A is -L10D-L10E-E;
L10D is a bond;
Embodiment 8. The compound of one of embodiments 1 to 3, wherein
-L10A-R10A is
Embodiment 9. The compound of one of embodiments 1 to 8, wherein R3A and R9A are joined to form a bioconjugate linker.
Embodiment 10. The compound of one of embodiments 1 to 8, wherein R3A and R9A are joined to form a covalent linker having the formula -LISA-L18B-L18C-L18D-L18E-L18F-; and
L18A, L18B, L18C, L18D, L18E, and L18F are independently bond, —SS—, —S(O)2—, —OS(O)2—, —S(O)2O—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
Embodiment 11. The compound of one of embodiments 1 to 8, wherein R3A and R9A are joined to form
Embodiment 12. The compound of one of embodiments 1 to 3, having the formula:
Embodiment 13. A compound having the formula:
wherein
L1B, L2B, L3B, L4B, L5B, L6B, L7B, L8B, L9B, L10B, L11B, L12B, and L13B are independently a bond, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene;
R1B, R8B, and R10B are independently substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2B, R3B, R4B, R9B, and R11B are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted aryl;
R5B is hydrogen, —OH, —NH2, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl;
R6B is hydrogen, —OH, —COOH, —NO2, —SO3H, —OSO3H, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl;
R7B, R12B, and R13B are independently hydrogen, —NH2, —CONH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, or substituted or unsubstituted heteroaryl;
two substituents selected from R1B, R2B, R3B, R4B, R5B, R6B, L7B, R8B, R9B, R10B, R11B, R12B, and R13B may optionally be joined to form a covalent linker;
R1D, R2D, R3D, R4D, R5D, R6D, R7D, R8D, R9D, R10D, R1HD, R12D, and R13D are independently hydrogen or unsubstituted C1-C4 alkyl; and
L16 is a covalent linker.
Embodiment 14. The compound of embodiment 13, having the formula:
Embodiment 15. The compound of embodiment 13, having the formula:
Embodiment 16. The compound of embodiment 13, having the formula:
Embodiment 17. A compound having the formula:
wherein
L1C, L2C, L3C, L4C, L5C, L6C, L7C, L8C, L9C, L10C, L11C, L12C, L13C, L14C, and L15C are independently a bond, substituted or unsubstituted alkylene, or substituted or unsubstituted heteroalkylene;
R1C is substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2C is hydrogen, —OH, —NO2, —CN, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl;
L3 is a bond or
R3C is hydrogen, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L4 is a bond or
R4C is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted aryl;
L5 is a bond or
R5C is substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L6 is a bond,
R6C is hydrogen, —CN, —NH2, —C(O)NH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHOH, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl;
R7C and R8C are independently hydrogen, —CN, —NH2, —C(O)NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHOH, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L9 is a bond,
R9C is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted aryl;
L10 is a bond,
R10C is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L11 is a bond or
R11C is hydrogen, —CN, —OH, —C(O)OH, —NO2, —SO3H, —OSO3H, —NH2, —C(O)NH2, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl;
R12C is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R13C is hydrogen, —OH, —NH2, —C(O)OH, —C(O)NH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted aryl;
L14 is a bond or
R14C is hydrogen, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L is a bond or
R15C is hydrogen, —NH2, —C(O)OH, —C(O)NH2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, substituted or unsubstituted alkyl, or substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two substituents selected from R1C, R2C, R3C, R4C, R5C, R6C, R7C, R8C, R9C, R10C, R11C, R12C, R13C, R14C, and R15C may optionally be joined to form a covalent linker;
R1D, R2D, R3D, R4D, R5D, R6D, R7D, R8D, R9D, R10D, R11D, R12D, R13D, R14D, and R15D are independently hydrogen or unsubstituted C1-C4 alkyl; and
L16 is a covalent linker.
Embodiment 18. The compound of embodiment 17, having the formula:
wherein
R3D, R4D, R5D, R6D, R9D, R10D, R11D, R13D, R14D, and R15D are hydrogen.
Embodiment 19. The compound of embodiment 18, having the formula:
Embodiment 20. The compound of embodiment 18, having the formula:
Embodiment 21. The compound of one of embodiments 1 to 20, wherein L16 is a bioconjugate linker.
Embodiment 22. The compound of one of embodiments 1 to 20, wherein L16 is a substituted or unsubstituted divalent amino acid.
Embodiment 23. The compound of embodiment 22, wherein L16 is a substituted or unsubstituted divalent δ-amino acid.
Embodiment 24. The compound of one of embodiments 1 to 20, wherein
L16 is -L16A-L16B-L16C-L16D-L16E-L16F-; and
L16A, L16B, L16C, L16D, L16E, and L16F are independently bond, —SS—, S(O)2—, —OS(O)2—, —S(O)2O—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.
Embodiment 25. The compound of embodiment 24, wherein
L16 is —NH-L16B-L16C-L16D-L16E-C(O)—;
L16C, L16D, and L16E are independently bond, —SS—, —S(O)2—, —OS(O)2—, —S(O)2O—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
L17 is -L17A-L17B-L17C-L17D-L17E-L17F-;
L17A, L17B, L17C, L17D, L17E, and L17F are independently bond, —SS—, —S(O)2—, —OS(O)2—, —S(O)2O—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and
R17 is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —COOH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a monovalent nucleic acid, a monovalent protein a detectable moiety, or a drug moiety.
Embodiment 26. The compound of embodiment 24, wherein L16 is a bond,
L17 is -L17A-L17B-L17C-L17D-L17E-L17F-;
L17A, L17B, L17C, L17D, L17E, and L17F are independently a bond, —SS—, —S(O)2—, —OS(O)2—, —S(O)2O—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and
R17 is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —C(O)OH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, a monovalent nucleic acid, a monovalent protein, a detectable moiety, or a drug moiety.
Embodiment 27. The compound of embodiment 24, wherein L16 is a bond,
Embodiment 28. A compound having the formula:
wherein
L17 is -L17A-L17B-L17C-L17D-L17E-L17F-;
L17A, L17B, L17C, L17D, L17E, and L17F are independently bond, —SS—, —S(O)2—, —OS(O)2—, —S(O)2O—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and
R17 is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —C(O)OH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a monovalent nucleic acid, a monovalent protein, a detectable moiety, or a drug moiety.
Embodiment 29. A compound having the formula:
wherein
L17 is -L17A-L17B-L17C-L17D-L17E-L17F-;
L17A, L17B, L17C, L17D, L17E, and L17F are independently bond, —SS—, —S(O)2—, —OS(O)2—, —S(O)2O—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and
R17 is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —C(O)OH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a monovalent nucleic acid, a monovalent protein, a detectable moiety, or a drug moiety.
Embodiment 30. A compound having the formula:
wherein
L17 is -L17A-L17B-L17C-L17D-L17E-L17F-;
L17A, L17B, L17C, L17D, L17E, and L17F are independently bond, —SS—, —S(O)2—, —OS(O)2—, —S(O)2O—, —NH—, —O—, —S—, —C(O)—, —NHS(O)2—, —S(O)2NH—, —C(O)NH—, —NHC(O)—, —NHC(O)NH—, —NHC(NH)NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; and
R17 is hydrogen, halogen, —CCl3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —C(O)H, —C(O)OH, —CONH2, —NO2, —SH, —SO3H, —OSO3H, —SO2NH2, —NHNH2, —ONH2, —NHC(O)NHNH2, —NHC(O)NH2, —NHC(NH)NH2, —NHSO2H, —NHC(O)H, —NHC(O)OH, —NHOH, —OCCl3, —OCF3, —OCBr3, —OCI3, —OCHCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2I, —OCH2F, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, a monovalent nucleic acid, a monovalent protein, a detectable moiety, or a drug moiety.
Embodiment 31. A compound having the formula:
Embodiment 32. The compound of one of embodiments 1 to 31, wherein said compound contacts the Switch 2 groove of human K-Ras protein.
Embodiment 33. The compound of one of embodiments 1 to 31, wherein said compound contacts a Switch 2 groove amino acid corresponding to G60, Q61, D69, D92, H95, Y96, or Q99 of human K-Ras protein.
Embodiment 34. The compound of one of embodiments 1 to 31, wherein said compound binds a human K-Ras protein-GTP complex more strongly than said compound binds a human K-Ras protein-GDP complex under identical conditions.
Embodiment 35. The compound of embodiment 34, wherein said compound binds a human K-Ras protein-GTP complex at least 2-fold stronger than said compound binds a human K-Ras protein-GDP complex under identical conditions.
Embodiment 36. The compound of embodiment 34, wherein said compound binds a human K-Ras protein-GTP complex at least 5-fold stronger than said compound binds a human K-Ras protein-GDP complex under identical conditions.
Embodiment 37. The compound of embodiment 34, wherein said compound binds a human K-Ras protein-GTP complex at least 40-fold stronger than said compound binds a human K-Ras protein-GDP complex under identical conditions.
Embodiment 38. The compound of embodiment 34, wherein said compound binds a human K-Ras protein-GTP complex at least 100-fold stronger than said compound binds a human K-Ras protein-GDP complex under identical conditions.
Embodiment 39. The compound of one of embodiments 1 to 38, wherein said compound binds a human K-Ras G12D protein more strongly than said compound binds a human K-Ras wildtype protein under identical conditions.
Embodiment 40. The compound of one of embodiments 1 to 38, wherein said compound binds a human K-Ras G12D protein at least 2-fold stronger than said compound binds a human K-Ras wildtype protein under identical conditions.
Embodiment 41. The compound of one of embodiments 1 to 38, wherein said compound binds a human K-Ras G12D protein at least 10-fold stronger than said compound binds a human K-Ras wildtype protein under identical conditions.
Embodiment 42. The compound of one of embodiments 1 to 38, wherein said compound binds a human K-Ras G12D protein at least 100-fold stronger than said compound binds a human K-Ras wildtype protein under identical conditions.
Embodiment 43. The compound of one of embodiments 1 to 42, wherein said compound is capable of binding a water molecule and wherein said water molecule simultaneously binds a D12 residue of a human K-Ras G12D protein.
Embodiment 44. The compound of one of embodiments 1 to 42, wherein said compound binds a human K-Ras G12D protein and wherein the shortest average distance between the compound and the D12 residue of said human K-Ras protein is from 1.5 Å to 6.0 Å.
Embodiment 45. The compound of one of embodiments 1 to 42, wherein said compound binds a human K-Ras protein-GTP complex and wherein the shortest average distance between the compound and terminal phosphate of the GTP of said human K-Ras protein-GTP complex is from 1.5 Å to 10.0 Å.
Embodiment 46. A pharmaceutical composition comprising the compound of any one of embodiments 1 to 45, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
Embodiment 47. A method of treating a cancer in a patient in need of such treatment, said method comprising administering a therapeutically effective amount of a compound of any one of embodiments 1 to 45 to said patient.
Embodiment 48. A method of modulating the activity of a human K-Ras protein, said method comprising contacting said human K-Ras protein with an effective amount of a compound of any one of embodiments 1 to 45.
Embodiment 49. The method of embodiment 48, wherein said human K-Ras protein is a human K-Ras G12D protein, a human K-Ras G12C protein, a human K-Ras G12S protein, a human K-Ras G12V protein, or a human K-Ras G12R protein.
Embodiment 50. The method of embodiment 48, wherein said human K-Ras protein comprises a Q61 mutation.
Embodiment 51. The method of one of embodiments 48 to 50, wherein the activity of the human K-Ras protein is GTPase activity, nucleotide exchange, GDP binding, GTP binding, differential GDP or GTP binding, effector protein binding, K-Ras binding to Raf, effector protein activation, guanine exchange factor (GEF) binding, GEF-facilitated nucleotide exchange, phosphate release, nucleotide release, nucleotide binding, K-Ras subcellular localization, K-Ras post-translational processing, or K-Ras post-translational modifications.
Embodiment 52. The method of one of embodiments 48 to 50, wherein the activity of the human K-Ras protein is K-Ras binding to Raf.
Embodiment 53. A method of modulating the activity of a human H-Ras protein, said method comprising contacting said human H-Ras protein with an effective amount of a compound of any one of embodiments 1 to 45.
Embodiment 54. A method of modulating the activity of a human N-Ras protein, said method comprising contacting said human N-Ras protein with an effective amount of a compound of any one of embodiments 1 to 45.
It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.
We report herein, inter alia, the identification of three cyclic peptide ligands of K-Ras(G12D) using an integrated in vitro translation-mRNA display selection platform. These cyclic peptides show preferential binding to the GTP-bound state of K-Ras(G12D) over the GDP-bound state and block Ras-Raf interaction. A co-crystal structure of peptide KD2 with K-Ras(G12D)·GppNHp reveals that this peptide binds in the Switch II Groove region with concomitant opening of the Switch II loop and a 40° rotation of the α2 helix, and that a threonine residue (Thr10) on KD2 has direct access to the mutant aspartate (Asp12) on K-Ras. Replacing this threonine with non-natural amino acids afforded peptides with improved potency at inhibiting the interaction between Raf1-RBD and K-Ras(G12D) but not wildtype K-Ras. The union of G12D over wildtype selectivity and GTP-state/GDP-state selectivity is particularly desirable, considering that oncogenic K-Ras(G12D) exists predominantly in the GTP state in cancer cells, and wildtype K-Ras signaling is important for the maintenance of healthy cells.
Missense mutations of the RAS genes (KRAS, HRAS, and NRAS) occur frequently in human cancer and drive oncogenic transformation (1). Among these, KRAS G12D is the most prevalent point mutation associated with poor clinical outcome. The G12D mutation impairs both intrinsic and GTPase-accelerating protein (GAP)-mediated GTP hydrolysis and liberates K-Ras protein from functional control by GTPase activity (2,3). As a result, K-Ras(G12D) is enriched in its GTP-bound, signaling-competent state, given the near 10-fold higher concentration of GTP than GDP inside the cell (4).
Though Ras proteins were historically considered “undruggable” due to their picomolar affinity for guanine nucleotides and the lack of deep accessible pockets, recent efforts have fueled the discovery of both small molecule and macromolecule direct binders of Ras (5,6,15-24, 7-14). Earlier work from our laboratory identified a class of compounds that bind to Ras in a highly dynamic pocket near the Switch II region (SII-P) and leverage the nucleophilicity of the acquired cysteine in K-Ras(G12C) to covalently capture K-Ras in its inactive, GDP-bound state (18). Further chemical optimization has yielded ligands with potent K-Ras(G12C) dependent antitumor effects (25-27), and three compounds (AMG510 (28,29), MRTX849 (30), JNJ-74699157 (31)) have entered clinical trials in patients with K-Ras(G12C) mutant tumors (32). This strategy is uniquely suited for the G12C mutant because intrinsic GTPase activity is not affected by the G12C mutation (3), allowing the conversion from GTP-bound state to the compound-accessible GDP-bound state at a clinically relevant rate. Efforts to develop K-Ras(G12C) inhibitors capable of binding to the GTP-state have thus far been unsuccessful. The SIIP is occluded in the GTP-state of K-Ras effectively blocking the drug binding pocket in this protein state.
The loss of intrinsic GTPase activity in K-Ras(G12D) presents an additional challenge—in cells with the G12D mutation, only a minor fraction of the K-Ras protein will be GDP-bound, and conversion from GTP-bound state to GDP-bound state is extremely slow. To target K-Ras(G12D), we envision that a GTP-state selective K-Ras ligand will be advantageous because 1) it will bind to the predominant K-Ras population in G12D-mutant cells, and 2) it will be less likely to affect healthy cells, which express wildtype K-Ras with a significant GDP-bound population. Previous work has demonstrated that targeting the GTP-state of Ras is feasible. For example, Gentile et al. discovered Switch II Groove (SII-G) ligands that can recognize both GDP- and GTP-states of Ras, albeit with a preference for the GDP-state (20). Sakamoto et al. reported K-Ras(G12D)-targeting cyclic peptides generated from a random T7 phage display library that are weakly selective for the GDP-state and inhibit Sos-mediated nucleotide exchange (9, 33, 34). Wu et al. identified artificial cyclic peptides that block K-Ras(G12V)/Raf1-RBD interaction from a bead-display library but did not study the nucleotide state preference (35). To the best of our knowledge, GTP-state selective ligands have not been documented. Here we present the discovery of GTP-state selective and mutant-selective cyclic peptide ligands of K-Ras(G12D) using the random nonstandard peptides integrated discovery (RaPID) platform (36), an in vitro translation-mRNA-display technology encoding >1012 macrocyclic peptides.
To target the GTP-state of K-Ras(G12D) we first considered a potential challenge: a ligand identified from a binding rather than a functional screen may not antagonize K-Ras oncogenic function. For example, an allosteric ligand that stabilizes the active conformation K-Ras(G12D)·GTP, but still allows effector binding, will render the protein constitutively active. To minimize this possibility, we took advantage of the two conformational states of Ras·GTP with distinct properties: State 1 (effector binding incompetent) and State 2 (effector binding competent) (37). While most Ras proteins exist in an equilibrium of these two interconverting states, a mutation of Thr35 to Ser locks the protein in State 1 (38). We therefore elected to use the double mutant K-Ras(G12D/T35S) for our initial selection, with the GppNHp-loaded protein as the selection target, and the GDP-loaded protein as the counter-target (
Starting from a high-diversity cDNA library (>1012 encoded compounds), we performed five rounds of selection, and examined the output cDNA libraries by next generation sequencing (NGS). Each round of selection included in vitro transcription, puromycin ligation, N-chloroacetyl-D-tyrosine-initiated in vitro translation with in situ cyclization, reverse transcription, negative and positive selection with target protein (K-Ras(G12D)) immobilized on streptavidin beads, and PCR amplification of the selected cDNA libraries. At the end of the fifth round of selection, we subjected the output library to an additional round of selection for quantitative comparison of the binders to empty beads, immobilized K-Ras(G12D)·GDP, or immobilized K-Ras(G12D)·GppNHp using PCR and NGS. This allowed us to calculate the GTP/GDP selectivity index (to evaluate GTP-state selectivity) and the GTP/beads selectivity index (to assess the level of non-specific binding). The top 20 binders (ranked by number of NGS reads after round 5) contained 16 cyclic peptides with GTP/GDP selectivity index of >1 (
Interestingly, when we performed a separate GTP-state positive selection using empty beads in lieu of GDP-loaded protein for negative selection, we obtained predominantly GDP-state selective binders (
With these three GTP-state selective cyclic peptide ligands, we assessed their impact on effector binding to K-Ras(G12D). We used a time-resolved fluorescence energy transfer (TR-FRET) assay which allows the quantitation of the Ras·Raf complex formation (
We next determined whether these cyclic peptides affect Sos-mediated nucleotide exchange, which takes GDP-state Ras as substrate. Inhibition of Sos-mediated nucleotide exchange required high concentrations of KD2 and KD17, and even near the solubility limit of 50 μM, KD1 only had a small effect on the rate of nucleotide exchange. By contrast, KRpep2d (a cyclic peptide ligand of K-Ras reported by Takeda (9)) is a highly potent inhibitor of nucleotide exchange, with an IC50 below the lower assay limit of the current assay format. None of these three peptides stabilized K-Ras(G12D) against thermal denaturation either in their GDP-bound or GppNHp-bound state (ΔTm<1.0° C.,
Owing to its GTP/GDP state selectivity (as revealed by selection NGS reads) and G12D/wildtype selectivity (as revealed by the Ras·Raf interaction assay), we focused our additional efforts on KD2. We successfully obtained co-crystals of KD2 and K-Ras(G12D) Cyslight·GppNHp (Cyslight) in a construct where all cysteines have been mutated to serine or leucine and which we previously found to have improved crystallization properties), and the crystal structure was determined by molecular replacement and refined to 1.6 Å (Table 1). The overall complex structure is shown in
KD2 forms an intricate hydrogen bond network both within the macrocycle and with residues on K-Ras(G12D). One intriguing observation was an ordered water molecule in the center of the macrocycle, forming hydrogen bonds with both side chain and backbone elements of cyclic KD2. We surmise that this water molecule may be critical to maintaining the conformation of the macrocycle. KD2 interacts with K-Ras(G12D) through residues on various domains (
To probe the structural perturbation of K-Ras(G12D) by all three cyclic peptides, we performed 1H-15N heteronuclear single quantum coherence (HSQC) experiments with 100 μM K-Ras(G12D)·GppNHp in the presence of 200 μM cyclic peptide. The low solubility of KD1 in aqueous buffer (˜50 μM) precluded the acquisition of the HSQC spectrum for this peptide. Both KD2 and KD17 caused drastic perturbations of nearly all peaks in the HSQC spectrum of K-Ras(G12D)·GppNHp, with additional new peaks that are not present in the spectrum of unliganded K-Ras(G12D)·GppNHp (
We next sought to improve the affinity and mutant/wildtype selectivity of KD2 to K-Ras(G12D) through structure-guided chemical modification. Asking whether we could enhance side-chain interaction between the cyclic peptide and Asp12 of K-Ras, we synthesized a set of KD2 analogs varying at the Thr10 position (
We tested these KD2 analogs in the TR-FRET-based Ras·Raf interaction assay (
We also considered rigidification of the cyclic peptide scaffold through the formation of a transannular bridge, a structural feature that has been found both in natural and synthetic peptides to improve their activity (39-41). To achieve this, we first identified two amino acids in KD2, Val3 and Arg9, that do not participate in intramolecular interactions or binding interaction with K-Ras (
It is conceivable that both the potency and the mutant selectivity of these peptides can benefit from further structural optimization with two distinct approaches—Thr10 modification and scaffold rigidification. Importantly, the data here indicates that substitution of Thr10 is well tolerated and may be tailored to target the GTP-state of other G12 mutants of K-Ras.
To demonstrate this, we wondered if we could repurpose KD2 to target the GTP-state of K-Ras(G12C) by incorporating an electrophile at the Thr10 position on KD2. Using whole protein mass spectrometry, we found that a chloroacetamide derivative of KD2, but not an acrylamide derivative, covalently engaged both K-Ras(G12C)·GppNHp and K-Ras(G12C)·GDP. While the covalent labeling was relatively slow and required a high concentration of the peptide (100 μM), we observed that the labeling of K-Ras(G12C)·GppNHp was twice as fast as that of K-Ras(G12C)·GDP, achieving 80% and 40% covalent modification after 24 h incubation at 23° C., respectively. Whether this difference originates from higher binding affinity (lower Ki) or faster covalent reaction (higher kinact) will require further kinetic investigation with more soluble analogs. It is worth noting that the same ligand did not covalently label K-Ras(G13C) or K-Ras(wildtype) in either GppNHp- or GDP-bound state. To our knowledge, this is the first mutant-selective, GTP-state selective covalent ligand for K-Ras(G12C).
We studied the cellular activity of these cyclic peptides in SW1990, a cell line with homozygous G12D mutation at the KRAS locus. When cells were treated with 10 μM KD1, KD2, or KD17 for 24 h, we did not observe any change in p-Akt or p-Erk levels. This was true for all the KD2 Thr10 variants we had synthesized. To understand the discrepancy between biochemical inhibitory activity and the lack of effect on K-Ras signaling output, we asked whether these peptides entered cells. We utilized the chloroalkane cell penetration assay (CAPA)42, which employs a cell line expressing HaloTag proteins on the outer membrane of mitochondria and monitors the cellular intake of chloroalkyl-tagged (ct) cargo compounds by quantifying the remaining unreacted HaloTag protein after exposure of cells to ct-cargo for a fixed amount of time. Whereas two control compounds, ct-tryptophan (ct-W) and ct-rapamycin (ct-Rapa), were shown to be highly cell permeable (CP50=125 nM and 28.5 nM, respectively), ct-KD2 did not readily enter cells under the assay conditions (CP50>10 μM). We questioned whether this limited cell permeability could be sufficient for proteolysis-targeting chimeras (PROTACs), as this class of compounds have a catalytic mechanism of action (43) and may be less restricted by low cellular permeability (44). We synthesized KD2-thalidomide and used it to treat SW1990 cells at various concentrations. However, under no conditions was reduction of K-Ras protein level observed. Treatment with either KD2 or KD2-thalidomide also did not alter the level of Ras-GTP inside the cell. All the current evidence suggests that cell permeability is a key limiting factor for cellular activity of KD2, and that improving permeability should be a critical task in future compound optimization.
Employing a high-throughput selection platform (the RaPID system), we have identified three distinct cyclic peptide scaffolds that preferentially bind to K-Ras(G12D) in its GTP state from an initial library of 1012 members. These cyclic peptides inhibit the interaction between K-Ras(G12D) and Raf1-RBD but are less effective for wildtype K-Ras protein. X-ray crystallography showed that one of these peptides binds to K-Ras in the Switch II Groove region previously discovered in a fragment screen. Structure-guided chemical diversification allowed rapid optimization of one initial hit into a compound with sub-micromolar potency at inhibiting Ras-Raf interaction. One remaining challenge is that these cyclic peptides do not readily enter cells, impeding their utility in a cellular setting. Cellular permeability of cyclic peptides is a complex problem under active research (45, 46). With guidance from abundant empirical rules and contemporary computational modeling, we are optimistic that this will be a surmountable problem after sufficient experimentation.
Our study has overturned the current understanding of the Switch II Pocket (SIIP) first revealed by the discovery of covalent ligands for K-Ras (G12C) and now extended by many more analogs which have advanced to the clinic. The K-Ras (G12C) ligands do not bind to the GTP state of K-Ras(G12C) and only bind in its GDP state, when switch II of K-Ras is open, exposing the SIIP. This understanding has dominated clinical trials for K-Ras (G12C) ligands because of the inability to identify ligands for the GTP state of K-Ras (G12C). This study set out to identify what we initially hypothesized would have to be a distinct pocket on K-Ras (G12D) in the GTP state since previous studies appeared to suggest SIIP was inaccessible. The co-crystal structure of KD2 bound to K-Ras(G12D)/GMPPNP was surprising because KD2 binds to the SIIP. This result suggests a previously unappreciated dynamic aspect of the switch II loop of K-Ras (G12D) in the GTP state exposing the SIIP for drug access. This is a promising therapeutic approach for many oncogenic K-Ras mutants that are devoid of GTPase activity and enriched in their GTP-bound state.
Our study shows that the dynamic Switch II Groove region is not only a viable drug pocket but can accommodate ligands of great size (in our example, 1800 Da). In addition, it provides possible direct access to mutant amino acid residues on the P-loop. The present work also demonstrates for the first time that GTP-state selective direct Ras ligands are present when exceptionally large libraries are accessed. This is a promising therapeutic approach for many oncogenic K-Ras mutants that are devoid of GTPase activity and enriched in their GTP-bound state.
Cyclic Peptide Selection
Selection
Selections were performed with thioether-macrocyclic peptide library against GppNHp-bound K-Ras(G12D/T35S), using the GDP-bound K-Ras(G12D/T35S) as the negative selection (
In the first round of selection, the initial cyclic peptide library was formed by adding puromycin ligated mRNA library (225 pmol) to a 150 μL scale flexible in vitro translation system, in the presence of 30 μM of ClAcDTyr-tRNAfMetCAU. The translation was performed at 37° C. for 30 min, followed by an extra incubation at 25° C. for 12 min. After an addition of 15 μL of 200 mM EDTA (pH 8.0) solution, the reaction solution was incubated at 37° C. for 30 min to facilitate cyclization. Then the library was reversed transcribed by M-MLV reverse transcriptase at 42° C. for 1 h and subject to pre-washed Sephadex G-25 columns to remove salts. The desalted solution of peptide-mRNA/cDNA was applied to GppNHp-bound K-Ras(G12D/T35S) immobilized Dynabeads M280 streptavidin magnetic beads and rotated at 4° C. for 1 h in selection buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 1 mM MgCl2 and 0.05% Tween 20) containing 0.5 mM GppNHp and 0.1% acetylated BSA. Bead amounts were chosen that the final concentration of GppNHp-bound K-Ras was 200 nM. This process is referred to as positive selection. The selected peptide-mRNA/cDNAs were isolated from the beads by incubating in 1×PCR reaction buffer heated at 95° C. for 5 min. The amount of eluted cDNAs was measured by quantitative PCR (Roche LightCycler 96). The remaining cDNAs were amplified by PCR, purified and transcribed into mRNAs as a library for the next round of selection.
In the subsequent rounds of selection, ligated mRNA from previous round (7.5 pmol) was added to a 5 μL scale reprogrammed in vitro translation system. This was incubated at 37° C. for 30 min and at 25° C. for 12 min. Then 1 μL of 100 mM EDTA (pH 8.0) was added and incubated at 37° C. for 30 min. After reverse transcription and subject to pre-washed Sephadex G-25 columns to remove salts, negative selections was performed by adding the desalted solution of peptide-mRNA/cDNA to GDP-bound K-Ras(G12D/T35S) immobilized Dynabeads M280 streptavidin magnetic beads and rotated at 4° C. for 30 min in selection buffer containing 0.1% acetylated BSA. This process was repeated several times by removing the supernatant to fresh beads immobilized with GDP-bound K-Ras(G12D/T35S). The supernatant from the last negative selection was then added to beads immobilized with GppNHp-bound K-Ras(G12D/T35S) (final conc. 200 nM), and rotated at 4° C. for 30 min in selection buffer containing 0.5 mM GppNHp and 0.1% acetylated BSA. As described in first round of selection, the cDNA was quantified with qPCR, amplified with PCR, transcribed and ligated to puromycin. The subsequent selection was repeated for several rounds until a significant enrichment of cDNA was observed for GppNHp-bound K-Ras(G12D/T35S). The recovered cDNA was then identified by Miseq sequencing (Illumina).
Comparison Selection
In comparison selections, ligated mRNA (7.5 pmol) from last round selection was added to a 5 μL scale reprogrammed in vitro translation system. After translation, cyclization, reverse transcription and prewashed with Sephadex G-25 columns, the desalted solution of peptide-mRNA/cDNA library was split equally into three fractions, and perform three paralleled selections with the same amount of blank, GDP-bound K-Ras(G12D/T35S) or GppNHp-bound K-Ras(G12D/T35S) immobilized Dynabeads M280 streptavidin magnetic beads. For each of the paralleled selections, the beads were rotate at 4° C. for 30 min, washed three times with selection buffer. The remaining cDNAs were then eluted from the beads, quantified by qPCR, followed by Miseq sequencing. Finally, the identified sequences were compared after normalization of the Miseq abundance with its qPCR read for each paralleled selection.
General Workflow
Linear peptide precursors with 2-chloroacetylated N-termini were synthesized on NovaPEG Rink-Amide resin using standard Fmoc solid-phase synthesis technology. After cleavage of the peptides from the resin, macrocyclization (SN2 between cysteine and chloroacetamide) was performed in solution under basic conditions, and the product was purified by preparative HPLC. Detailed protocols are provided below.
57 mg NovaPEG Rink-Amide resin (0.44 mmol/g, 25 μmol) was swelled with 4 mL of DMF for at least 20 min. The resin was washed three times with DMF (4 mL each wash). To remove the Fmoc group, 4 mL 20% Piperidine (in DMF) was added to the resin and the mixture was rotated at 23° C. for 2+12 min. The resin was washed sequentially with DMF (3×4 mL), DCM (3×4 mL) and DMF (3×4 mL).
Amino Acid Coupling
For each amino acid to be coupled to the polypeptide, a mixture of Fmoc-amino acid (600 μL of 0.5 M solution in DMF, 300 μmol), COMU (600 μL of 0.45 M solution in DMF, 270 μmol) and DIPEA (300 μL of 2.0 M solution in NMP, 600 μmol) was added to the resin and the mixture was vigorously shaken for 1 h. The resin was washed sequentially with DMF (3×4 mL) and DCM (3×4 mL). Chloranil test was performed to confirm complete coupling (a few resin beads mixed with 5 μL 2% acetaldehyde/DMF and 5 μL 2% chloranil/DMF; coupling is complete if resin is orange/yellow, incomplete if resin is blue/green/black). If coupling is incomplete, an additional round of coupling was performed using identical amounts of reagents. When coupling is complete, 4 mL of 20% piperidine (in DMF) was added and the mixture was rotated for 2+12 min to remove the Fmoc group. The resin was washed sequentially with DMF (3×4 mL), DCM (3×4 mL) and DMF (3×4 mL).
Note: In certain cases, Fmoc deprotection was performed with 4 mL 40% 4-methylpiperidine in DMF in lieu of 20% piperidine.
N-Terminal Capping with Chloroacetamide
N-hydroxylsuccinmide chloroacetate (2 mL of 0.2 M solution in NMP) was added to peptide-conjugated resin and the mixture was rotated at 23° C. for 1 h. A few resin beads were taken for TNBS test. Briefly, the beads were mixed with 5 uL of 10% DIPEA/DMF+5 uL 1% 2,4,6-trinitrobenzenesulfonic acid (TNBS)/DMF and incubated at 23° C. for 10 min. Capping is complete ok if beads are colorless, but not if they are yellow/orange. The resin was washed by DMF (5×4 mL) followed by DCM (5×4 mL) and dried under reduced pressure overnight.
Deprotection and Cleavage
A cleavage solution was prepared as follows, chilled on ice and added to vacuum-dried resin (2 mL/25 μmol resin). The mixture was incubated on ice for 10 min, then at 23° C. for 3 h with gentle rotation. The supernatant was filtered into a 15 mL tube, and the resin was washed with trifluoroacetic acid (3×1 mL). The filtrates were combined. The bulk of TFA was removed under reduced pressure on a centrifugal evaporator to ˜1 mL volume. 20 mL ice-cold ether was added to the residue, giving rise to a while suspension, which was kept at −20° C. for 1 h. The precipitated peptide was pelleted by centrifugation and the supernatant was discarded. The pellet was washed with diethyl ether (5×5 mL) by resuspension and re-pelleting, then dried under vacuum.
Cyclization
The precipitated peptide was dissolved in 5 mL DMSO. TCEP (200 μL of 500 mM solution in water) and triethylamine (100 μL) were added sequentially. The pH of the mixture should be 8. If not, adjust pH to 8 with additional triethylamine. The mixture was incubated at 23° C. Reaction progress was monitored by LC-MS every hour. When cyclization was complete, trifluoroacetic acid (60 μL) was added to the reaction mixture to quench the reaction. The mixture was diluted with 5 mL 0.1% TFA/water and filtered through a 0.45-μm PTFE filter. The filtered solution was purified by preparative reverse-phase HPLC (Waters XBridge C18 column 5 μm particle size 30×250 mm, 10-70% acetonitrile-water+0.1% formic acid, 40 min, 20 mL/min). Product containing fractions were concentrated under reduced pressure and lyophilized to afford the product peptide as a white powder. The counter ion was exchanged from formate to chloride by repeated (three times) dissolution of the peptide in 5 mM HCl in 50% acetonitrile/water and removal of solvent under vacuum.
To prepare C-terminally modified cyclic peptides, the parent cyclic peptide (KD2) was prepared on Wang resin in lieu of Rink resin to afford the cyclic peptide with free carboxylic acid on the C-terminus (KD2-CO2H). KD2-CO2H (5 μmol) was dried by azeotropic distillation from of a suspension in benzene (three times), then was dissolved in DMF (100 μL). Amine coupling partner (100 μmol) was added as a solution in DMF (100 μL) to a solution of KD2-CO2H (5 μmol) in DMF (100 μL). DIPEA (100 μL of 2.0 M solution in DMF, 200 μmol) and HATU (100 μL of 1.0 M solution in DMF, 100 μmol) were added sequentially, the reaction mixture was incubated at 23° C., and the reaction progress was monitored by LC-MS. Typically, the reaction did not achieve completion and the reaction was terminated after 16 h. The reaction mixture was diluted with 50% acetonitrile-water+0.1% formic acid to a volume to 5.0 mL, filtered through a 0.45-μm PTFE filter. The filtered solution was purified by preparative reverse-phase HPLC (Waters XBridge C18 column 5 μm particle size 30×250 mm, 10-70% acetonitrile-water+0.1% formic acid, 40 min, 20 mL/min). Product containing fractions were concentrated under reduced pressure and lyophilized to afford the product peptide as a white powder. The counter ion was exchanged from formate to chloride by repeated (three times) dissolution of the peptide in 5 mM HCl in 50% acetonitrile/water and removal of solvent under vacuum.
Except the example noted below, Thr10 variants were prepared following the general synthesis protocol using appropriate Fmoc-protected amino acids.
KD2-T10Dap (5 μmol), in which Thr10 of KD2 was replaced with L-diaminopropanoic acid was dried by azeotropic distillation from of a suspension in benzene (three times), then was dissolved in DMF (100 μL). A freshly prepared solution of N-hydroxysuccinimide chloroacetate (1.0 M in DMF, 50 μL, 50 μmol) was added to the cyclic peptide solution, the reaction mixture was incubated at 23° C., and the reaction progress was monitored by LC-MS. Typically the reaction was complete in 8 h. The reaction mixture was diluted with 50% acetonitrile-water+0.1% formic acid to a volume to 5.0 mL, filtered through a 0.45-μm PTFE filter. The filtered solution was purified by preparative reverse-phase HPLC (Waters XBridge C18 column 5 μm particle size 30×250 mm, 10-70% acetonitrile-water+0.1% formic acid, 40 min, 20 mL/min). Product containing fractions were concentrated under reduced pressure and lyophilized to afford the product peptide as a white powder. The counter ion was exchanged from formate to chloride by repeated (three times) dissolution of the peptide in 5 mM HCl in 50% acetonitrile/water and removal of solvent under vacuum.
Protein Expression and Purification
K-Ras(G12D) CysLight
K-Ras(G12D) CysLight (for crystallization only) was expressed and purified following previously reported protocols (7,8).
Biotinylated K-Ras Proteins
pET-Duet plasmids encoding BirA biotin-protein ligase and His-Avi-TEV-tagged K-Ras proteins were constructed using standard molecular biology techniques. Biotinylated K-Ras proteins were produced in BL21(DE3) E. coli strain. Briefly, chemically competent BL21(DE3) cells were transformed with the corresponding pET-Duet plasmid and grown on LB agar plates containing 100 μg/mL carbenicillin. A single colony was used to inoculate a culture at 37° C., 220 rpm in terrific broth containing 100 μg/mL carbenicillin. When the optical density reached 0.6, the culture temperature was reduced to 20° C., and protein expression was induced by the addition of IPTG to 1 mM and Biotin to 5 μM. After 16 h at 20° C., the cells were pelleted by centrifugation (6,500×g, 10 min) and lysed in lysis buffer [20 mM Tris 8.0, 500 mM NaCl, 5 mM imidazole] with a high-pressure homogenizer (Microfluidics, Westwood, Mass.). The lysate was clarified by high-speed centrifugation (19,000×g, 15 min) and the supernatant was used in subsequent purification by immobilized metal affinity chromatography (IMAC). His-Avi-TEV tagged K-Ras protein was captured with Co-TALON resin (Clonetech, Takara Bio USA, 2 mL slurry/liter culture) at 4° C. for 1 h with constant end-to-end mixing. The loaded beads were then washed with lysis buffer (50 mL/liter culture) and the protein was eluted with elution buffer [20 mM Tris 8.0, 500 mM NaCl, 300 mM imidazole]. The protein was further purified with anion exchange chromatography (HiTrapQ column, GE Healthcare Life Sciences) using a NaCl gradient of 50 mM to 500 mM in 20 mM Tris 8.0. Nucleotide loading was performed by mixing the ion exchange-purified protein with an excess of GDP (5 mg/liter culture) or GppNHp (5 mg/liter culture) and 5 mM EDTA at 23° C. for 30 min. The reaction was stopped by the addition of MgCl2 to 10 mM. For GppNHp, an additional calf intestine phosphatase treatment was performed as follows to ensure high homogeneity of the loaded nucleotide. The protein buffer was exchanged into Phosphatase Buffer [32 mM Tris 8.0, 200 mM ammonium sulfate, 0.1 mM ZnCl2] with a HiTrap Desalting Column (GE Healthcare Life Sciences). To the buffer-exchanged protein solutions, GppNHp was added to 5 mg/mL, and Calf Intestine Phosphatase (NEB) was added to 10 U/mL. The reaction mixture was incubated on ice for 1 h, and MgCl2 was added to a final concentration of 20 mM. After nucleotide loading, the protein was concentrated using an 10K MWCO centrifugal concentrator (Amicon-15, Millipore) to 20 mg/mL and purified by size exclusion chromatography on a Superdex 75 10/300 GL column (GE Healthcare Life Sciences). Fractions containing pure biotinylated Ras protein were pooled and concentrated to 20 mg/mL and stored at −78° C. In our hands, this protocol gives a typical yield of 5-15 mg/liter culture.
GST-Raf1-RBD and Soscat
The GST-tagged RBD domain of Raf1 (residues 1-149, GST-Raf1-RBD) was expressed and purified following published protocol (9).
The catalytic domain of Sos (residues 466-1049, Soscat) was expressed and purified following published protocol (10).
Other Proteins
GST-tagged full-length B-Raf protein (GST-BRAF) was purchased from MRC PPU (University of Dundee).
Cell Culture
SW1990 cells were obtained from ATCC and maintained in DMEM (Gibco)+10% heat-inactivated FBS (Axenia Biologix) supplemented with penicillin and streptomycin (Gibco). When indicated, cells were treated with drugs at 60-80% confluency at a final DMSO concentration of 1%. At the end of treatment period, cells were placed on ice and washed once with PBS. The cells were scraped with a spatula, pelleted by centrifugation (500×g, 5 min) and lysed in RIPA buffer supplemented with protease and phosphatase inhibitors (cOmplete and phosSTOP, Roche) on ice for 10 min. Lysates were clarified by high-speed centrifugation. Concentrations of lysates were determined with protein BCA assay (Thermo Fisher) and adjusted to 2 mg/mL with additional RIPA buffer. Samples were mixed with 5×SDS Loading Dye and heated at 95° C. for 5 min.
Gel Electrophoresis and Western Blot
Unless otherwise noted, SDS-PAGE was run with Novex 4-12% Bis-Tris gel (Invitrogen) in MES running buffer (Invitrogen) at 200V for 40 min following the manufacturer's instructions. Protein bands were transferred onto 0.45-μm nitrocellulose membranes (Bio-Rad) using a wet-tank transfer apparatus (Bio-Rad Criterion Blotter) in 1×TOWBIN buffer with 10% methanol at 75V for 45 min. Membranes were blocked in 5% BSA-TBST for 1 h at 23° C. Primary antibody binding was performed with the indicated antibodies diluted in 5% BSA-TBST at 4° C. for at least 16 h. After washing the membrane three times with TBST (5 min each wash), secondary antibodies (goat anti-rabbit IgG-IRDye 800 and goat anti-mouse IgG-IRDye 680, Li-COR) were added as solutions in 5% skim milk-TBST at the dilutions recommended by the manufacturer. Secondary antibody binding was allowed to proceed for 1 h at 23° C. The membrane was washed three times with TBST (5 min each wash) and imaged on a Li-COR Odyssey fluorescence imager.
Differential Scanning Fluorimetry
The protein of interest was diluted with SEC Buffer [20 mM HEPES 7.5, 150 mM NaCl, 1 mM MgCl2] to 8 μM and mixed with a 100×DMSO solution of the ligand of interest. When no ligand was added, DMSO was used. SYPRO Orange Dye (Invitrogen) was added as a 500× solution in DMSO to a final nominal concentration of 5×. The resulting mixture was dispensed into wells of a white 96-well PCR plate in triplicate (25 μL/well). Fluorescence was measured at 0.5° C. temperature intervals every 30 s from 25° C. to 95° C. on a Bio-Rad CFX96 qPCR system using the FRET setting. Each data set was normalized to the highest fluorescence and the normalized fluorescence reading was plotted against temperature in GraphPad Prism 6.0. Tm values were determined as the temperature(s) corresponding to the maximum(ma) of the first derivative of the curve.
Sos- or EDTA-Mediated Nucleotide Exchange Assay
This assay was performed as previously reported (7, 11-13) with slight modifications.
BODIPY-GDP-loaded Avi-KRas(G12D) was prepared freshly as follows. To a 10 μM solution of Avi-KRas(G12D)·GDP in SEC Buffer (1 mL) was added sequentially BODIPY-GDP (5 mM, 40 μL, Thermo Fisher, final concentration 200 μM) and Na-EDTA pH 8.0 (0.5 M, 5 μL, final concentration 2.5 mM). The mixture was incubated at 23° C. for 1 h, and a solution of MgCl2 (1.0 M, 20 μL, final concentration 10 mM) was added to the reaction mixture. The protein solution was run through a PD-10 column to remove the excess nucleotide following the manufacturer's protocol. Briefly, sample (˜1.0 mL) and excess buffer (1.5 mL) were loaded onto the column (equilibrated with NucEx Buffer), and desalted protein was eluted with NucEx Buffer (3.5 mL). Protein concentration was measured with Bradford assay and adjusted to 1.25 μM with NucEx Buffer.
50 μL protein solution was mixed with 0.5 μL DMSO solution of the test compound and the mixture was incubated at 23° C. for 15 min. 12 μL of this solution (triplicate for each condition) was added to wells of a black 384-well low-volume assay plate (Corning 4514). 3 μL of either 1 mM GDP, 1 mM GDP+5 μM Sos, or 1 mM GDP+40 mM EDTA (all prepared in NucEx Buffer) was added via a multichannel pipet rapidly to the wells. This should take less than 15 s to finish. The plate was immediately placed in a TECAN Spark 20 M plate reader, and fluorescence for BODIPY (excitation 488 nm, emission 520 nm) was read every 30 s over 1 h. Fluorescence intensity was normalized to values at time 0 and plotted again time. Observed rate constant (kobs) was derived by fitting the curve to first-order kinetic equation
F=(F0-F∞)exp[−kobst]+F∞
and plotted against time.
Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay
TR-FRET assay was performed using recommended conditions from Cisbio with slight modifications. For GST-Raf1-RBD assays, biotinylated Ras proteins were diluted in TR-FRET buffer to 25 nM, and GST-Raf1-RBD was in TR-FRET buffer to 25 nM. For GST-BRAF assays, biotinylated Ras proteins were diluted in TR-FRET buffer to 250 nM and GST-BRAF was diluted to 250 nM. These concentrations were determined previously with titrations of both reagents to allow the maximal assay window. The difference between the GST-Raf1-RBD assay and GST-BRAF likely reflects the lower affinity of full length BRAF for Ras (Fisher et al. J. Biol. Chem. 2007, 282, 26503-26516). Anti-GST-Tb (Cisbo) was diluted to 500 ng/mL. Streptavidin-XL665 (Cisbio) was diluted to 10 μg/mL. Compounds were prepared at 5×testing concentrations in TR-FRET assay buffer (5% DMSO). For each replicate of each assay condition, 4 μL compound solution, 4 μL of diluted Ras protein, 4 μL diluted GST-Raf1-RBD or GST-BRAF was mixed in a well of a black low-volume 384-well plate (Corning 4514), and the mixture was incubated at 23° C. for 1 h. 4 μL of Anti-GST-Tb and 4 μL of Streptavidin-XL665 were then added sequentially to each assay well, and the mixture was incubated at 23° C. for an additional 1 h. Time-resolved fluorescence was read on a TECAN Spark 20 M plate reader with the following parameters:
Lag time: 60 μs
Integration time: 500 μs
Read A: Excitation filter 320(25) nm, Emission filter 610(25) nm, Gain 130
Read B: Excitation filter 320(25) nm, Emission filter 665(8) nm, Gain 165
TR-FRET signal was calculated as the ratio fluorescence intensity [Read B]/[Read A]. The ratiometric signal was further normalized to a negative control containing GDP-bound Ras protein. Three replicates were performed for each assay condition.
Chloroalkane Cell Penetration (CAPA) Assay
This assay was performed following published protocols (Peraro et al. 2018).
Briefly, Hela cells stably expressing HaloTag-GFP-Mito were seeded in a 96-well plate the day before the experiment at a density of 4×104 cells per well. The day of the experiment the media was aspirated, and 100 μL of Opti-MEM was added to the cells. Test compounds at 500× assay concentration were diluted in Opti-MEM to 5×, and serial dilutions of the peptides were performed in a separate 96-well plate (final DMSO: 1%). 25 μL of compound solution was added to each well, and the plate was incubated for 4 h at 37° C. with 5% CO2. The contents of the wells were aspirated off, and wells were washed using fresh Opti-MEM for 15 min. The wash was aspirated off, and the cells were chased using 5 μM ct-TAMRA (Promega) for 15 min, except for the control wells, which were incubated with Opti-MEM alone. The contents of the wells were aspirated and washed with fresh Opti-MEM for 30 min. After aspiration, cells were rinsed once with phosphate-buffered saline (PBS). The cells were then trypsinized, resuspended in PBS, and analyzed using an Attune NxT flow cytometer (Thermo Fisher Scientific). Data analysis was performed on GFP positive cell population, and median fluorescence intensity (MFI) in the TAMRA channel, normalized to DMSO treatment control, was plotted against peptide concentration.
Crystallization
GppNHp-loaded K-Ras Cyslight (G12D/C51S/C80L/C118S) purified by size exclusion chromatography was concentrated to 20 mg/mL and 100 μL protein was mixed with 5 μL 30 mM cyclic peptide solution in DMSO and 5 μL 100 mM GppNHp in SEC buffer. The mixture was incubated at 23° C. for 24 h and centrifuged (21,000×g, 30 min) to remove particulates. The supernatant was transferred into new tubes. For crystallization, 0.1 μL of the protein was mixed with 0.1 μL well buffer containing 0.1 M Tris 9.0, 0.2 M lithium sulfate, 30% PEG4000. Crystals were grown at 20° C. in a 96-well plate using the hanging-drop vapor diffusion method. Maximal crystal growth was achieved after 25 days. The crystals were transferred to a cryoprotectant solution (0.1 M Tris 9.0, 0.2 M lithium sulfate, 30% PEG4000, 20% glycerol) and flash-frozen in liquid nitrogen.
X-Ray Data Collection and Structure Determination
Dataset was collected at the Advanced Light Source beamline 8.2.2 with X-ray at a wavelength of 0.999907 Å. The dataset was indexed and integrated using iMosfim (Battye et al., 2011), scaled with Scala (Evans, 2006) and solved by molecular replacement using Phaser (McCoy et al., 2007) in CCP4 software suite (Winn et al., 2011). The crystal structure of GppNHp-bound K-Ras(G12D) (PDB code: 5USJ) was used as the initial model. The structure was manually refined with Coot (Emsley et al., 2010) and PHENIX (Adams et al., 2010). Data collection and refinement statistics are listed in Table 1. In the Ramachandran plot of the final structure, 97.86% and 1.95% of the residues are in the favored regions and allowed regions, respectively. One residue, Arg41, directly adjacent to the partially disordered Switch I region (32-40), is calculated as an outlier.
Heteronuclear Single-Quantum Coherence (HSQC)
Samples of 15N-labeled, GppNHp-bound K-Ras(G12D) for NMR spectroscopy were prepared as follows. A 30 μL aliquot of protein at 1.0 mM in storage buffer (40 mM HEPES pH 7.4, 150 mM NaCl, 4 mM MgCl2, 5% v/v glycerol, 7% v/v D2O) was diluted with 240 μL of buffer (40 mM HEPES pH 7.4, 150 mM NaCl, 4 mM MgCl2, 7% v/v D2O) in a 1.2 mL Eppendorf tube on ice. Then, 30 μL of either dmso-d6, or a cyclic peptide at 4.0 mM in dmso-d6 were added, the sample was mixed, and the resulting solution was transferred to a 5 mM D2O-matched Shigemi NMR tube (BMS-3). The final concentrations of protein and cyclic peptide were 100 and 400 μM, respectively.
1H-15N HSQC spectra (fhsqcf3gpph) were acquired on an 800 MHz Bruker Neo spectrometer at 288 K with 1024 and 512 points, 8 scans, and GARP decoupling. Chemical shifts were referenced to the HDO signal at 4.70 ppm.
Materials
Guanosine 5′-[β,γ-imido]triphosphate trisodium salt hydrate (GppNHp) and Guanosine 5′-diphosphate sodium salt were ordered from Sigma (St. Louis, Mo., USA). Sephadex™ G-25 fine was ordered from GE healthcare (Uppsala, Sweden). Acetylated bovine serum albumin (nuclease and protease tested) were ordered from Nacalai Tesque, Inc. (Kyoto, Japan). M-MLV Reverse Transcriptase and RNasin Plus RNase inhibitor were obtained from Promega (Madison, Wis., USA). Dynabeads M280 streptavidin was purchased from Thermo Fisher Scientific (Baltics, USA).
List of Protein Sequences Used in this Study
Underlined texts indicate the affinity tags that were cleaved during purification.
MHHHHHHSSGRENLYFQGMTEYKLVVVGADGVGKSALTIQLIQNHFVDEY
Characterization Data for Cyclic Peptides
Mass Spectrometry
DYIIVTEKFIWVHHCG
DYFVNFRNFRTFRCG
DYNYPYRPLELGWYCG
DYFVNFRNFRHFRCG
DYFVNFRNFRKFRCG
DYFVNFRNFRRFRCG
DYFVNFRNFR(Dap)FRCG
DYFVNFRNFR(Cit)FRCG
DYFVNFRNFR(Pip)FRCG
DYFVNFRNFR(ClAcDap)FRCG
DYFVNFRNFRTFRCG-CO2H
DYFVNFRNFRTFRCG-Ct
DYFVNFRNFRTFRCG-Thal
This application is the national stage filing under 35 U.S.C. § 371 of International Application No. PCT/US2021/028874 filed Apr. 23, 2021, which claims the benefit of U.S. Provisional Application No. 63/014,596, filed Apr. 23, 2020, which are incorporated herein by reference in their entirety and for all purposes.
This invention was made with government support under the Platform Project for Supporting Drug Discovery and Life Science Research Program (Basis for Supporting Innovative Drug Discovery and Life Science Research) of Japan Agency for Medical Research and Development (AMED). The government has certain rights in the invention.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2021/028874 | 4/23/2021 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63014596 | Apr 2020 | US |
